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Abstract 
The HER family of receptors plays a major role in a variety of cancers including breast 
cancer. Several researchers have shown that HER family overexpression in breast 
cancer is a significant prognostic factor, especially for survival and relapse. Therefore, 
many therapeutics are being developed to test the impact of HER family blockade in 
breast cancer. Although numerous therapies have been developed, many have not been 
very successful in the clinic. This is often a consequence of cancer cells developing 
new mechanisms to activate HER family signalling indirectly through cross talk with 
compensatory pathways. Thus, it is vital to consider the biology of the HER signalling 
network to a greater extent, which includes RAS/MAPK, PI3K/AKT, mTOR, 
JAK/STAT, ER and AhR pathways and, also identify breast cancer patient populations 
that will benefit from specific targeted therapies that target these pathways.  
In the current study, 6 breast cancer cell lines (MCF7, T47D and ZR-75-1, SKBR3, 
MDA-MB 468 and MDA-MB 231) representing distinct molecular subtypes of breast 
cancer have been used to investigate anti-cancer effects of a variety of agents. These 
agents include clinical as well as currently experimental and entirely novel 
pharmacological agents alone or in combination. Among the clinical agents studied, it 
was found that EGF and Gefitinib were significantly potent against the HER2 
overexpressing SKBR3 cell line, out of the panel of cell lines studied. EGF and 
Gefitinib showed a slightly different spectrum of activity from each other against the 
SKBR3 cell line. However, more research is needed to determine whether EGF could 
be used as a therapy for HER2 overexpressing breast cancer. Even though Gefitinib is 
currently used as a treatment in the clinic, the therapeutic window of this agent is 
drastically narrowed by its poor bioavailability, acquired resistance and systemic 
toxicity. Thus, in the current study, encapsulation of Gefitinib within the cavity of 
human heavy chain (H) apoferritin (AFt), provided a route for sustained release of 
Gefitinib from the H-AFt cavity, which demonstrated enhanced anti-tumour activity, 
at a longer duration against the SKBR3 cell line compared to Gefitinib alone.  
Overexpression of HER2 is considered to confer a more aggressive phenotype in 
breast cancer. Many patients have shown resistance to existing clinical agents such as 
Trastuzumab, demonstrating the need for novel therapies. Hence, 2 novel HER2 
targeting human H and light chain (L)-AFt-fusion proteins were tested, and it was 
found that the nanoagent - H-AFt-fusion protein was very potent against the SKBR3 
cell line compared to the L-AFt-fusion protein. This novel H-AFt-fusion protein 
abolished SKBR3 colony formation completely, caused a G1 arrest and a reduction in 
the orchestration of S and G2/M cell cycle events and also induced a large SKBR3 
apoptotic population demonstrating its potent cytotoxic effects. Furthermore, this 
agent down-regulated the HER2 protein remarkably which resulted in significant 
down-regulation of the RAS/MAPK, PI3K/AKT and JAK/STAT signal transduction 
pathways in SKBR3 cells.  
Previous research has shown that a combination of pharmacological agents are more 
effective against cancer than individual agents due to up-regulation of compensatory 
signalling pathways which cancer cells use to thrive and acquire resistance to agents. 
Thus, several agents were tested in combination. Out of the agents tested it was found 
that 3 dual PI3K/mTOR inhibitors were potent against the triple negative breast cancer 
cell line - MDA-MB 468 and the HER2 overexpressing SKBR3 cell line. Further, 
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Gefitinib in combination with an experimental AhR ligand - 5F 203, showed 
synergistic growth inhibition against the SKBR3 cell line by inducing CYP1A1, 
thereby resulting in a large apoptotic population. It was observed that the effect of 
Gefitinib was mainly potentiated by the effect of 5F 203 within the agent combination. 
There is a momentous unmet medical need for the development of effective therapies 
that can stabilise or slow the progression of breast cancer, therefore, these results may 
contribute to existing knowledge or enhance further understanding of the HER 
signalling network and therapies targeting this network. It may also guide potential 
treatment options which might lead to significant improvements in breast cancer 
therapy in the clinic thereby personalising therapy for patients with breast cancer. 
Below is a flowchart which provides a short description of each chapter in the thesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1   Introduction to the thesis. 
Chapter 3 ✁ A description of the clinically available agents targeting the HER family of 
receptor network that were tested against a panel of breast cancer cell lines. EGF and small 
molecule inhibitor Gefitinib, demonstrated potent activity against the HER2 overexpressing 
SKBR3 cell line. Gefitinib was chosen to be encapsulated within a human H-AFt nano carrier 
which is described in chapter 4. 
Chapter 2 
✁
 Materials and methods used in the study. 
Chapter 4 ✁ A description of preparation of H-AFt-encapsulated-Gefitinib nanoparticles, and 
descriptions of characterisation and functionality of H-AFt-encapsulated-Gefitinib. The novel 
nanoagent showed enhanced anti-tumour activity with sustained release of Gefitinib. 
Chapter 5 ✁ HER2 overexpression is associated with aggressive disease. Thus, the effects of 2 
novel H and L-AFt-fusion proteins were tested and these results are described within this 
chapter. The agents were tested against the HER2 overexpressing SKBR3 cell line and MDA-
MB 231 cell line which lacks HER2. The H-AFt-fusion protein was found to be extremely 
potent out of the 2 fusion proteins tested demonstrating cytotoxic effects against the SKBR3 
cell line. The activity of this novel agent was compared to the activity of Trastuzumab. 
Chapter 6 
✁
 Cancer cells demonstrate cross talk to thrive and gain acquired resistance to anti-
cancer agents. Thus, a combination approach was evaluated using 4 dual combination options 
and these results are described within this chapter. Dual PI3K/mTOR inhibitors showed potent 
activity against the tested MDA-MB 468 and SKBR3 cell lines. Further, Gefitinib in 
combination with 5F 203 portrayed synergistic activity, where 5F 203 mainly potentiated the 
effect of Gefitinib against the SKBR3 cell line.  
Chapter 7 ✁ General discussion, conclusion and future directions of the study.  
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observed in many Western countries from the late 1990s could be because of increased 
screening intensities [9].  
 
Age is one of the strongest risk factors for breast cancer and it has been shown that the 
incidence of this disease rises with age [2] [10]. In Asia, the incidence of this disease 
peaks among premenopausal women in their forties, whereas in the West, breast 
cancer peaks among postmenopausal women in their sixties [2] [3]. Development of 
breast cancer at an earlier age could be due to mutations in the breast cancer 
susceptibility genes carried by individual Asian populations. In addition it could be 
due to adapting to a modernised lifestyle, having denser breasts and due to vitamin D 
deficiencies [2] [8]. On the other hand, in the West, postmenopausal women tend to 
be more obese. Obese women tend to have high levels of circulating oestrogens due 
to their greater peripheral conversion of androgens to oestrogens by aromatase in 
adipose tissues which may contribute to breast cancer [11].  
 
Compelling evidence suggests that reproductive factors such as age at menarche 
(before age of 12), age at menopause (after the age of 55), age at first live birth (after 
the age of 35), a reduced duration of breast feeding and low parity are strong risk 
factors for breast cancer development [3] [10]. Further, the use of exogenous 
hormones such as hormone replacement therapy and oral contraceptives have also 
been shown to have an association with an increase in risk of the disease [10]. A 
number of lifestyle factors have also been linked to breast cancer which include the 
use of tobacco, alcohol consumption, consumption of a high fat diet, obesity and a 
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sedentary life style [10]. It has been outlined that the risk of breast cancer is increased 
2-to 3-fold in women with a first degree relative with breast cancer [12]. Nevertheless, 
it has been shown that only about 10% of women are at increased risk due to inherited 
mutated forms of breast cancer susceptibility genes such as breast cancer gene 1 
(BRCA1) and breast cancer gene 2 (BRCA2) and the remaining cases develop sporadic 
breast cancer [12]. Maintaining a healthy life style is the best available strategy to 
reduce the risk of developing breast cancer [9]. Early detection of the disease has 
shown to increase treatment options and reduce mortality [13].  
 
Breast cancer is derived from the epithelial cells found in the terminal duct lobular 
unit of the breast [14]. These epithelial cancer cells that disseminate outside the 
basement membrane of the ducts and lobules into the adjacent surrounding tissues 
become invasive carcinomas [14]. Invasive carcinomas of the breast are divided into 
2 major histopathological classifications - ductal and lobular carcinomas where they 
both arise from the terminal duct lobular unit of the breast [14]. Invasive ductal 
carcinoma comprises the majority of all breast cancers with a frequency of 50 - 80% 
and invasive lobular carcinomas present with a frequency of 5 - 15% around the world 
[15]. There are some morphologically distinct special types of breast cancers that 
represent minor groups which comprise around 5 - 10% of breast cancers including 
mixed ductal and lobular, cribriform, mucinous, medullary and papillary carcinomas 
[15].  
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Invasive breast cancer is diagnosed by several investigation methods such as by a 
clinical and radiological examination that involve a mammography and a whole breast 
ultrasound [14]. If there is any evidence of suspected disease it may be further 
confirmed by a pathological examination which most often involves a fine needle 
aspiration or a core needle biopsy [16]. With certain cases a surgical biopsy may be 
needed such as an excisional or an incisional biopsy to establish exact diagnosis [16]. 
After diagnosis, breast tumours are classified into different stages which may have 
prognostic implications. This is known as the tumour node metastasis (TNM) system 
[14]. The TNM system includes the size of the tumour, the involvement of regional 
lymph nodes and the number of metastatic tumours present [14]. Metastatic tumours 
of the breast commonly spreads to the lung, liver, bone, adrenal glands and brain [15].   
 
Currently, breast tumours are also classified according to the degree of differentiation 
of the tumour tissue compared to the appearance of normal breast tissue, which is 
graded from 1 - 3 where grade 1 represents a well differentiated tumour while grade 3 
represents a poorly differentiated tumour with higher risk of recurrence and death [17]. 
The most frequently used histological grading system of breast cancer is the 
Nottingham grading system. The Nottingham grading system has been combined with 
the breast cancer tumour staging system to develop the Nottingham prognostic index. 
The Nottingham prognostic index is widely used to determine prognostic information 
for patients with breast cancer in the United Kingdom [17]. Ki67 which is a nuclear 
protein is also evaluated most often to determine cellular proliferation [18]. In 
addition, classifications according to biomarkers such as hormone receptors by 
immunohistochemistry and growth factor receptors such as human epidermal growth 
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factor receptor 2 (HER2) either by immunohistochemistry or fluorescence in situ 
hybridisation exist to guide therapeutic options [14]. Thus, breast cancer is currently 
classified by many different parameters in the clinic. However, with advances in 
molecular biology it is evident that breast cancer is no longer one disease but a 
heterogeneous disease and there are different types of breast cancers, which behave 
differently. While these classification systems have incorporated differences in types 
of breast tumours, some tumours may not demonstrate correlation between these 
parameters used with the predicted clinical outcome and the effective therapeutic 
options to be used [14].  
 
The main treatment options available for breast cancer are surgery, radiotherapy, 
chemotherapy and targeted therapy [14] [19]. Most patients with breast cancer may 
have local treatment to control the disease and also systemic treatment to combat any 
micrometastatic disease. Local treatment may comprise of surgery and radiotherapy 
[14]. There are 2 types of breast cancer surgery. Surgery can be excision of the tumour 
with adjacent normal breast tissues (wide local excision) which is also known as breast 
conservation surgery or removal of the whole breast which is known as mastectomy 
[14] [20].  
 
Radiotherapy which uses x-rays to damage deoxyribonucleic acid (DNA) in tumour 
cells is commonly given to patients after surgery which will reduce local recurrence 
[14]. Chemotherapy which is also known as adjuvant therapy is the treatment given 
after surgery that will help eradicate breast metastatic disease. In some cases, 
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chemotherapy may be given before surgery which may be used to shrink a large 
tumour prior to surgery which is then known as neo-adjuvant therapy. However, older 
women who are more than 70 years of age are offered a customised treatment option 
which takes into account age dependent variances such as physical capability, stage of 
the tumour, personal preferences and also predicted life expectancy to reduce 
treatment related morbidity and mortality compared to younger women. Most often, 
majority of patients of this group may benefit from surgical treatment, however, frail 
elderly patients may not benefit from surgical treatment with respect to overall 
survival. These patients are rarely given standard chemotherapy as well. However, if 
nodal disease is identified, radiotherapy might be given as a better option with adjusted 
protocols which will provide local control of the disease, or endocrine therapy if the 
tumour is oestrogen receptor (ER)+ [20].  
 
Standard chemotherapy has shown a wide range of acute and long term side effects 
that substantially affects  ✁✂ ✄☎ ✆✂✝ ✞✟ ✠✡☎☛✆ ☞ of life [15]. Targeted therapies are a 
special type of chemotherapy that will be active on an underlying molecular target 
critical in breast cancer pathogenesis, offering a reduced effect on normal cells in the 
body thereby reducing the level of toxicity [19]. These molecular targets will assist in 
tailoring the treatment st✌☎ ✂✍✆✂✟  ✎ ✆✝✏✆✑✆✏✡☎☛ ✄☎ ✆✂✝ ✞✟  ✡✒✎✡✌ [15]. Some of the 
molecular targets are growth factor receptors, components of intracellular signalling 
pathways and hormonal receptors [19]. However, the selection of patients for targeted 
therapy remains a challenge and molecular characterisation of breast cancer sub 
populations may guide better selection of patients and reduce resistance to therapy 
[21].  
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experiment [18]. Seminal studies evaluating these genetic profiles have classified at 
least 6 molecular subtypes in breast cancer [24]. The ultimate goal of identifying breast 
cancer subtypes is to contribute to a personalised model of breast cancer management, 
where therapeutic agents can be tailored to individual patients [25]. These subtypes 
are: luminal A, luminal B, HER2, normal-like, basal and recently identified claudin 
low [24] [25]. Luminal A and luminal B are amenable to hormone therapy [24]. 
Luminal A tumours portray high expression of ER. They also have lower proliferation 
rates and tend to be of low histological grade as such they tend to have the best 
prognosis [18] [22]. Most often older women demonstrate tumours with ER+ and 
lower histological grade and fall into this subgroup [20]. Luminal B tumours show 
lower expression of ER, they are more often of higher histological grade and have 
higher proliferation rates. As such patients with these tumours will have a worse 
prognosis when compared to patients having luminal A tumours [18] [22].  
 
The HER2 subtype demonstrates HER2 gene amplification and receptor 
overexpression. This subtype is amenable to therapies that target the HER2 receptor 
and often demonstrate aggressive clinical behaviour. Many patients have showed 
resistance after initiating treatment against HER2+ disease, thus, novel therapies are 
necessary to improve survival [18] [24]. The normal-like subtype, as the name 
suggests demonstrates similar expression patterns to normal breast adipose tissue [18]. 
The significance of this subtype is yet to be determined, and some researchers argue 
that it may represent a mere contamination of samples with normal breast tissue [18] 
[22] [24]. Thus, this subtype was not explored further in the current study. The basal 
subtype is positive for epidermal growth factor receptor (EGFR) expression and also 
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for expression of basal cytokeratins 5/6 and cytokeratins 14/17 [18] [26]. This group 
is negative for the expression of ER, progesterone receptor (PR) and HER2 related 
genes. Thus, this group is associated with triple negative breast cancers (TNBC) [26]. 
Further, basal breast cancers demonstrate high histological grade and high Ki67 [18]. 
Interestingly, a large proportion of BRCA1 associated breast cancers appear to have a 
basal molecular profile, suggesting a common pathway of carcinogenesis in patients 
with this molecular profile. In contrast a basal molecular profile might not necessarily 
incorporate BRCA mutations [22]. Further it has been shown that a higher frequency 
of younger premenopausal women will fall into the TNBC category [26].  
 
The claudin low subtype which is the latest molecular subtype identified, demonstrates 
the lack of expression of claudin proteins (claudin-3 and claudinin-4), which are 
important in cell to cell adhesion [24]. Around 25 - 39% of TNBCs fall into the claudin 
low subtype [26]. Due to inconsistent expression of cytokeratins and a significantly 
lower expression of Ki67 this subtype differs from the basal subtype [24]. Both basal 
and claudin low subtypes are not amenable to hormone therapy nor to therapy targeting 
the HER2 receptor. These 2 subtypes are biologically more aggressive and often have 
poor prognosis [24]. As such, it is especially important that novel therapeutic targets 
are developed for women with these tumours.  
 
Molecular testing in breast cancer is still evolving [22]. However, in order to 
understand the underlying biology of breast cancer, molecular gene expression 
profiling, has contributed immensely. Further, it has enabled characterisation of vital 
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genes and pathways that are deregulated in each subtype thereby identifying novel 
targets for therapeutic interventions and selection of patient populations that can be 
targeted with the potential for personalised treatment which otherwise is a challenge 
in breast cancer [18] [21]. Molecular characteristics of the breast cancer subtypes are 
summarised in the below table (Table 1.1). 
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Subtype
 
  
Immunoprofile Common 
histological 
grades and 
histological 
types 
Other 
characteristics 
Prognosis 
Luminal A
 
  
ER+, PR+/-, 
HER2- 
Grade 1/2, 
invasive 
ductal 
carcinoma, 
lobular, 
cribriform, 
mucinous 
Ki67 low, 
responsive to 
hormone therapy, 
often responsive to 
chemotherapy 
Good 
Luminal B
 
  
ER+, PR+/-, 
HER2+/- 
Grade 2/3, 
invasive 
ductal 
carcinoma, 
papillary 
Ki67 high, usually 
responsive to 
hormone therapy, 
variable to 
chemotherapy, 
might be 
responsive to 
therapies that target 
HER2 
Intermediate 
HER2 
  
ER-, PR-, HER2+ Grade 2/3, 
invasive 
ductal 
carcinoma, 
papillary  
Ki67 high, 
responsive to 
therapies that target 
HER2, responsive 
to chemotherapy 
Poor 
Basal  ER-, PR-, HER2- Grade 3, 
invasive 
ductal 
carcinoma, 
medullary 
Ki67 high, EGFR+, 
BRCA mutations 
shown, often 
responsive to 
chemotherapy  
Poor 
Claudin low ER-, PR-, HER2- Grade 3, 
invasive 
ductal 
carcinoma, 
medullary 
Ki67 lower than 
Basal subtype, 
intermediate 
response to 
chemotherapy 
Poor 
Table 1.1: Molecular characteristics of breast cancer subtypes [18] [22] [24] . 
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Table 1.2: Cell lines representing each of the breast cancer subtypes, HER receptor statuses, hormone receptor statuses and common 
genetic mutations associated with each cell line [24] [27] [28] [29].  
Subtype Cell line EGFR HER2 HER3 HER4 ER PR TP53 PTEN PIK3CA 
Luminal A MCF7 Very low 
expression 
Very low 
expression/
negative 
Moderate 
expression 
Moderate 
expression 
Positive Positive Wildtype Wildtype Mutant 
T47D Moderate 
expression 
Moderate 
expression 
Moderate 
expression 
Very low 
expression/
negative 
Positive Positive Mutant Wildtype Mutant 
Luminal B ZR-75-1 Moderate 
expression 
Very low 
expression/
negative 
Negative Negative Positive Negative Wildtype Mutant Wildtype 
HER2 SKBR3 Moderate 
expression 
Over 
expression 
Moderate 
expression 
Negative Negative Negative Mutant Wildtype Wildtype 
Basal MDA-MB 468 Over 
expression 
Negative Low 
expression 
Negative Negative Negative Mutant Mutant Wildtype 
Claudin low MDA-MB 231 Over 
expression 
Negative Moderate 
expression 
Negative Negative Negative Mutant Wildtype Wildtype 
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1.3.1 MCF7 cell line 
The MCF7 breast cancer cell line was derived from a pleural effusion taken from a 69 
year old female patient with metastatic invasive ductal carcinoma [27] [28]. MCF7 
cells as shown in table 1.2 belong to the luminal A subtype. These cells form tightly 
cohesive structures demonstrating robust cell to cell adhesions [24]. As these cells are 
ER+ and PR+ they are extensively used in studies aimed at analysing the mechanisms 
by which hormones and endocrine therapy affect cell proliferation and protein 
synthesis [27] [28]. Further, no overexpression of the HER family receptors are 
observed in this cell line [29].  
 
1.3.2  T47D cell line 
 ✁✂  ✄☎✆ ✝✂✞✞ ✞✟✠✂ ✡☛☞ ✟☞✌✞☛✍✂✎ ✏✑✌✒ ☛ ✓✄ ✔✂☛✑ ✌✞✎ ✏✂✒☛✞✂ ✕☛✍✟✂✠✍✖☞ ✕✞✂✗✑☛✞ ✂✏✏✗☞✟✌✠
having invasive ductal carcinoma [27]. This cell line is also categorised under Luminal 
A subtype and displays epithelial morphology and demonstrates tightly cohesive 
structures like the MCF7 cell line [24]. Further, it has been shown that these cells 
demonstrate enhanced ER levels than MCF7 cells [30]. Furthermore, T47D cells 
express all 4 members of the HER receptor family, but none of the receptors are found 
to be overexpressed as shown in the above table (Table 1.2). However, when compared 
to the MCF7 cell line, once again this cell line expresses more EGFR levels and HER2 
levels [29].  
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1.3.3  ZR-75-1 cell line 
The ZR-75-1 cell line is derived from a 63 year old female ✁ ✂✁✄☎✆✝✁ ✞✟✠☎✡ with invasive 
ductal carcinoma [27]. This cell line has been reported to be categorised under luminal 
B subtype, however some researchers have categorised this cell line under luminal A 
subtype which is controversial [24] [31]. ZR-75-1 cells exhibit an epithelial 
morphology and they grow as fused colonies [32].  
 
1.3.4  SKBR3 cell line 
The SKBR3 cell line was isolated from a pleural effusion from an adenocarcinoma of 
the breast of a 43 year old female patient [27]. These cells are epithelial and found to 
form loosely cohesive grape like structures [24]. Previous studies have shown that 
SKBR3 cells show low levels of EGFR compared to the amount of HER2 levels they 
express as these cells overexpress HER2 [31]. SKBR3 cancer cell are found to express 
between 1,000,000 and 2,000,000 HER2 receptors per cell compared to normal cells 
that express ~ 20,000 HER2 receptors [33]. 
 
1.3.5  MDA-MB 468 cell line 
This cell line was first isolated from the pleural effusion of a metastatic breast 
adenocarcinoma from a 51 year old female [27]. These cells possess an epithelial 
morphology and form a loosely cohesive grape like structure. They are also consistent 
with a more invasive phenotype [24]. This cell line is reported to be TNBC that is - 
ER-, PR- and HER2- [27]. MDA-MB 468 cells overexpress EGFR, expressing 
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between 1,300,000 and 2,000,000 EGF binding sites per cell compared to normal cells 
that express ~ between 10,000 and 100,000 receptors per cell [34] [35] [36]. Although 
these cells overexpress EGFR they do not express detectable levels of HER2 [31]. 
 
1.3.6  MDA-MB 231 cell line 
MDA-MB 231 cells were obtained from a 51 year old female. These cells were 
isolated from a pleural effusion of a metastatic breast adenocarcinoma. MDA-MB 231 
cells appear phenotypically as a stellate structure and they are also TNBC [24] [27]. 
This cell line represents the claudin low breast cancer subtype which demonstrates 
highly invasive characteristics with poor prognosis [24] [27]. These cells overexpress 
EGFR but the levels are not as high as in MDA-MB 468 cells. MDA-MB 231 cells 
express ~ 130,000 EGF binding sites per cell and HER2 receptors are undetectable in 
these cells [31] [35].  
 
Evidence demonstrates that carcinogenesis is a multistep process [37]. This process 
involves the activation or modification of expression in growth promoting oncogenes 
or the loss of activation of growth regulatory tumour suppressor genes or a 
combination of these pathogenic events [37]. These cancer gene mutations might 
occur in the germline leading to hereditary predispositions to breast cancer or in single 
somatic cells leading sporadic breast cancer. Ultimately these mutations enhance cell 
growth which drives normal cells to a neoplastic state by acquiring many biological 
capabilities during this multistep process [37] [38].  
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1.4.1  Self-sufficiency in growth signals 
Proliferation of normal cells occur only when supplied with appropriate mitogenic 
growth factors/growth signals [37]. These growth signals are transmitted via 
transmembrane receptors that bind to specific classes of signalling molecules which 
enable normal cells to proliferate; usually such signal transduction is strictly regulated 
[37]. These normal cells are unable to proliferate in the absence of mitogenic growth 
stimulatory signals. In contrast, tumour cells, invariably show a greatly reduced 
dependence on exogenous mitogenic growth factors/growth signals. Tumour cells are 
able to generate many of their own mitogenic growth stimulatory signals, which 
results in reduced dependence on stimulation from their normal tissue 
microenvironment [37] [39]. Further in cancer, growth factor receptors are often 
overexpressed and this overexpression of receptors enables cells to be hyperresponsive 
to growth factor signalling, leading to sustained proliferation. Furthermore, receptors 
may demonstrate ligand independent signalling via structural modifications of 
receptors [37] [39].   
 
1.4.2  Insensitivity to growth inhibitory signals  
Numerous anti-proliferative signals operate to maintain cellular quiescence and tissue 
homeostasis within normal cells [37]. These signals are growth inhibitors, inhibitors 
embedded in the extracellular matrix and on the surfaces of surrounding cells [37]. 
These inhibitors act on the cell cycle (Figure 1.2) by forcing cells out of the active 
proliferation into the quiescent (G0) state which usually involves terminal 
differentiation of the cell [37]. In contrast, cancer cells are able to escape these anti-
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proliferative signals by mutations and hence inactivation of tumour suppressor genes 
[39]. A few main examples of such mutated tumour suppressor genes are 
retinoblastoma (Rb) and TP53 genes [39]. It has been shown that the Rb protein plays 
a major role in the G1 checkpoint where it blocks S phase entry and cell growth by 
promoting cell cycle exit [40]. However, cancer cells with mutations in the Rb gene 
may not control entry into the cell cycle permitting continuous cell proliferation [40] 
[41]. TP53 determines whether the cell cycle should progress, halt or whether the cell 
should undergo apoptosis [40] [41]. Around 50% of human cancers demonstrate 
mutations in the TP53 gene and if the cancer cells possess mutated TP53 then cells 
may demonstrate aberrant cell cycle progression [37] [39] [40]. Further, this becomes 
important in the face of DNA damage as the TP53 protein evokes cell cycle arrest in 
response to DNA damage to allow DNA repair. However, when TP53 is mutated, 
DNA repair is inhibited which results in propagation of genetic errors that will lead to 
cancer [18].  
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Figure 1.2: The mammalian cell cycle. Figure adapted from [42]. G0 phase - The 
phase where the cell has left the cell cycle and in a resting phase. Gap 1 (G1) phase - 
Cells increase in size preparing for DNA synthesis in G1. The G1 checkpoint ensures 
that all conditions are favourable for cell division to proceed in the synthesis (S) phase. 
S phase - DNA synthesis occurs in the S phase. Gap 2 (G2) phase - The cells will 
continue to grow and at the end of the G2 phase the G2 checkpoint ensures whether 
the cell can proceed into the mitosis phase and divide. Mitosis (M) phase- Cell growth 
stops and the M checkpoint ensures that the cell is ready to complete cell division. 
Cyclins and cyclin-dependent kinase (CDKs) complexes are shown to regulate the 
progression through the cell cycle. For instance, cyclin D1 is required for progression 
through G1 phase. Cyclin D1 is a regulatory subunit of CDK4 and CDK6. Thus, cyclin 
D1 dimerises with CDK4 and CDK6 to regulate the G1/S phase transition and entry 
into the S phase. Following anti-proliferative signals or DNA damage, p21cip1 and 
p27kip1 which are cyclin-dependent kinase inhibitors are shown to bind to cyclin-CDK 
complexes to induce cell cycle arrest [40].  
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1.4.3  Evading apoptosis 
Apoptosis is a form of programmed cell death by which cells undergo death in the 
event of DNA damage [37]. Cancer cells in contrast can bypass this mechanism by 
acquiring resistance to apoptosis. During the course of tumorigenesis or as a result of 
anti-cancer therapy, apoptosis is triggered in response to various physiological stresses 
in cancer cells [37]. Based on the source of stress signals received apoptosis can be 
triggered via the extrinsic apoptotic pathway where signals are received extracellularly 
or the intrinsic apoptotic pathway where the signals are received intracellularly [39]. 
Regardless of the initial source of the signals the apoptotic pathways culminate by 
caspase activation which proceeds to initiate a cascade of proteolysis involving 
effector caspases responsible for the execution phase of apoptosis, in which the cell is 
gradually broken down and then consumed, both by its nearby cells and by phagocytic 
cells. It has been shown that the apoptotic process is regulated by counterbalancing 
pro and anti-apoptotic members of the B-cell lymphoma 2 (Bcl-2) family [39]. In 
cancer, expression of anti-apoptotic regulators are increased by down-regulating pro-
apoptotic factors and also by short circuiting the apoptotic pathways which allows 
cancer cells to evade apoptotic mechanisms. Further, TP53 also plays a role in evoking 
apoptosis in response to damage of DNA. However, in cancer, the loss of TP53 tumour 
suppressor function eliminates critical DNA damage sensors from the apoptosis 
inducing circuitry, leading to tumour progression [37]. Additionally hyper-expression 
of oncogenes such as RAS or loss of expression of tumour suppressor genes such as 
phosphatase and tensin homolog (PTEN), up-regulates the phosphatidylinositol-3-OH 
kinase (PI3K)/AKT8 virus oncogene cellular homolog (AKT) pathway which is likely 
to be involved in mitigating apoptosis in cancer cells [37]. The multiplicity of 
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apoptosis evading mechanisms demonstrates the selective pressure overriding 
apoptosis during the multistage carcinogenesis [37] [39].  
 
1.4.4  Limitless replication potential 
Passing through successive cell growth and division cycles are limited for normal 
cells. This limitation has been associated with senescence [37] [39]. Senescence is an 
irreversible entry into a nonproliferative state where the cells are still viable that 
ultimately involves cell death. In contrast, cancer cells require unlimited replicative 
potential in order to generate macroscopic tumours. In cell culture, cancerous cells are 
immortalised, a characteristic that most established cell lines retain with the ability to 
proliferate in culture without evidence of either senescence or apoptosis [39]. 
Unlimited proliferation in cells has been shown to be associated with telomerase 
activity [39]. In normal cells the length of telomeric DNA is shortened during each 
cell cycle leading to senescence and ultimately cell death. However, 85 - 90% of 
cancers portray up-regulation of telomerase, the specialised DNA polymerase that 
maintains telomeric DNA which leads to limitless replication [37] [39].  
 
1.4.5  Sustained angiogenesis 
Cancerous cells require a high amount of nutrients and oxygen as well as an ability to 
evacuate metabolic wastes and CO2 [39]. This is because of the enhanced levels of 
proliferation and continuous replication potential, cancer cells demonstrate that leads 
to increased angiogenesis. Angiogenesis is the development of new blood vessels from 
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existing blood vessels. During tumour development and progression, an  angiogenic 
✁✂✄☎✆✝✞ ✄✁ triggered and remains switched on, which drives continual development of 
new blood vessels which will assist in sustaining and expanding neoplastic growth 
[39]. Many tumours show increased expression of vascular endothelial growth factor 
(VEGF) as a result of hypoxia and oncogene signalling which in turn stimulates 
angiogenesis [39]. Further, an angiogenesis inhibitor thrombospondin-1 has been 
found to be regulated by TP53. Loss of TP53 causes reduction of thrombospondin-1 
levels and ultimately allows increased angiogenesis in cancer cells [37].  
 
1.4.6  Tissue invasion and metastasis 
Cancer cells are able to escape from the primary tumour by invading surrounding 
tissues and travelling to distant sites where they may succeed in developing new 
colonies [37] [39]. These newly formed colonies are able to form metastases which 
has shown to be the cause for > 90% of human cancer deaths [39]. Metastasis is the 
last step in multistep primary tumour progression [39]. The loss of E-cadherin which 
is a cell to cell adhesion molecule in carcinoma cells is associated with invasion and 
metastasis. Down-regulation or inactivation of E-cadherin by mutations is shown to 
be strongly associated with invasion and metastasis in cancer [37] [39]. Cancer cells 
in the course of invasion and metastasis is able to activate epithelial mesenchymal 
transition (EMT). This is a process by which transformed epithelial cells lose their cell 
polarity and cell to cell adhesion, and gain migratory and invasive properties thereby 
become mesenchymal stem cells. These cells are recruited to distant sites via the 
cardiovascular and lymphatic system and reverted back to form epithelial tissues.  
Metastasis can be categorised into 2 major phases - cancer cells being disseminated 
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from the primary tumour to distant tissues and the adaptation of these cancer cells 
from micrometastases into macroscopic tumours. However, in some patients including 
in breast cancer patients these micrometastases which have disseminated stay dormant 
for long periods of time and never progress to macroscopic metastatic tumours. This 
is because of suppressor factors released by the primary tumour. For instance, it has 
been shown that in patients with breast cancer, brain metastasis can stay dormant for 
a long period and appear years after diagnosis of the primary tumour [39].  
 
1.4.7  Emerging hallmarks and enabling characteristics 
 ✁✂✄☎ ✆✝✞✝✟✝✞ ✝✞✠ ✡✄☛✞☞✄☎✌✍✎ ✎✄✏☛✞✝✑ ✝☎✂☛✒✑✄ ☛✞ ✓✔✔✔ with the 6 notable hallmarks 
of cancer, 2 additional emerging hallmarks were introduced in 2011 [39]. These are 
reprogramming energy metabolism and evading immune destruction. Further, 2 
additional enabling characteristics were also introduced, which are genome instability 
and mutation and tumour promoting inflammation [39].  
 
Cancer cells are able to reprogramme energy metabolism by modifying cellular 
metabolism to support cancer cell proliferation. Cancer cells can reprogramme to 
select glycolysis as the metabolic program over mitochondrial oxidative 
phosphorylation, even in the presence of oxygen. Glycolysis has been shown to be 
associated with mutant tumour suppressor genes such as TP53 and activated 
oncogenes such as RAS where alterations in cancerous cells have been selected 
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It has been found that HER receptors play a role in mammary gland development 
during menarche, pregnancy and also in postnatal mammary development [49]. EGFR 
has shown to promote ductal growth in the mammary gland development whereas 
HER2 and HER4 play a major part in lobuloalveolar differentiation and lactation 
during pregnancy [51]. HER3 is also expressed and active during pregnancy. In 
contrast HER4 is down-regulated and inactivated which is shown to be important 
during the latter stages of pregnancy and to sustain lactation. Further, HER3/HER4 
heterodimers have also demonstrated a role in proliferation and differentiation both in 
pregnancy and after childbirth [51]. Overall, HER family members possess a variety 
of functions at multiple stages in the development of the mammary gland. Thus, it is 
likely that both expression and activity of the HER receptors in the endogenous 
mammary epithelium, sets the stage for the selection of precancerous cells in which 
HER receptor activity is overexpressed [52].  
 
As outlined in section 1.4, overexpression of growth factor receptors is a hallmark of 
oncogenesis [37]. This overexpression of receptors enables cells to be hyperresponsive 
to growth factor signalling leading to sustained proliferation [37] [39]. Many types of 
human cancers including breast cancer have shown overexpression of HER receptors, 
which is correlated to deregulation of HER signalling [49] [51]. Thus, the role of HER 
receptors in cancer has been studied extensively in the recent past [52]. Especially, 
EGFR and HER2 has shown to have important roles in the development of breast 
cancer [52]. 
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1.5.1  EGFR 
EGFR is a 170 kDa plasma membrane glycoprotein which is encoded by the EGFR 
gene on chromosome 7 and there are several homologous ligands that can bind 
specifically to EGFR [36]. These ligands include EGF, transforming growth factor-
alpha (TGF-✁  ✂✄☎ ✂✆✝✞✟✠✡☛☞✌✟n (AR) that binds specifically to EGFR while heparin-
binding EGF (HB-EGF), epiregulin and betacellulin binds to EGFR and HER4 
demonstrating dual specificity [46] [53]. EGFR, most widely expressed in epithelial 
and mesenchymal cells, plays an important role in growth and differentiation including 
in the mammary gland as outlined above [52]. It has been shown that around 14 - 91% 
of human breast cancers express EGFR [53]. The role of EGFR in breast cancer 
biology has been a subject of intense study and controversy, thus, more studies are 
warranted to understand the function of EGFR [48]. For instance, EGFR expression 
has been associated with poor prognosis along with high histological grade and lymph 
node involvement, and controversies exist between EGFR expression and survival in 
breast cancer [36] [48]. Further, EGFR overexpression is commonly expressed in 
TNBC (basal and claudin low subtypes) [36] [51]. Breast cancer patients harbouring 
TNBCs fail to respond to endocrine therapy [51]. Hence, EGFR is a vital target for 
anti-cancer therapy for this category of patients.  
 
1.5.2  HER2 
The second member of the HER family which is HER2 is a 185 kDa transmembrane 
protein encoded on chromosome 17 [36]. A mutation (G to A polymorphism) at amino 
acid codon 655 of the HER2 gene alters the structure of the receptor transmembrane 
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domain leading to active HER2 homodimers which ultimately results in continuous 
uncontrolled growth [36] [48] [54]. This genetic mutation is associated with the risk 
of breast cancer [36]. Gene amplification or overexpression of the HER2 receptor is 
found approximately in 9 - 39% of breast cancers [44] [53]. Further, HER2 
overexpression is shown to be correlated with an aggressive phenotype of breast 
cancer with increased rates of recurrence and poorer survival especially in patients 
with node+ breast cancer [36] [48] [51]. Furthermore, HER2 gene amplification and 
protein overexpression have most often been associated with a high cellular 
proliferation rate, negative receptors for oestrogen and progesterone and also TP53 
mutation, which is linked to metastatic occurrences of breast cancer [51]. As outlined 
before HER2 is a unique member of the HER family because no known ligand is 
bound to HER2 with high affinity  [36] [49]. Nevertheless, HER2 is able to act as a 
co-receptor with high affinity for other HER receptors of the family and is the 
preferred heterodimeric partner [49]. It has been portrayed that homo and 
heterodimerisation leads to the activation of the HER signalling network and 
heterodimers are more potent and mitogenic [49]. Heterodimerisation is shown to 
provide additional phosphotyrosine residues for the recruitment of binding partners 
which is responsible for strong and prolonged activation of downstream signalling 
pathways [46] [49]. Moreover, co-expression of HER2 with EGFR and also HER2 
with HER3 has been shown to depict an aggressive phenotype compared with the 
expression of a single HER protein in many carcinomas including breast cancer [49] 
[53]. Thus, HER2 needs to be considered as an ideal therapeutic target [55]. 
Monoclonal antibodies directed against HER2 and small molecule tyrosine kinase 
inhibitors (TKIs) that compete with the ATP pocket in the tyrosine kinase domain of 
the receptor are used currently in the clinic as HER2 inhibitors against breast cancer 
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[55]. Nevertheless, many patients with HER2+ metastatic breast cancer demonstrate 
acquired resistance to these HER2 inhibitors and this remains a major challenge to 
successful treatment. In this regard additional studies are indeed necessary to 
determine novel therapeutics and also to retool existing clinical agents which will 
expand the treatment options available [55]. Furthermore, concurrent blockade of 
several HER receptors such as EGFR, HER2 and HER3 might result in more 
significant anti-cancer effects compared with treatment with agents that block a single 
receptor [53].  
 
1.5.3  HER3 
The HER3 gene, located on chromosome 12 encodes a 180 kDa glycoprotein [48] [56]. 
HER3 overexpression is found to be associated with poor prognosis in breast cancer 
and around 22 - 90% of breast cancers overexpress HER3 [53] [57]. HER3 
overexpression is often co-expressed with overexpression of EGFR and HER2 [48] 
[57]. NRG1 binds to HER3 with high affinity [56]. HER3 signalling relies on the 
formation of heterodimers with other HER family members because HER3 receptor 
has no intrinsic kinase activity [57]. Even though it is kinase defective, HER3 can be 
phosphorylated by other receptors such as HER2 [52]. HER2/HER3 has been shown 
to be the most potent mitogenic heterodimer compared to EGFR/HER2 in HER2+ 
breast cancer [49] [57]. Thus, many studies have shown that HER3 plays a role in 
HER2 mediated breast carcinogenesis, as HER3 is commonly co-expressed with 
HER2 in breast cancer [56] [57]. In this regard, it has been revealed that the efficacy 
of anti-HER2 therapeutics is related to HER3 inhibition in breast cancer and 
reactivation of HER3 is reported to contribute significantly to acquired resistance to 
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these anti-cancer therapies [52] [57]. Furthermore among all HER receptors, when 
HER3 is phosphorylated it has been shown to have the highest affinity for PI3K and 
results in a strong activation of the PI3K/AKT signalling pathway promoting cell 
survival [48] [52] [56] [57]. Thus, HER3 is likely to become increasingly a centre of 
attention for breast cancer therapeutics. 
 
1.5.4  HER4 
HER4 is a 180 kDa transmembrane glycoprotein which is encoded by chromosome 2 
[36] [56]. The encoded protein can be activated by both NRGs and ligands of the EGF 
family including HB-EGF, epiregulin and betacellulin. In contrast to the other HER 
receptors, overexpression of HER4 has been associated with well differentiated 
tumours [53] [58]. Thus, HER4 expression is shown to be a favourable prognostic 
factor with increased survival [36] [51] [58]. Around 58 - 82% of breast cancers 
overexpress HER4 [53] [58]. Further, HER4 expression has been correlated with ER+ 
status [58]. Although HER4 has been most often associated with better survival, a few 
reports have shown no association with survival while some with poor survival in 
breast cancer [48] [58]. This may be due to co-expression of 2 or more members of 
the HER family which is shown to be associated with an adverse effect on breast 
cancer prognosis [58]. Thus, these details may suggest that the combined profile 
expression patterns of the HER receptor family members may provide more precise 
information on the breast tumour behaviour than studying the expression of each 
receptor individually [58]. 
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which are adaptor proteins then bind to the phosphotyrosine residues of the activated 
receptor. Subsequently, GRB2 then bind to son of sevenless (SOS) which is a guanyl 
nucleotide-release protein [63]. When the GRB2-SOS complex docks to the 
phosphorylated receptor, SOS becomes activated. Activated SOS causes the small G 
protein RAS to release GDP and exchange it for GTP. When RAS has GTP bound to 
it, it becomes active [47]. RAS is a sub family of H-RAS, N-RAS and K-RAS [62]. It 
has been revealed that the oncogenic mutations of these human RAS genes are 
uncommon in breast cancer with a low frequency of < 2% of RAS mutations [64]. 
Activation of RAS leads to the activation of the mitogen activated protein kinase 
kinase kinases (MAPKKK) (RAF). RAF is a sub family of A-RAF, B-RAF and RAF-
1 [62]. RAF-1 is also known as C-RAF [62]. C-RAF is mainly found to activate 
mitogen activated protein kinase kinases (MAPKK)/MAPK/ERK kinase (MEK1/2) 
[62]. Activated MEK1/2 then phosphorylates and activates MAPK, also known as 
ERK1/2 respectively [47] [63]. This pathway subsequently results in the enhanced 
transcription of the anti-apoptotic survival factors such as Bcl-2 family members 
thereby promoting cell survival in cancer [47] [63].  
 
The SAPK/JNK pathway plays a critical role in physiological processes such as 
cellular proliferation, differentiation, apoptosis and survival in response to many types 
of stresses including UV irradiation, growth factors, toxins and cytokines [65] [66]. 
JNKs are part of a 3 kinase signalling pathway. Activation of JNK are mediated by 
MAPKKK, MAPKK and MAPK though sequential protein phosphorylation [66]. 
MAPKKK, typically known as MEKK1   MEKK4 phosphorylates and activates 
MKK4 and MKK7. Upon activation MKK4 and MKK7 activate JNKs (JNK1 - 3) 
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where tyrosine and threonine residues are sequentially phosphorylated in living cells 
[65]. Activated SAPK/JNK translocates to the nucleus and regulates a diverse set of 
responses such as induction of apoptosis and enhancing cell survival according to the 
stimuli, the strength and duration of JNK activation. SAPK/JNK dysregulation has 
been implicated in cancer. Although the role of SAPK/JNK has been known the 
underlying mechanism in which this role is established remains controversial [65] 
[66].  
 
The p38 pathway is also activated by environmental stress responses similar to the 
SAPK/JNK pathway [62]. MAPKKKs- MEKK1 - MEKK4 are shown to 
phosphorylate downstream MKK3 and MKK6 which ultimately phosphorylates the 
p38 isoforms (✁  ✂  ✄ ☎✆✝ ✞)  [67]. Further, it has been shown that MKK4, the upstream 
✟✠✆☎✡☛ ☞✌ ✍✎✏✑✒✓✔✑  ☎✡✡✠✡✕✡ ✠✆ ✕✖☛ ☎✗✕✠✘☎✕✠☞✆ ☞✌ ✙✚✛✁ ☎✆✝ ✙✚✛✞ ✠✆ ✡✙☛✗✠✌✠✗ ✗☛✜✜ ✕✢✙☛✡ 
[62] [67]. In fact, overexpression of MAPKKKs results in the co-activation of both 
p38 and JNK pathways [67].  The downstream signalling of p38 is quite divergent and 
coordinates cellular processes such as apoptosis, cell cycle progression, growth and 
differentiation according to specific cell types [62]. Thus, it is evident that all 3 MAPK 
pathways (ERK, SAPK/JNK and p38) are regulated by cross cascade interactions and 
loss of control ultimately promotes tumourigenesis (Figure 1.5).  
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different isoforms ( ✁✁✂✄☎  ✁✁✂✆☎  ✁✁✂✝☎ ✞✟✠  ✁✁✂✡☛ [70] [71]. The PIK3CA gene, 
☞✌✍✎✌ ✏✟✎✑✠✏✒ ✓✌✏  ✁✁✂✄ ✍✒✑✔✑✕✖ ✒✌✑☞✒ ✞ ✌✍✗✌ level (18 - 32.5%) of mutations in 
breast cancer [72] [73]. Activation of PI3K catalyses the transfer of a phosphate group 
✔✕✑✖ ✘✙✚ ✓✑  ✌✑✒ ✌✞✓✍✠✛✜✍✟✑✒✍✓✑✜ ✗✏✟✏✕✞✓✍✟✗ ✞ ✢✣-phosphatidylinositol phosphate 
(PIP) 2 [47]. PI3K then phosphorylates PIP2 to produce PIP3 [69]. PIP3 is a second 
messenger that promotes the translocation of AKT to the cell membrane. PTEN 
dephosphorylates and reduces PIP3 to PIP2, thereby reversing the action of PI3K [69]. 
Interestingly, around 30% of breast cancer tumours show PTEN mutations with low 
or loss of PTEN activity that increases EGF mediated AKT activation and cell survival 
[47] [74]. Membrane translocated AKT is phosphorylated and activated by 
phosphoinositide dependent kinase 1 (PDK1) [69]. PDK1 is found to phosphorylate 
AKT on threonine at position 308 (Thr308). This in turn phosphorylates and 
inactivates the tumour suppressor complex comprising the tuberous sclerosis complex 
1/2 (TSC1 and TSC2), resulting in the activation of mTORC1 by Rheb-GTP [69]. Full 
activation of AKT occurs only following an additional phosphorylation, on serine at 
position 473 (Ser473) which is mediated by the downstream, mTOR complex 2 
(mTORC2) of the mTOR pathway [69]. Activated AKT then translocates to the 
cytoplasm and the nucleus after dissociating from the membrane where it 
phosphorylates multiple proteins involved in cell proliferation and survival [69]. Some 
of these proteins are members of the Bcl-2 family, glycogen synthase kinase (GSK)-
✢✆ and MKK4 [47]. GSK-✢✆ ✍✒ ✞ ✠✑☞✟✒✓✕✏✞✖ ✓✞✕✗✏✓ ✔✑✕ ✘✤✙  ✌✑✒ ✌✑✕✛✜✞✓✍✑✟✥ ✦✓ ✌✞✒
been shown that phosphorylation of AKT inactivates GSK-✢✆ ✧✍✟✞✒✏ ✞✎✓✍★✍✓✛ by 
blocking transcription and regulation of metabolism. This inactivation of GSK-✢✆, in 
turn protects cells from apoptosis. However, the exact mechanism is yet to be 
determined [47]. Interestingly, it has been demonstrated that AKT phosphorylation 
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inhibits MKK4 activity of the SAPK/JNK pathway portraying cross talk between 
pathways [47]. This inhibition prevents activation of JNK which is found to mediate 
apoptosis in certain cells [47]. 
 
Much evidence reveals the importance of the PI3K/AKT pathway in determining 
sensitivity and resistance of tumour cells with overexpressed HER receptors such as 
HER2 or tumours with mutated PTEN to targeted inhibitors [71]. The PI3K/AKT 
pathway is disrupted in many types of cancers including breast cancer. It has been 
found that breast cancers that overexpresses the HER2 receptor maintain high PI3K 
activity and that HER2 achieves high PI3K activity via HER3 [71]. Further, breast 
cancer tumours that overexpress HER2 is shown to up-regulate another receptor, c-
MET in varying degrees. c-MET and its ligand hepatocyte growth factor (HGF) is 
shown to be up-regulated in breast tumours resulting in activation of PI3K/AKT 
pathway [71] [75]. In addition PI3K is also shown to cross talk between the 
RAS/MAPK pathway since PI3K is found to activate RAS and vice versa leading to 
increased cell survival in cancer [47] [72] (Figure 1.6).   
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Figure 1.6: The PI3K/AKT pathway. Upon growth factor binding, the receptor 
activates PI3K which converts PIP2 to PIP3. AKT is then activated following 
recruitment to the cell surface by PIP3 and acts downstream of PI3K which controls 
cellular processes such as cell survival. mTOR is one of the key proteins within the 
signalling cascade which acts both upstream and downstream of AKT. Figure adapted 
from [76].  
 
 
1.6.3 mTOR pathway 
mTOR is a central regulator of cell growth proliferation and survival. mTOR resides 
in 2 distinct multi protein complexes, mTOR complex 1 (mTORC1) and mTORC2 
[74] [77]. mTORC1 plays a major role in controlling protein synthesis. When PDK1 
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in the PI3K/AKT pathway activates AKT, this in turn inactivates TSC1/2 leading to 
activation of mTORC1 by Rheb-GTP [77] [78]. As PTEN negatively regulates the 
PI3K/AKT pathway, the loss of PTEN activity increases AKT activity, which thereby 
increases mTORC1 signalling [78]. As a result, eukaryotic initiation factor 4E (eIF4E) 
binding protein 1 (4E-BP1) and phosphorylation of 70-kDa ribosomal S6 kinase 1 
(p70S6K1) are phosphorylated by mTORC1 which in turn promotes protein synthesis 
[74] [77]. The phosphorylation of 4E-BP1 prevents its binding to eIF4E, enabling 
eIF4E to interact with the scaffold protein eIF4G permitting assembly of the eIF4F 
complex which will promote cap dependent translation [78]. The second important 
target of mTOR is p70S6K1. Activation of p70S6K1 results in increased messenger 
RNA (mRNA) translation including translation of mRNAs that encode for ribosomal 
proteins, elongation factors and insulin growth factors [79]. mTORC2 which was more 
recently discovered, promotes cellular survival by phosphorylating AKT serine at 
position 473 (Ser473) which is required for maximal activation of AKT of the 
PI3K/AKT pathway as outlined before [77]. A further layer of complexity is added on 
to this pathway by the negative feedback loop from the mTOR-p70S6K1 pathway to 
the upstream insulin receptor substrate pathway. Activation of mTORC1 and 
p70S6K1 controls the insulin receptor substrate pathway through direct 
phosphorylation on specific residues which prevent its recruitment and binding to 
receptor tyrosine kinases resulting in a negative feedback regulation in PI3K/AKT and 
RAS/MAPK pathways. Thus, in human cancer direct inhibition of mTORC1 by anti-
cancer agents relieves this negative feedback loop by paradoxically activating AKT. 
Further, inhibition of mTORC1 may also lead to the activation of ERK1/2 of the 
RAS/MAPK pathway [78]. Interestingly, eIF4E is also shown to be a target of the 
RAS/MAPK pathway. It is shown that ERK1/2 and p38 phosphorylates MAP kinase 
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interacting kinase 1 (MNK1) and MAP kinase interacting kinase 2 (MNK2) in 
response to multiple extracellular stimuli. Subsequently, MNK1 and MNK2 
phosphorylate serine 209 of eIF4E within the eIF4F complex [78] [80]. Thus, MNKs 
play an important role in controlling cap dependent translation [80]. The existence of 
these negative feedback loops and cross talk between signalling pathways add 
complexity and promote cell survival in cancer [69] [77] (Figure 1.7).  
 
 
Figure 1.7: The mTOR pathway. mTOR forms complexes with mTORC1 (Raptor) 
or mTORC2 (Rictor). Activation of the PI3K/AKT pathway leads to mTORC1 
activation. AKT is pivotal in mTOR signalling, since it is both an upstream activator 
of mTORC1 and downstream effector of mTORC2. Figure adapted from  [81].  
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1.6.4 JAK/STAT pathway 
EGF also initiates the JAK/STAT pathway which has been implicated in cancer [47]. 
JAK activation triggers cell proliferation, differentiation, migration and apoptosis 
[82]. STATs comprise a family of 7 structurally and functionally related proteins - 
STAT1 - 4, 5A, 5B and 6 and JAKs represent a family of 4 non receptor tyrosine 
kinases - JAK1 - 3 and tyrosine kinase 2 [47]. Upon ligand binding conformational 
changes are produced in receptors that alters the alignment of receptor associated 
JAKs, which allows phosphorylation of particular tyrosine residues that converts 
inactive JAKs into catalytically active tyrosine kinases [82]. Subsequently, active 
JAKs phosphorylate tyrosine residues in the cytoplasmic region of the receptor 
creating binding sites that recruit STATs [82]. STATs are latent proteins that reside in 
the cytoplasm until activated. STATs can homodimerise or heterodimerise with other 
types of STAT molecules [82]. Upon dimerisation, STAT proteins are translocated to 
the nucleus where they activate gene transcription that promotes cellular proliferation, 
differentiation and survival [82] [83]. Generally cancer cells demonstrate persistent 
activation of STATs which can contribute to malignancy [84]. Interestingly, in normal 
cells, STAT5 (both STAT5A and STAT5B) promotes terminal differentiation of 
mammary epithelial cells necessary for lactation [84]. Further, prolactin a hormone 
which stimulates lactation during pregnancy induces STAT5 activity through JAK2. 
However, JAK2/STAT5 has shown controversial activity in breast cancer. Restoring 
prolactin receptor expression in TNBC cell lines, has been shown to decrease the 
invasive capacity of the tumours. In contrast, blocking JAK2/STAT5 activity in 
luminal breast cancer cell lines increases invasiveness, suggesting that prolactin 
activation of STAT5 restricts the metastatic potential of TNBC [84]. Taken together 
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1.6.5 ER pathway 
Oestrogen plays a major role in the mammary gland by initiating growth, 
development, reproduction, and maintenance. Oestrogen also plays a role in breast 
cancer development and progression [86]. Binding of oestrogen to ER, induces 
receptor phosphorylation, modifies its confirmation and triggers receptor dimerisation 
[60]. Subsequently, the ligand activated ER translocates to the nucleus and stimulates 
gene transcription [86]. These transcriptional effects of the ER are modulated by 
interactions with coregulatory proteins that function as either coactivators or 
corepressors [60]. The transcriptional outcome of ER is controlled by dynamic 
chromatin modifications of the histone tails, and ligand bound ER facilitates these 
modifications via recruitment of coregulatory proteins [86]. For instance, coactivators 
such as steroid receptor coactivator 1 (Src)1 and amplified in breast cancer 
(AIB1/Src3) have been demonstrated to possess histone acetyltransferase activity 
which is favoured by the altered confirmation of ER that increases gene expression. 
In contrast, corepressors are associated with histone deacetylases [60] [86]. 
Interestingly, each coregulatory protein does not perform an overlapping function in 
vivo. However, in cancer, expression of coregulatory proteins is distinct from normal 
tissue and their functions are altered resulting in tumour progression [86]. For instance, 
coactivators such as Srcs exhibit elevated expression in breast cancer and they are 
known to play a role in the development of breast cancer [87] [88]. Furthermore, ER 
has shown to function as a coactivator protein itself by binding to other transcription 
factors and recruiting acetyltransferase activity [87]. ER localised outside the nucleus, 
on the cell membrane and within the cytoplasm is involved in activating receptor 
tyrosine kinases, such as EGFR, HER2 and also PI3K/AKT and RAS/MAPK 
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pathways demonstrating cross talk between signalling pathways. This process 
involves activation of Srcs and matrix metalloproteinases (MMP) which helps to 
activate the HER networking cascades. This provides another mechanism for the 
growth promoting effects of oestrogen, which in turn may contribute to hormonal 
therapy resistance in breast cancer [60] [87] [89] (Figure 1.9).  
 
 
 
Figure 1.9: The ER pathway. Oestrogen which is shown as E2 in the diagram 
phosphorylates (which is shown by P) nuclear ER and dimerises the receptor, that 
promotes gene transcription. Membrane bound ER and cytosolic ER are also activated 
by oestrogen which in turn interacts with signalling molecules such as Src that 
mediates signalling via RAS/MAPK and PI3K/AKT cascades. Figure adapted from 
[90].  
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1.6.6 AhR pathway 
AhR is highly expressed in the breast [91]. It is a ligand activated transcription factor 
that induces expression of genes encoding drug metabolising enzymes, such as 
cytochrome p450 (CYP) - CYP1A1, CYP1A2 and CYP1B1 [92]. AhR is shown to 
have a physiological function by detoxification of environmental pollutants [93]. AhR 
was first discovered as the receptor that binds to 2,3,7,8✄tetrachlorodibenzo-p-dioxin 
(TCDD) with high affinity; which is described as a tumour promoter  [91] [92]. It has 
been shown that when TCDD is bound to AhR; it is capable of sustaining 
hyperactivation, resulting in a number of toxicological outcomes such as liver and skin 
carcinogenesis in rodents [91]. AhR is constitutively present in the cytosol as an 
inactive complex together with a 90 kDa heat shock protein 90 (Hsp90) and a 
chaperone protein, p23. Hsp90 serves as a chaperone for AhR, preventing nuclear 
translocation in the absence of a ligand and also by preventing premature dimerisation 
with DNA binding partners while keeping AhR in a configuration that favours ligand 
binding [92] [94]. The hydrophobic ligands that bind to AhR, enter the cell by 
diffusion. Ligand binding triggers a conformational change in AhR that increases the 
affinity of AhR for DNA, and slowing the rate of ligand dissociation. This event 
releases AhR from the cytosolic complex and promotes nuclear translocation. 
Following translocation into the nucleus, AhR heterodimerises with the aryl 
hydrocarbon receptor nuclear translocator (ARNT), which is also known as hypoxia 
inducible factor 1✂  ✁☎✆)-✝✂ [92] [94]. Transcription is activated following binding of 
this heterodimer to xenobiotic responsive elements (XRE) or to the core binding motif 
of dioxin responsive elements within the promoter regions of genes in the AhR battery 
[92]. This then activates AhR controlled genes that encode phase I and phase II drug 
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metabolism enzymes such as CYP1A1. These CYP enzymes favour AhR agonists and 
activation of this signalling pathway appears as a defence system aimed at the 
elimination of the inducer and its metabolites [92] [94]. Many signalling pathways are 
implicated to cross talk with the AhR pathway thus, AhR has shown to influence 
cellular functions including cell proliferation, vascularisation and hypoxia [61] [92]. 
Some of these signalling pathways include ER, EGFR, RAS/MAPK [94] [95]. 
Research has demonstrated that AhR ligands such as TCDD are able to activate EGFR 
and in contrast it has been depicted that EGFR ligands are able to block AhR signalling 
in an autocrine/paracrine manner [61] [96]. Further, depending on the cell type 
investigated, TCDD has been shown to activate the RAS/MAPK pathways by 
activating  ERK1/2, SAPK/JNK and p38 [97]. On the other hand, MAPKs are also 
known to regulate AhR demonstrating mutual cross talk between AhR and 
RAS/MAPK pathways [97]. Thus, it seems that AhR signalling impinges upon 
number of signalling molecular pathways and the exact molecular mechanisms by 
which AhR ligands exert their effects still remain ambiguous as further investigations 
are warranted to determine the cross talk between AhR and other signalling pathways 
[92] [94] [97] (Figure 1.10). 
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small-cell lung cancer [98] [99]. Interestingly, Gefitinib is shown to inhibit other HER 
receptors such as HER2 as well. Although initially used for advanced non small-cell 
lung cancer, Gefitinib is shown to inhibit the growth of a range of human cancers such 
as breast, colon, ovarian and gastric cancers both in vitro and in vivo [100]. It has been 
shown that in vitro, Gefitinib inhibits EGFR kinase activity potently with very low 
concentrations. Further, it has been shown that Gefitinib inhibits the growth of human 
cancer cells in vitro and in vivo by inhibiting molecular signalling pathways thereby 
inducing cell cycle arrest and/or apoptosis [100]. Erlotinib is also shown to be active 
in a similar tumour subset to Gefitinib with a related mechanism of action [98]. 
Although, Gefitinib is a highly promising molecular targeted anti-cancer agent, the 
results from monotherapy clinical studies of advanced breast cancer patients have been 
relatively unsuccessful. This may reflect inadequate patient selection that will better 
predict those patients likely to respond favourably to these EGFR inhibitors [21]. 
Moreover, EGFR overexpression and response to EGFR inhibitor therapy may not 
appear straight forward due to the complexity of the HER signalling network as 
outlined [100]. Most often c-MET amplification has been reported in many patients, 
which contribute to resistance of Gefitinib [101]. Furthermore, toxicities such as 
diarrhoea, nausea and skin rashes correlated with the EGFR inhibitors limit the use of 
these agents [98] [102].  
 
HER2 overexpression is also associated with aggressive disease and decreased 
survival in breast cancer as mentioned before [53]. Thus, taking into consideration the 
role that HER2 plays in this disease, a number of therapeutic approaches have been 
developed. Trastuzumab, was the first humanised anti-HER2 monoclonal agent that 
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was approved for therapeutic use for breast cancer patients with HER2+ tumours. As 
HER2 activates multiple cellular signalling pathways such RAS/MAPK and 
PI3K/AKT, Trastuzumab is able to bind to HER2 and reduce the signalling of these 
pathways promoting cell cycle arrest and apoptosis [103]. Despite the advances that 
have been brought by Trastuzumab, many patients with HER2+ metastatic breast 
cancer who initially responded to Trastuzumab ultimately develop resistance [55]. 
This has been shown as mainly due to increased signalling via the PI3K/AKT 
pathways or loss of function of the PTEN gene which is the negative regulator of AKT 
that results in resistance to this agent [55].  
 
Thus, resistance to anti-HER2 therapies have shown to arise as a result of aberrant 
activation of signalling pathways downstream of the HER2 receptor such as 
PI3K/AKT and also due to activation of compensatory pathways such as c-MET in 
order to rescue cancer cells from the inhibitory effects of blocking just one target or 
one pathway [55]. In this regard, identification of specific patient populations 
according to molecular subtypes of breast cancer who are likely to benefit from 
targeted therapy might be a crucial step towards making targeted therapy effective in 
the clinic. For those patients in which HER signalling represents a dominant driving 
force in cancer progression, it is unlikely that these patient populations will achieve 
durable disease control by just monotherapy [21]. This is especially relevant with 
reference to the HER receptor family members that are known to be mostly 
interdependent and are found to interact with each other in signal transduction, 
although in certain cases monotherapy has shown efficacy [19] [21]. Thus, the use of 
a combination approach that will combine existing molecular targeted agents that may 
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act on 2 or more signalling pathways and also on compensatory pathways might 
improve outcomes. Further, this will improve the effects of the agents relative to using 
as single agents.  
 
Further, it is important that continued research takes place in order to optimise targeted 
agents that are already in the clinic. One approach would be reducing toxicities in 
order to improve the quality of life of patients receiving these agents. Nanotechnology 
based drug delivery systems can be used to reduce such toxicities [104] [105]. In 
addition, fuelling the design of novel targeted therapies taking into consideration the 
interactions of the HER family signalling is very crucial. This is because development 
of new targeted agents is yet a slow process with particularly high failure rates [106]. 
Most of these novel agents fail during clinical trials. These clinical trials help to 
identify the effectiveness and the safety of novel agents in humans [107]. Number of 
clinical trials have been conducted with TKIs and monoclonal antibodies either alone 
or in combination. Section 1.7.2 summarises the findings of a few major clinical trials 
carried out in the recent past with anti-HER agents.  
 
1.7.2 Clinical trials of targeted pharmacological agents 
In the beginning, TKIs such as Gefitinib and Erlotinib were indicated for second and 
third line treatment for patients with advanced non small-cell lung cancer after failure 
of at least one initial platinum treatment [108]. As stated before, however, Gefitinib 
as a monotherapy has showed only low activity and the response rates have not shown 
significant improvement in patients with breast cancer [21] [109]. Nevertheless, many 
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reports have shown that combining Gefitinib with other anti-cancer agents enhanced 
the effect of Gefitinib in patients with breast cancer [109]. Further, monoclonal 
antibodies such as Trastuzumab has shown successful improvements in patients with 
metastatic HER2+ breast cancer which helped it to gain food and drug administration 
(FDA) approval in 1998. Many clinical trials to date have studied its role in adjuvant, 
neoadjuvant and in a metastatic setting. In 1998, Trastuzumab was first approved as a 
first line therapy to be administered in combination with Paclitaxel and also to be 
administered as a single agent for patients who have failed one or more chemotherapy 
regimens before [109]. Pivotal clinical trials have shown that when this agent was 
combined with other anti-cancer agents the results were more impressive than it was 
used as a single agent in both early stage and metastatic breast cancer [110].  
 
There have been number of clinical trials lately, which have showed the efficacy of 
novel targeted agents alone and in combination for HER2+ breast cancer. Ado-
Trastuzumab-Emtansine (T-DM1) is a novel therapy for HER2+ cancer. This is an 
antibody drug conjugate where Trastuzumab is linked with a potent microtubule 
inhibitor named Emtansine. When T-DM1 alone was compared with Trastuzumab and 
Docetaxel as a first line treatment in patients with metastatic breast cancer in a phase 
II clinical trial, it was found that T-DM1 demonstrated a favourable safety profile with 
a significant 5 month improvement in progression free survival compared to 
Trastuzumab and Docetaxel. These results were validated in the MARIANNE trial 
which ended in 2014 [110]. This trial evaluated 3 HER2 targeted regimens in 
previously untreated metastatic and locally advanced HER2+ breast cancer patients. 
The targeted agents included T-DM1, Trastuzumab and Pertuzumab. Pertuzumab is a 
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novel humanised monoclonal antibody that inhibits the dimerisation of both HER2 
and HER3. The trial looked at the efficacy of T-DM1 with or without Pertuzumab 
which was compared to Trastuzumab with a taxane. The results showed similar 
progression free survival among the 3 arms [110]. The CLEOPATRA trial looked at 
first line treatment of Pertuzumab, Trastuzumab and a taxane (Docetaxel) which was 
compared with a placebo, Trastuzumab and Docetaxel in HER2+ metastatic breast 
cancer patients. They found that, Pertuzumab, Trastuzumab and Docetaxel improved 
overall survival providing an increase of survival of 15.7 months [111].  
 
The results of these clinical trials validate that the successful development of novel 
agents such as T-DM1 and Pertuzumab, and also the effects of Trastuzumab, have 
helped to improve the disease biology by treating the underlying molecular driver. 
These new HER2+ targeted therapies such as Pertuzumab and T-DM1 are now being 
used in the clinic and have earned regulatory approval based on the data of clinical 
trials. However, it should be noted that, while the results associated with breast cancer 
has been dramatically improved with the use of these targeted agents, resistance to 
these approaches such as cross talk still remain as an unmet clinical need. Thus, it is 
very important to understand the mechanisms of resistance which leads to improving 
existing therapeutic agents and developing novel therapeutic agents.  
 
Therefore, a number of clinical, currently experimental and novel pharmacological 
agents were tested as single agents and in combination against the chosen panel of 
breast cancer cell lines. All agents tested are described in section 1.9. Nanotechnology 
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tumour. Thus, NPs demonstrate enriched biodistribution via leaky vasculature 
surrounding the tumours by the enhanced permeability and retention (EPR) effect. By 
this effect tumours are able to retain more NPs than other tissues. The lymphatic 
drainage system is also impaired in tumours, further entrapping NPs. Moreover, with 
the longer blood circulation time achieved by nanomedicine, the accumulation of NPs 
through the EPR effect increases within the tumour. In active targeting, targeting 
ligands are attached at the surface of the NPs for binding to certain receptors expressed 
at the target site while eliminating off target adverse effects in normal tissues.  These 
ligands for instance are antibodies, affibody molecules, nucleic acid aptamers or 
carbohydrates. The binding affinity of these ligands influences the penetration to the 
diseased site which might be triggered by receptor mediated endocytosis [112].  
 
A further advantage of drug delivery systems is that the encapsulated drug is released 
in a controlled manner ensuring that optimal concentrations are maintained for a 
desired duration at the tumour site. NPs may commonly release the encapsulated drug 
by diffusion or alternately drug release can be triggered by the environment or other 
external events such as variations in pH, temperature, or the presence of an analyte 
such as glucose. Thus, controlled release by NPs may increase the efficacy of the drug 
and enhance the facility to use highly toxic and poorly soluble drugs [113].  
 
There are various nanomedicine vehicles researched and some of them for example 
are liposomes, dendrimers, polymers and proteins [105]. Out of most of these vehicles, 
protein based drug carriers are shown to be superior due to being naturally self-
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assembled subunits, being biocompatible and biodegradable which is associated with 
low toxicity. Protein cages which is a sub group of protein based carriers have emerged 
to overcome some of the drawbacks of other carriers such as polymer based drug 
delivery systems due to their uniform nanometer size. This size allows loading of 
relatively even amounts of delivery drug, and avoidance of random macromolecular 
aggregation of NPs. The interior and exterior of protein cages can also be easily 
modified chemically and genetically, without affecting the whole architecture for 
encapsulating drugs or for attaching targeting ligands [107]. Some of the commonly 
used proteins cages are ferritin/apoferritin (AFt), viral capsids and small heat shock 
proteins [114]. Human AFt was chosen as a targeted NP in the current study because 
human AFt is extracted from bodily tissues and it links nanomedicine with 
personalised medicine perfectly. The results associated with AFt NPs are described in 
chapters 4 and 5.  
 
At present a variety of therapeutic nanodrugs have been exploited by number of 
researchers. However, there are only a few approved agents in clinical practice. Some 
of these drugs are used to treat breast cancer. Doxil a Doxorubicin encapsulated 
liposome is the first nanodrug to gain FDA approval to treat acquired immune 
deficiency syndrome- ✁✁✂✄☎ ✆✝✞ ✟ ✠✂✁☎✡✁ ✁ ☛✄✂☞ ✌ ✍✁ ✂✎ ✏✑✑✒, this agent is used for 
metastatic breast cancer. Doxil liposomes entail a single lipid bilayer membrane 
composed of hydrogenated soy phosphatidylcholine and cholesterol with an internal 
compartment encapsulated with Doxorubicin. The vesicle has a size of 80 - 90 nm. 
Around 15,000 Doxorubicin molecules are encapsulated within the internal 
compartment as Doxorubicin is a small molecule. In order to accumulate at the tumour 
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site via the vascularity of the tumours, Doxil vesicles depend on a passive targeting 
mechanism along with the EPR effect. Further, it has been shown that the long 
circulation which is around 2 to 3 days enhances the distribution throughout the 
tumour site compared to Doxorubicin which has a half-life of around 5 min in vivo. 
Many studies have also shown that the efficacy of Doxil is a lot higher than the free 
drug. Regardless of its longer circulation time compared to the free drug, Doxil has 
shown less severe side effects than Doxorubicin. In particular, Doxil has demonstrated 
a drastic decrease in the cardiotoxicity for which cardiotoxicity is the dose limiting 
side effect of the free drug. Phase I and II clinical trials with Doxil has demonstrated 
that the cardiotoxicity in solid tumour patients was negligible attributed to minimal 
distribution of Doxil in the heart [107].  
 
Abraxane which is a Paclitaxel encapsulated albumin is given to patients with 
advanced breast cancer. Albumin has shown to be an ideal vehicle for nanomedicine 
as it is a natural carrier due to biocompatibility. Paclitaxel has been broadly used as a 
chemotherapeutic agent for many types of cancers, however, the original formulation 
has showed a number of adverse reactions in patients, such as acute hypersensitivity. 
Thus, a nonpolar carrier had been used  ✁✂ ✄☎ ✆✝✞✟✠✄✝✡✂✟☛☞ ✌✍ ✎☎✏✌☎✑✠✞ ✒✝✄✁✎✂ to make 
it clinically viable. In this case, albumin has worked as an ideal carrier as it is a natural 
carrier of hydrophobic molecules such as hormones and vitamins with favourable 
noncovalent binding interactions in the human body. The nanoconjugates of Paclitaxel 
and albumin are synthesised by mixing the agent with human serum albumin in an 
aqueous solvent by passing the solution through a high pressure jet, resulting in 
nanoparticles in the size of around 130 nm. Upon injection into biological systems, 
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Table 1.3 Agents tested summarising their molecular target and activity [70] [78] 
[92] [108] [115] [116] [117].  
 
Agent Novel, 
experimental 
or in clinical 
use 
Molecular 
target of 
the agent  
Brief description  ✁ ✂✄☎ ✆✝☎✞✂✟✠
activity 
EGF Experimental  EGFR  Binds to EGFR and activates the HER family 
network.  
Gefitinib Clinical  EGFR  Binds to EGFR and inhibits the activation of 
the HER family network.  
Erlotinib Clinical  EGFR  Binds to EGFR and inhibits the activation of 
the HER family network. 
Raloxifene Clinical  ER  Binds to ER and prevents the transcription 
activation of genes that contain the estrogen 
response element in the mammary tissue.  
Heavy (H) or 
Light (L) chain-
AFt-fusion 
protein 
Novel  HER2  Binds with high affinity to the HER2 receptor 
and inhibits the activation of the HER family 
network. 
H-AFt-
encapsulated-
Gefitinib 
Novel EGFR  Released Gefitinib from the H-AFt cavity will 
bind to EGFR and inhibit the activation of the 
HER family network. 
Trastuzumab Clinical HER2  Binds to the HER2 receptor and inhibits the 
activation of the HER family network. 
Sirolimus Clinical mTOR Binds to cytosolic FK-binding protein 12. The 
Sirolimus- FK-binding protein 12 complex 
inhibits mTOR.  
CGP57380 Clinical MNK1 and 
MNK2 
Binds to MNK1 and MNK2 of the 
RAS/MAPK pathway and inhibits the activity 
of MNK1 and MNK2. 
5F 203 Experimental  AhR Binds to AhR as an AhR agonist which is 
followed by induction of CYP1A1 that 
converts 5F 203 to a nitrenium ion that is 
potent in certain cancer cells. 
Gedatolisib 
(MS-73) 
Experimental PI3K and 
mTOR 
Binds to PI3K and mTOR by competing with 
the ATP binding sites of these molecules and 
inhibits the activity of PI3K/AKT and mTOR 
pathways.  
MS-74 Novel PI3K and 
mTOR 
Binds to PI3K and mTOR by competing with 
the ATP binding sites of these molecules and 
inhibits the activity of PI3K/AKT and mTOR 
pathways. 
MS-76 Novel PI3K and 
mTOR 
Binds to PI3K and mTOR by competing with 
the ATP binding sites of these molecules 
which in turn inhibits the activity of 
PI3K/AKT and mTOR pathways. 
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1.9.1 EGF 
 
 
 
 
 
 
 
Figure 1.11: EGF (shown in red) binds to the extracellular domain of its receptor 
which is EGFR (shown in blue). Figure adapted from [118].  
EGF belongs to an extensive class of growth factors [119]. It is a 6,045 Da protein 
with 53 amino acids that has distinct biological properties [119]. It has been shown 
that levels of EGF is higher in females compared to males. It is further enhanced by 
pregnancy and exogenous hormones in females which are conditions that drastically 
alter mammary gland growth [120]. EGF specifically binds to EGFR and activates an 
extensive network of signalling pathways as mentioned before, thus, EGF may 
regulate growth of mammary epithelium [47] [120]. The effect of EGF was 
investigated against the panel of breast cancer cell lines in the current study. 
Recombinant, human EGF expressed in E. coli was used. This is demonstrated to be 
identical to human EGF except for an additional N-terminal methionine [121]. 
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1.9.5  AFt (H and L chains) and affibody molecules 
AFt (H and L chains) 
 
 
 
Figure 1.15: Protein structure of human H-AFt with the exterior surface view 
and interior cavity. Figure adapted from [114]. 
In biological systems the protein cage ferritin is used to store iron, preventing 
accumulation of toxic levels in humans through to invertebrates, plants and 
microorganisms [129]. When the iron atoms are removed from ferritin, AFt is formed. 
AFt protein cages are composed of 24 subunits, which assemble into hollow cages 
consisting of an outer diameter of 12 nm and an inner diameter of 8 nm [114] [129]. 
The interior of AFt can accommodate up to a maximum of 4,500 iron atoms. The 
mammalian protein subunits are of 2 types, heavy (H) and light (L) chains of 21,000 
Da and 19,000 Da respectively. The 2 classes of subunits share nearly identical 
homology. However, the subunits are expressed in different ratios depending upon the 
tissue type examined [129]. H and L subunits are shown to play different roles [130]. 
H chain is known to catalyse iron oxidation (Fe2+ to Fe3+) and also facilitates 
accumulation of iron [130]. The L subunit lacks ferroxidase activity but facilitates iron 
nucleation [114]. The AFt cage can disassemble into subunits at low pH (pH = 2.0) 
allowing release of cargo and it is able to reassemble at higher pH (pH > 5.0). Thus, 
AFt can be used as an ideal NP for drug encapsulation due to its size, hollow cage and 
sequestration by viable cells. In addition to its ability to encapsulate anti-cancer agents, 
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AFt is able to bind to a variety of cell types due to the presence of transferrin receptors 
on the cell surface namely transferrin receptor 1 (TfR1). AFt internalisation within 
cells is carried out by clathrin-mediated endocytosis during the acidification of 
endosomes and lysosomes which gradually releases the cargo. The AFt protein cage 
can also be genetically modified. For instance, this modification may show high 
affinity towards a particular tumour cell. Further AFt can also be fused with other 
peptides in order to produce chimeras. Furthermore, due to its unique cavity structure, 
AFt can be used in further applications such as encapsulation of drugs which makes it 
an ideal drug delivery system, in diagnostics and in imaging which makes it suitable 
for thernostic applications [131].  ✁✂✄☎ high stability, biodegradability, 
biocompatibility, and its unique structure, makes AFt a successful platform for drug 
delivery systems. Moreover, since it can withstand number of environmental 
influences, AFt may eliminate the early release of its cargo that may protect tissues 
against the adverse effects of numerous pharmacological agents. Also, the size 
uniformity of the protein cage offers simplicity and reproducibility for the 
encapsulation of cargo [131]. 
 
Affibody molecules (Targeting protein) 
Affibody molecules are a new class of relatively small molecules ~ 7,000 Da. They 
are high affinity proteins, structurally based on a 58 amino acid scaffold derived from 
the Z domain of Staphylococcus aureus protein A, produced by combinatorial protein 
engineering [132]. In the development of next generation therapeutics, these high 
affinity proteins have become vital tools. Their capability to bind to a given molecular 
structure with high affinity, selectivity and robustness are seen to be important key 
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features. Further, affibody proteins are isolated by non-immunoglobulin scaffolds 
using synthetic combinatorial libraries and in vitro selection systems in contrast to 
monoclonal antibodies which are generated by immunisation of laboratory animals 
combined with hybridoma technology. These affibody molecules are currently utilised 
in a variety of applications. For instance, affibody molecules are currently used in 
imaging. Imaging improves diagnosis and in cancer, it will show a global view of the 
metastatic tumours in the body compared to a biopsy which is restricted to a local 
lesion. High specificity and affinity will be ideal characteristics of an imaging agent 
for its target. Further, rapid biodistribution and tissue penetration which will lead to 
high local concentrations at the particular tumour site together with rapid clearance of 
unbound tracer will help in high contrast tumour imaging between the injection and 
examination. Recent investigations have shown that affibody molecules are among the 
most promising tracers for HER2 specific molecular imaging compared to antibodies 
or antibody fragments with the above mentioned characteristics [133]. Sorensen et al, 
2014, has carried out a first in humans imaging study with affibody molecules. It was 
carried out to evaluate the distribution, safety, efficacy and uptake in tumour 
metastases and also to compare the background uptake in normal organs of the 
affibody molecules. Additionally, this investigation determined the HER2+ status in 
metastatic breast cancer tumours. These affibody molecules have been selected from 
a library of several billion unique variants providing high affinity binders to a variety 
of targets such as HER2. Interestingly, this research group found that the mean 
effective dose given to humans were safe to use and well tolerated without any adverse 
side effects. The highest normal tissue uptake was in the kidneys, which has been 
followed by the liver and spleen. Further, they have found that 1 breast cancer patient 
out of the 7 patients used in the trial demonstrated a HER2- metastatic tumour who 
Chapter 1 
95 
 
initially had a HER2+ primary tumour. These results validate that affibody molecules 
are safe to be used in humans and that it is a promising tool to be used in the clinic 
[134].  
 
Another interesting application of affibody molecules are providing affinity mediated 
recognition cellular targets. This recognition enhances the specificity. It has been 
shown previously that uptake and cytotoxicity was increased significantly in HER2 
targeted particles carrying the anti-cancer agent Paclitaxel as compared to the non-
targeted particles in vitro studies. However, when compared to imaging applications, 
when affibody molecules are used for targeted therapy to direct a payload to a specific 
disease site, one property which is necessary to optimise is extending its half-life. This 
is because sufficient drug exposure in a controlled manner is important to obtain a 
desired therapeutic effect. There are a few technologies available to increase its half-
life such as fusion of small proteins. Thus, fusion of affibody molecules to proteins 
can transform these molecules from optimal imaging tracers to potent candidates for 
targeted therapy. Furthermore, affibody molecules have also been used in 
biotechnology applications where it has been used for bioseparation of antibodies in 
immunoprecipitation and other bead based assays. These descriptions illustrate that 
affibody molecules which are vital tools have favourable properties which can be used 
in a multitude of applications [133]. Thus, affibody molecules were used as a 
successful targeting protein to target HER2+ breast cancer cells in the current study. 
The affibody molecule/the targeting protein used in the current study has a MW of ~ 
10,279 Da.  
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1.9.11  5F 203 
 
 
 
Figure 1.19: Chemical structure of 5F 203. Figure adapted from [137].  
2-(4-Amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203) is an experimental anti-
tumour agent. 5F 203 was originally synthesised as part of a programme which 
developed a series of novel anti-cancer benzothiazoles. It is a high affinity AhR ligand, 
sequestered and metabolised by sensitive cancer cells only [92] [94] [138]. It is shown 
to induce CYP1A1 in sensitive cancer cell lines in vitro and also in vivo [94]. The MW 
of 5F 203 is 258.3 Da [139].  
 
1.9.12  Gedatolisib (MS-73) 
 
 
 
 
 
Figure 1.20: Chemical structure of MS-73.  
Gedatolisib, is also known as PKI-587 and PF-05212384 (Pfizer) [140]. In the current 
study Gedatolisib is named as MS-73. This agent is a highly potent dual PI3K/mTOR 
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inhibitor and is shown to be a pan PI3K inhibitor displaying potency against PI3K 
 ✁✂✄✂☎✆✁ ✝✞✟✟✠✡☛ ✞✟✟✠☞☛ ✞✟✟✠✌☛ ✍✎✏ ✞✟✟✠✑✒✓ ✔✕ ✁ ✍✖✗✎✘ ✕✍✁ ✙✚☎☎✗✎✘✛✜ ✗✎✘✗☎✗✏ phase I 
clinical trials for patients with malignant solid tumours who were unresponsive to 
previous therapy [70]. The MW of MS-73 is 615.7 Da. In order to investigate the 
structure-activity relationship of MS-73, 2 novel analogues have been developed - 
MS-74 and MS-76. Further, the analogues had been designed to increase solubility 
because MS-73 is found to be poorly soluble.  
 
1.9.13 MS-74 
 
 
 
 
 
 
Figure 1.21: Chemical structure of MS-74. 
MS-74 is a novel agent. It is an analogue of MS-73 and the MW of MS-74 is 628.7 
Da. 
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breast cancer [51] [53]. Thus, the agents listed under section 1.9 were tested against 
the panel of breast cancer cell lines described, representing the molecular subtypes of 
breast cancer. This analysis may help to understand the HER signalling network 
further and identify patient populations that would ideally benefit from these therapies 
as single agents or in combination and ultimately guide treatment strategies tailored to 
individual patients thereby enhancing personalising therapy.  
 
Objectives 
1. The first objective was to test clinically available pharmacological agents 
targeting the HER family, especially EGFR and HER2 and retool these 
existing agents by identifying specific breast cancer patient populations who 
will ideally benefit from these therapies using the panel of breast cancer cell 
lines. In the pursuit of developing new therapies for breast cancer, it is crucial 
to characterise existing agents as well, which in turn would expand the variety 
of therapies beneficial for breast cancer patients [141]. The results associated 
with this objective are discussed in chapter 3.  
 
2. Nanomedicine has the potential to revolutionise cancer therapy. Many of the 
existing anti-cancer agents are shown to incorporate poor bioavailability and 
toxicities which degrades the quality of life of patients receiving these agents. 
Therefore in this context, human H-AFt NPs were incorporated as a carrier to 
encapsulate existing clinical agents. The results associated with this objective 
are discussed in chapter 4.  
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3. There is an enormous need for the development and evaluation of novel 
therapies for breast cancer. Novel agents associated with nanomedicine are 
revolutionising the treatment of cancer. Thus, 2 novel agents targeting the 
HER2 receptor in breast cancer were investigated and compared to existing 
pharmacological agents. The results associated with this objective are 
discussed in chapter 5.  
 
4. Targeting a distinct HER receptor or a molecule within a signalling pathway 
by a single agent may most often contribute to activation of alternative and 
compensatory signalling pathways, multiple feedback loops and cross talk 
within the complex signalling network thereby acquiring resistance to therapy 
[142]. These complexities mandate to study agents in combination which may 
combat drug resistance and enhance the effect of pharmacological agents in 
breast cancer [143]. Thus, agents alone and in combination were evaluated for 
synergistic effects. The results associated with this objective are discussed in 
chapter 6.  
 
 
 
 
  

Chapter 2 
105 
 
were used. For each cell line a new batch of cells were taken out of liquid nitrogen 
storage (- ✁✂ ✄☎✆ ✝✞✟ ✠✝✡✡✝☛☞✟ ✌ ✍ - 4 months before being discarded and a new batch 
of cells thawed for culture to minimise genotypic and phenotypic drift during 
continuous culture. As a part of quality control, cells were tested regularly for 
mycoplasma infection which is one of the most common contaminants present in cell 
culture laboratories. The MycoAlert mycoplasma detection kit (Lonza, PC - LT07-
118) was used for this purpose. The breast cancer cell lines used in this study were - 
MCF7, T47D, ZR-75-1, SKBR3, MDA-MB 468 and MDA-MB 231.  
 
2.1.3 Reviving frozen cells 
Each cell line used was preserved in liquid nitrogen. A database with cell bank 
information was checked to retrieve the specific location of stored cell vials within the 
liquid nitrogen storage. Afterwards, the vials were taken out of liquid nitrogen storage 
and they were thawed rapidly at 37 °C. Subsequently these vials were carefully 
sterilised by wiping the vials with 70% industrial methylated spirit (IMS) in dH2O. All 
procedures from this point onwards were carried out under strict aseptic conditions. 
The cells were re-suspended in vented T25 cm2 culture flasks with 7 ml of RPMI-1640 
medium with 10% FBS (pre-warmed complete growth medium). All culture flasks 
were labelled with the name of the cell line, initials of user, date and passage number. 
Cells were allowed to attach overnight incubated at 37 °C in an atmosphere of 5% 
CO2. Cells were then examined under the microscope for cell adhesion, viability and 
accurate morphology. Thereafter, medium was replaced to remove DMSO and any 
unattached cells, and incubated further. When cells were ~ 80% confluent they were 
passaged twice to resume normal growth before experiments were initiated. 
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2.1.4 Freezing and storing cells 
For long term maintenance cell lines were cryopreserved. In order to carry out this 
procedure, medium was aspirated and cells washed with sterile PBS (pre-warmed) to 
remove dead cells and serum. PBS was then aspirated and viable cells were detached 
using a minimum amount of 1x trypsin- ✁✂✄☎ ✆✝✞✟✝✠ ✡☛☛ ☞✌ ✍✎ ✏✑✒✓✔✕✞-EDTA was 
added to the flasks and the flasks were gently agitated to ensure complete coverage of 
the trypsin-EDTA solution over the cells. The flasks were then incubated at room 
temperature and after ~ 2 min, trypsin-EDTA was aspirated. Afterwards, these flasks 
were incubated at 37 °C to allow cells to detach for a further 1 - 2 min and then re-
suspended in 1 ml of sterile freezing medium. The cell suspension was transferred to 
sterile cryogenic vials labelled with the name of the cell line, initials of user, date and 
passage number. Cryogenic vials were frozen overnight at -20 °C in a well-insulated 
box then at -80 °C for 1 - 2 days before being transferred to liquid nitrogen for long 
term storage. 
 
2.1.5 Passaging of cells 
All cell culture techniques were carried out in a class II biological safety cabinet which 
was decontaminated with 70% IMS before use. All cell lines were routinely passaged 
in T25 cm2 culture flasks using RPMI-1640 medium supplemented with 10% FBS. 
Logarithmic growth was maintained by passaging T47D, ZR-75-1, SKBR3 and MDA-
MB 468 cell lines once a week and other cell lines twice per week. Passaging was 
carried out when cells were ~ 80% confluent. Subsequently, compete growth medium 
was aspirated and 1 ml of 1x trypsin-EDTA solution was added. SKBR3 and MDA-
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the cell lines were as follows - MCF7, T47D, ZR-75-1, MDA-MB 231 - 2 x 104, 
SKBR3, MDA-MB 468 - 5 x 104. 
 
The initial seeding cell densities for SKBR3 and MDA-MB 468 cells had to be 
increased as their growth was much slower, especially at low cell densities. As 
described in section 2.1.5, cells were harvested by trypsinisation. Subsequently 
clumped cells were dispersed using a syringe equipped with a 23-gauge needle to 
obtain a near single cell suspension. Cells were counted using a haemocytometer and 
seeded at the desired densities in 3 ml culture medium. The cells were incubated 
overnight at 37 ºC to allow cell attachment and commencement of mitosis. Afterwards, 
cell counting was performed daily until cell growth reached a plateau phase and cells 
died. Medium was replaced every 4 days in all plates in order to maintain nutrient 
availability. Prior to cell counting, medium in each well was aspirated and cells were 
 ✁✂✄☎✆✝☎✞ ✟✠✝  ✡☛☛ ☞✌ ✍✎ ✏✑ ✝✂✒✓✆✠✔-✕✖✗✘✙ ✚✍✌✌✍✟✠✔✛ ✞✠✆✓☎✂✆✁✌ ✍✎ ✜☎✌✌✆✢ ✣☛☛ ☞✌ ✍✎
medium was added into each well to make the total volume to 1 ml. Once again the 
cell suspension was passed gently through a syringe equipped with a 23-gauge needle, 
in order to obtain a single cell suspension. The resulting cell suspension was 
transferred to labelled bijou tubes for all 6 cell lines to facilitate cell counting. Cells 
were counted using a hemocytometer. When preparing the haemocytometer for 
counting the counting chambers and the cover-slip were carefully cleaned with 70% 
IMS. A coverslip was placed over the counting surface prior to introducing the cell 
suspension. Cell suspension (~ 
✡☛ ☞✌
✤
✟✁✆ ✠✔✝✂✍✞
✥
✜☎✞ ✠✔✝✍
✦
✍✝  ✆✠✞☎✆ ✍✎ ✝ ☎ ✜✍
✥
✔✝✠✔✛
chamber using a pipette. The area under the cover-slip was filled by capillary action. 
Cell counts for each bijou tube were repeated if the difference in counts in both sides 
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Table 2.1 with the concentration ranges that were used. Some of the concentrations 
ranges were guided by previous literature.  
Agent tested Obtained from Final concentration 
range  
1. EGF Calbiochem 0.01 nM   10 nM 
2. Gefitinib Cayman chemical 0.01 µM - 25 µM 
3. Erlotinib Cayman chemical 0.01 µM - 25 µM 
4. Raloxifene Cayman chemical 0.005 µM   25 µM 
5. H-AFt-
encapsulated-
Gefitinib 
Novel testing agent 
synthesised by author 
with the assistance of  
Dr. Lei Zhang 
0.05 µM   25 µM 
6. H-AFt and L-
AFt 
Kindly provided by 
Prof. Neil Thomas  
0.004 µM   20 µM 
7. H-AFt-fusion 
protein and L-
AFt-fusion 
protein 
Novel testing agents 
synthesised by Dr. Lei 
Zhang and kindly 
provided for testing 
0.003 µM   2 µM 
8. Targeting 
protein 
Kindly provided by 
Prof. Neil Thomas  
0.01 µM 
 
 5 µM 
9. Trastuzumab Roche 0.0006 µM   0.3 µM 
10. Sirolimus Cayman chemical 0.1 nM - 1 µM 
11. CGP57380 Cayman chemical 0.01 µM   100 µM 
12. 5F 203 Experimental testing 
agent kindly provided 
by Dr. Tracey D. 
Bradshaw 
1 nM 
 
 10 µM  
13. MS-73, MS-74 
and MS-76 
Experimental and 
novel testing agents 
kindly provided by Dr. 
Michael Stocks 
0.5 nM   10 µM 
14. DMSO Sigma-Aldrich 0.01% - 1% 
 
Table 2.1: Agents tested during the study period. DMSO was used as a solvent to 
dissolve agents 2, 3, 4, 10, 11, 12 and 13. Thus, effects of DMSO alone were also 
tested. All test agents except DMSO were stored at -20 °C.  
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2.3.3 Method 
Cells from flasks that were ~ 80% confluent were harvested by trysinisation. 
Subsequently, the cell suspension was gently passed through a syringe equipped with 
a 23-gauge needle to obtain a near single cell suspension. Cells were counted using a 
hemocytometer and decanted with RPMI-1640 medium supplemented with 2% FBS 
(used for MTT experiments described in chapter 3) or 10% FBS, according to the 
required seeding density (seeding density for 24 h drug exposure - 5 x 103, 72 h drug 
exposure - 2.5 x 103 and 120 h drug exposure - 2.5 x 103 cells per well). Thereafter 
180 µl or 160 µl (used for combination MTT experiments where 2 agents were tested 
together, described in chapter 6) of cell suspension was added into each well of 96 
well microtiter plates (Nunclon) (VWR, PC - 734-2097). The 2 peripheral lanes of the 
plate were filled with 300 µl of medium only, to minimise evaporation from 
experimental wells. Cells were allowed 24 h to adhere before treatment. In addition a 
time zero (T0) plate was also set up to determine the absorbance of cells (optical 
density (OD)) at the time of test agent treatment.  
 
In each plate one column contained cells that were untreated (control). The other 
columns containing cells were exposed to increasing concentrations of the 
pharmacological agents listed in table 2.1. The agent concentrations were prepared to 
10 x the final concentrations required prior to each experiment by serial dilutions using 
FBS-free RPMI- ✁✂✄ ☎✆✝✞✟☎✠ ✡☛✆☞ ✌✄ ✍✎ ✏✑ ✒☛✆ ✓✔✆☞✒✕ ✖✆✗✆ ✓✝✝✆✝ ✞☞✒✏ ✆✓✘☛ ✖✆✎✎ ✒✏
☎✓✙✆ ✟✚ ✓ ✑✞☞✓✎ ✛✏✎✟☎✆ ✏✑ ✌✄✄ ✍✎✠ ✜✢✣-✑✗✆✆ ☎✆✝✞✟☎ ✏☞✎✤ ✥✌✄ ✍✎✦ ✖✓✕ ✓✝✝✆✝ ✒✏ ✒☛✆
control wells. In each experiment ~ 8 wells received the same agent concentration. 
MTT assays were also performed at pH 7.0 (used for MTT experiments described in 
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chapter 4). Standard RPMI-1640 medium supplemented with 10% FBS is at pH 7.5. 
Concentrated 1 M HCl (Fisher Scientific, PC - 10487830) was introduced into RPMI 
medium drop-wise to obtain the desired pH level of 7.0. 
 
Cells were then incubated at 37 °C in an atmosphere of 5% CO2 for the required 
exposure period (24 h, 72 h or 120 h). After the required time or at the time of drug 
addition for the T0 plate, 50 µl MTT was added to cells and incubated for a further 2.5 
h. Medium was then carefully aspirated and insoluble formazan produced by the 
metabolism of MTT by mitochondrial dehydrogenases was solubilised by the addition 
of 150 µl DMSO per well. Subsequently, all plates were shaken for 5 min using a plate 
shaker (Amersham) to ensure complete formazan solubilisation. The coloured 
formazan product was then quantified by measuring OD using a microtiter plate reader 
(PerkinElmer precisely - Envision 2104 mulilabel reader) at 550 nm. The OD values 
were obtained by Wallac Envision manager software (version 1.12) and the values 
obtained were directly related to viable cell numbers. Graphs with OD values against 
drug concentrations were plotted and the concentration required to achieve 50% 
growth inhibition (GI50) values were determined for each agent as below - [(OD of 
control- OD of T0)/2] + OD of T0 = OD at GI50 and thereafter the GI50 values were 
calculated by interpolation. This served as an index of growth inhibition by the tested 
agents and the GI50 values obtained from the MTT experiments were used in 
successive experiments.  
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2.5.1.1 Materials  
Hypotonic fluorochrome solution stored at 4 °C (50 µg/ml PI (Sigma-Aldrich, PC   
81845 - 25 mg), 0.1 mg/ml ribonuclease A stored at -20 °C (Sigma-Aldrich, PC - 
R4642), 0.1% v/v Triton X-100 (Sigma-Aldrich, PC - X100 - 5 ml), 0.1% w/v sodium 
citrate (Sigma-Aldrich, PC   1613859 - 1 g) in PBS).  
 
2.5.1.2 Method 
Cell cycle analysis was carried out using the method based on Nicoletti et al, 1991. 
Cells were trypsinised and seeded in 6 well plates at a density of 3 x 105 (24 h), 2 x 
105 (48 h), and 1 x 105 (72 h) cells per well in 2 ml complete growth medium according 
to treatment exposure time. Cells were allowed to attach for 24 h prior to treatment. 
Cells were treated with pharmacological agents at desired concentrations. Following 
the required exposure period, medium within the wells with any floating cells was 
decanted to a labelled fluorescence activated cell sorter (FACS) tube and kept on ice. 
Subsequently, cells were harvested by adding 200 µl 1x trypsin-EDTA and pooled 
together with addition of 800 µl of medium. Cells were then centrifuged at 1,200 rpm 
for 5 min, at 4 ºC. Supernatant was discarded and the pellets were broken down by 
gently flicking the tube. Next, 1 ml chilled PBS was added and the FACS tubes were 
vortexed. Thereafter the cells were centrifuged as before. The supernatant was 
discarded and the pellet was broken down by gently flicking the FACS tube and the 
cells were re-suspended in 500 µl cold hypotonic fluorochrome solution and stored 
overnight at 4 ºC protected from light. Cells were vortexted and passed gently through 
a 23-gauge needle immediately prior to analysis to obtain a single cell suspension. The 
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samples were analysed on a Beckman Coulter Epics-XL MCL flow cytometer and 
10,000 - 20,000 events were recorded for each sample. The results obtained were 
analysed using EXPO32 software.  
 
2.5.2 Annexin V- Fluorescein isothiocyanate (FITC)/PI apoptosis assay 
The annexin V-FITC/PI assay is used to measure the percentage of cells that are 
actively undergoing apoptosis. Phosphatidylserine (PS), a phospholipid which is 
confined to the inner leaflet of the plasma membrane translocates to the outer leaflet 
of the plasma membrane during apoptosis thereby exposing PS to the external 
environment. Annexin V bound to FITC can bind specifically in the presence of 
calcium, to PS. Annexin V-FITC can be used with dyes such as PI to determine the 
different stages of apoptosis such as early and late apoptotic populations and necrotic 
populations. Viable cells possess intact membranes and will exclude PI [150].  
 
2.5.2.1 Materials 
Annexin V-FITC apoptosis detection kit stored at 4 °C (BD Pharmingen, PC - 
556547). The kit contained -FITC annexin V, PI staining solution, 10 x annexin V 
binding buffer (diluted 1 part 10 x annexin V binding buffer to 9 parts dH2O). 
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2.5.2.2 Method 
Cells were trypsinised and seeded in 6 well plates at densities of 3 x 105 (24 h), 2 x 
105 (48 h) and 1 x 105 (72 h) cells per well in 2 ml complete growth medium according 
to treatment exposure times. Cells were allowed to attach for 24 h. Following treatment 
with pharmacological agents at particular concentrations, cells were trypsinised with 
200 µl of 1x trypsin-EDTA and once detached pooled together with any floating cells 
in a total of 1 ml complete growth medium. Subsequently the cells were decanted to 
labelled FACS tubes and kept on ice. Cells were then centrifuged at 1,200 rpm for 5 
min at 4 ºC. Thereafter, the supernatant was discarded and the pellet disrupted by 
gently flicking the tube. Cold PBS (1 ml) was added and the cells were centrifuged as 
before. The supernatant was discarded and the pellet disrupted by gentle flicking the 
tube, this step was repeated once more. Afterwards, 100 µl of 1x annexin binding 
buffer and 5 µl annexin V-FITC was added to each tube. The tube was briefly vortexed 
and incubated at room temperature for 15 min in the dark. Next, 400 µl 1x annexin 
binding buffer and 5 µl of PI solution were added to each tube which was vortexed 
and incubated for 10 min at room temperature in the dark prior to analysis on the flow 
cytometer. Samples were analysed within 1 h of completion of the above protocol. 
The samples were analysed by Beckman Coulter Epics-XL MCL flow cytometer and 
10,000 - 20,000 events were recorded for each sample. The results obtained were 
analysed using EXPO32 software. 
 
During analysis by flow cytometry, 4 populations were identified in the quadrant plots. 
The lower left quadrant contained the viable cell population (A3- annexin V-/PI-), the 
upper left quadrant contained the necrotic population (A1- annexin V-/PI+), the upper 
Chapter 2 
118 
 
right quadrant contained the late apoptotic population or dead cells (A2- annexin 
V+/PI+) and the lower right quadrant contained the early apoptotic population (A4- 
annexin V+/PI-) [21]. Early and late apoptotic populations were summed to determine 
the total apoptotic population of cells.    
 
2.5.3 ✂-H2AX assay 
 -H2AX expression is an indicator of DNA double strand breaks (DDSBs). When 
✁✁✄☎✆ ✝✞✞✟✠ ✡☛✆☞✝✌✍ ✎✏✑✒ ✓✍✞✝✔✍✆ ✠✕✖☛✗✘✙ ✖✡✝✆✖✡✝✠✙✘✕☞✍✗ ✕☞ ✄✍✠✚✛✜ ✢✝✠✔☛✌✣  -
H2AX visible as nuclear foci. Previous research has shown that dephosphorylation of 
 -✎✏✑✒ ✕✌✗ ✗☛✆✖✍✠✆✕✘ ✝✢  -H2AX foci in irradiated cells correlates with the repair of 
DNA DDSBs [151] [152]. Thus, ✕✌✕✘✙✆☛✆ ✝✢  -H2AX can be used to determine DDSBs 
in a cell population after certain agent treatment.   
 
2.5.3.1 Materials 
Formaldehyde (1% formaldehyde in PBS) stored at 4 °C (1 ml 16% MeOH-free 
formaldehyde  (Life technologies, Pierce, PC - 28906) in 15 ml ddH2O), 0.4% Triton 
X-100 in PBS stored at 4 °C (40 µl Triton X-100 in 20 ml PBS), 1% FBS in PBS, anti-
phospho-histone H2A.X (Ser139) mouse monoclonal primary antibody (1° antibody) 
(Merck Millipore, PC - 05-636), goat anti-mouse secondary antibody (2° antibody) 
(Alexa fluorophore 488 conjugate (Life technologies, PC - A-10684)). 
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2.5.3.2 Method 
Cells were trypsinised and seeded in 10 cm tissue culture treated petri dishes (Corning, 
PC - 430167) at a seeding density of 1 x 106 (24 h exposure) and 5 x 105 (72 h 
exposure) in 10 ml complete growth medium. After 24 h, cells were treated with 1x 
GI50 concentrations of agents. Following the required exposure period, medium was 
decanted with any floating cells into labelled 15 ml falcon tubes. Afterwards, cells in 
the petri dishes were washed with 1 ml PBS and aspirated. Cells were trypsinised with 
500 µl of 1x trypsin-EDTA and transferred to falcon tubes. Cells were then centrifuged 
at 1,250 rpm for 10 min, at room temperature. Subsequently, supernatant was aspirated 
and the pellet disrupted by gentle flicking the tube. This was followed by adding 1 ml 
of PBS and the cells were centrifuged at 1,250 rpm for 10 min at room temperature, 
PBS was aspirated and the pellet was disrupted as before. Thereafter, cells were fixed 
by adding 500 µl 1% formaldehyde in PBS, which was followed by pipetting the cell 
suspension up and down several times to ensure a single cell suspension. Samples 
were then incubated for 5 min at room temperature, and the tubes were gently flicked 
occasionally. Thereafter, 500 µl of 0.4% Triton X-100 in PBS were added and the 
tubes were flicked gently as before to permeabilise the cells. After around 5 min, the 
tubes were centrifuged at 1,250 rpm for 10 min at room temperature; supernatant was 
aspirated and the pellet was spun down. FBS (1 ml 1% in PBS) was added and mixed 
gently. Samples were incubated for 30 min at room temperature; centrifuged and the 
supernatant was aspirated as before. Subsequently, 200 µl 1° antibody (1:5000 diluted 
in 1% FBS in PBS) was added and the solution was pipetted up and down several 
times followed by a 1.5 h incubation period at room temperature. Subsequently, 1 ml 
1% FBS in PBS was added, centrifuged and aspirated as mentioned before and 2° 
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2.8.1 Preparation of protein lysates 
2.8.1.1 Materials 
Nonidet-P40 (NP40) lysis buffer (10 ml) stored at 4 °C   (NP40 (Fluka, PC - 74385) 
(100 µl), 1 M NaCl (1.5 ml), 1 M Tris pH 8.0 (500 µl), dH2O (7.9 ml), 1 tablet each 
of protease inhibitors (Roche (complete ultra-tablets), PC - 05892791001) and 
phoshatise inhibitors (Roche (PhosSTOP), PC - 04906845001).  
 
2.8.1.2 Method 
All cell lines were harvested by trysinisation and the cells were seeded in 10 cm petri 
dishes in 10 ml of complete growth medium at a seeding density of 1 x 106. The petri 
dishes were incubated for 24 h at 37 °C allowing cells to attach. After 24 h, cells were 
treated with the required pharmacological agent and incubated for a further 24 h. After 
the exposure period, cells were lysed with NP40 lysis buffer. During this procedure, 
the petri dishes with cells were kept on ice. Medium was aspirated and cells were 
washed 2 x with PBS. Lysis buffer (300 µl) was added to each petri dish. Cells were 
harvested by scraping using a cold plastic cell scraper and transferred to labelled 
microcentrifuge tubes. These tubes were kept on ice. Subsequently, the dishes were 
washed with an additional 200 µl of lysis buffer to disperse any remaining adherent 
cells and added to the labelled microcentrifuge tubes. The tubes were centrifuged at 
1,500 rpm at 4 °C for 5 min. The microcentrifuge tubes were incubated on ice for 30 
min with occasional flicking. After 30 min the tubes were centrifuged at 13,000 rpm 
for a further 10 min at 4°C to pellet insoluble material. The soluble supernatant was 
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transferred to new labelled microcentrifuge tubes and the protein cell lysates were 
stored at -20 ºC.  
 
2.8.2 Determining protein concentration 
The Bradford assay introduced by Marion M. Bradford in 1976 is a colorimetric assay 
used to determine the protein concentration. It involves the binding of coomassie 
brilliant blue G-250 to a particular protein which causes a shift in the absorption 
maximum of the dye from 465 to 595 nm, and this increase in absorption at 595 nm is 
measured [155].  
 
2.8.2.1 Materials 
Bradford reagent (Sigma-Aldrich, PC - B6916) and bovine serum albumin (BSA) 
(Sigma-Aldrich, PC   05470 - 1 g). 
 
2.8.2.2 Method 
Protein standard solutions of BSA using NP40 lysis buffer were prepared as follows - 
0.25, 0.5, 1, 1.5 and 2 mg/ml. Protein lysates were thawed on ice and centrifuged at 
13,000 rpm for 5 min at 4 ºC to remove any insoluble proteins and cell debris before 
protein analysis. Prepared protein lysates and ✁✂✄ ☎✆✝✞✟✝✠✟☎ ✡☛ ☞✌✍ ✎✏✠✏ ✑✒✑✏✆✆✏✟ ✝✞✟
added in triplicate into a 96 well microtiter plate. The protein lysates were then diluted 
10 x with the NP40 lysis buffer. Subsequently, 250 µl of the Bradford reagent was 
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added into all wells and the plate was shaken for 2 min using the plate shaker to ensure 
all reagents were mixed well. Afterwards the plate was incubated for 15 - 45 min at 
room temperature and the OD was measured at 595 nm using a microtiter plate reader 
(PerkinElmer precisely - Envision 2104 multilabel reader). The OD values were 
obtained by Wallac Envision manager software (version 1.12) and the average OD 
readings were calculated for both protein lysates and for BSA standards. A standard 
curve was plotted for the BSA standards with their average OD values versus their 
concentrations in mg/ml. The standard curve was then used to determine the protein 
concentrations in the volumes of the protein lysates used for the assay according to the 
principle of Beer-Lambert law. Subsequently, protein content for each cell lysate 
 ✁✂✄☎✆✂✆✂✝ ✞✟✠✡✞ ☛✝ ☞✌✁✄✍✆✂ ✎✍✌✍  ☎✏ ✑✏☎✄✍✒✓ 
 
2.8.3 Sodium dodecyl sulfate (SDS) - polyacrylamide gel electrophoresis 
(PAGE) (SDS-PAGE) 
This method is used to separate proteins by electrophoresis according to MWs of 
proteins. A polyacrylamide gel is used as a support medium with SDS to denature the 
proteins. Thus, this technique is called sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) [156] [157]. 
 
2.8.3.1 Materials 
Molecular marker (Thermo Scientific, PageRuler plus prestained protein ladder, PC 
- 26619). 
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4 x loading buffer in a total volume of 10 ml - 4 ml glycerol (Sigma-Aldrich, PC - 
G5516 - 100 ml), 2.4 ml Tris 1M (pH 6.8), 0.8 g SDS, 4 mg bromophenol blue, 0.5 ml 
✂-mercaptoethanol (Sigma-Aldrich, PC-M6250 - 10 ml) and 3.1 ml dH2O. 
1.5 M Tris (pH 8.8) - 90.8 g Tris (Sigma-Aldrich, PC - T6066 - 1 kg) was dissolved 
in 500 ml of dH2O and adjusted to the desired pH concentration with HCl. 
1 M Tris (pH 6.8) - 60.57 g of Tris was dissolved in 500 ml of dH2O and adjusted to 
the desired pH concentration with HCl. 
10% SDS (Sigma-Aldrich, PC - L3771 - 25 g) - 1 g SDS dissolved in 10 ml of dH2O. 
10% APS (Sigma-Aldrich, PC - A3678 - 100 g) - 1 g of APS dissolved in 10 ml of 
dH2O. 
10% resolving gel in a total volume of 10 ml - 4.0 ml dH2O, 3.3 ml 30% 
acrylamide/bis acrylamide stock solution (Sigma-Aldrich, PC - A2917 - 100 ml), 2.5 
ml 1.5 M Tris (pH 8.8) (prepared as above), 100 µl 10% SDS (prepared as above), 100 
 ✁ ✄☎✆ ✝✞✟ ✠✡☛☞✡✌☛☞✍ ✌✎ ✌✏✑✒☞✓ ✌✔✍ ✕  ✁ ✖✗ ✖✗ ✖✘✗ ✖✘-tetramethylethylenediamine 
(TEMED) (Sigma-Aldrich, PC - T9281 - 25 ml). 
4% stacking gel in a total volume of 4 ml - 2.7 ml dH2O, 670 µl 30% acrylamide/bis 
acrylamide stock solution, 500 µl 1.0 M Tris (pH 6.8) (prepared as above), 40 µl 10% 
SDS, 40 µl 10% APS and 4 µl TEMED. 
1 x running buffer- 3.03 g Tris, 14.4 g glycine and 1 g SDS were dissolved in 1 l 
dH2O. 
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2.8.3.2 Method  
The first step in SDS-PAGE was to prepare the gels. A 10% resolving gel and a 4% 
stacking gel were cast in a gel cassette (Life technologies, PC - NC2015) immediately 
prior to running the gel. Initially, the resolving gel was allowed to polymerise at room 
temperature for 30 min after removing any air bubbles formed within the gel by drops 
of isopropanol (Sigma-Aldrich, PC - 563935-1 l). Once the resolving gel had set, the 
isopropsanol was removed by H2O and the 4% stacking gel was prepared and poured 
on top of the resolving gel. A 10 well electrophoresis gel comb was placed 
immediately within the stacking gel solution and gels were allowed to set for 30 min 
at room temperature. Subsequently, protein lysates were thawed on ice and centrifuged 
and samples containing 50/75 µg of protein were prepared for SDS-PAGE analysis by 
denaturation with heat. The protein lysates were mixed with 4 x loading buffer and 
heated for 5 min at 95 °C. The samples were then centrifuged (5,000 rpm, 1 min) and 
sonicated for 30 sec before being loaded into sample wells of the stacking gel. 
Sonication was done to shear DNA and reduce sample viscosity. Molecular markers 
(10 µl) were also loaded into one of the peripheral lanes of the gel. The proteins were 
separated by SDS-PAGE in 1 x running buffer at 100 V for 2.5 h. 
 
2.8.4 Western blotting 
With the use of specific antibodies Western blotting allows identification of proteins 
that have been separated from one another according to their size by SDS-PAGE.  
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2.8.4.1 Materials 
Nitrocellulose membrane (0.45 µm) (Bio-Rad, PC - 162-0115), blotting 
paper/chromatography paper (Whatman, PC - 3030 672). 
1x transfer buffer - 3.03 g Tris, 14.4 g glycine, 0.375 g SDS, 200 ml MeOH were 
dissolved in 800 ml dH2O.  
1 x TBS-T - 8 g NaCl and 2.42 g Tris were dissolved in 1 l dH2O and added conc. 
HCl was added to adjust to pH 7.6, tween (0.5 ml) (Fisher Scientific, PC - 10485733) 
was also added and mixed.  
10% non-fat milk - 5.0 g non-fat dried milk in 50 ml TBS-T. 
All antibodies used in Western blotting are listed in table 2.2 
Antibodies 
EGFR (PC - 4267) 
P-EGFR (Tyr1068) (PC - 3777) 
HER2 (PC - 4290) 
P-HER2 (Tyr 1221/1222) (PC - 2243) 
HER3 (PC - 4754) 
P-HER3 (Tyr1222) (PC - 4784) 
HER4 (PC - 4795) 
P-HER4 (Tyr1284) (PC - 4757) 
ER (Sigma-Aldrich, PC - E0521) 
SAPK/JNK (PC - 9258) 
P-SAPK/JNK (Thr183/Tyr185) (PC - 9251) 
p38 (PC - 9212) 
P-p38 (Thr180/Tyr182) (PC - 4511) 
ERK1/2 (p44/42) (PC - 4695) 
P-ERK1/2 (P-p44/42) (PC - 4370) 
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CRAF (PC - 9422) 
P-CRAF (Ser259) (PC - 9421) 
AKT (PC - 4691) 
P-AKT (Ser473) (PC - 4060) 
P-AKT (Thr308) (PC - 2965) 
PTEN (PC - 9188) 
P-PTEN (Ser380) (PC - 9551) 
GSK- ✁ ✂✄☎ - 12456) 
P-GSK-
 ✁ ✂✆✝✞✟✠ ✂✄☎
- 5558) 
P-PDK1 (Ser241) (PC - 3438) 
P-JAK2 (Tyr1007/1008) (PC - 3776) 
P-STAT5 (Tyr694) (PC - 9351) 
Cyclin D1 (PC - 2922) 
4E-BP1 (PC - 9644) 
P-4E-BP1 (Ser65) (PC ✡ 9451) 
eIF4E (PC ✡ 2067) 
P-eIF4E (Ser209) (PC ✡ 9741) 
c-MET (PC ✡ 8198) 
CYP1A1 (Sigma-Aldrich, PC ✡ 
SAB1410273) 
GAPDH (PC - 5174) 
✁
-actin (PC ✡ 3700) 
Anti-rabbit immunoglobulins, horseradish 
peroxidase (HRP) - 2°  (PC - 7074) 
Anti-rabbit immunoglobulins, HRP - 2° 
(Dako, PC - P044801-2) 
Table 2.2: List of 1° and 2° antibodies. All antibodies were purchased from Cell 
signalling technologies except ER and CYP1A1 which were purchased from Sigma-
Aldrich. All 1° antibodies were of rabbit origin except 
✁
-actin which was mouse 
origin. One of the anti-rabbit goat immunoglobulins HRP 2° antibodies was purchased 
from Dako. All 1° antibodies were diluted 1:1000, except for CYP1A1, where a 
dilution of 1:500 was used and 2° antibodies were diluted 1:2000 for Western blotting. 
All 1° antibodies including the 2° antibody from Cell signalling - PC - 7074 were 
stored at -20 °C and the 2° antibody from Dako, PC - P044801-2 was stored at 4 °C.  
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2.8.4.2 Method 
Following gel electrophoresis, the separated proteins were transferred to a 
nitrocellulose membrane by semi dry transfer for further analysis. The gel was 
equilibrated in transfer buffer for ~ 2 - 4 min. During equilibration the nitrocellulose 
membrane and chromatography paper were cut to the dimensions of the gel and the 
membrane was then placed in 50 ml 1 x transfer buffer for 2 min. At the same time 
chromatography papers were also soaked in 50 ml 1 x transfer buffer for 2 min. 
Subsequently, the transfer apparatus (Invitrogen) was assembled from gel to 
membrane as a  ✁✂✄☎✆✝✞✂ ✆✄☎✟✠✡☛☞✌.  All trapped air bubbles were removed and protein 
transfer was conducted at 25 V for 1.5 h.  
 
To block nonspecific protein binding, the membrane was blocked in 10% non-fat milk 
for 1 h at room temperature with gentle agitation. Subsequently, the membrane was 
washed 3 x 5 min with TBS-T and then incubated with the appropriate 1° antibody 
(Table 2.2) in 5% non-fat milk with TBS-T overnight at 4 ºC with gentle agitation. 
The membrane was then washed again 3 x 10 min in TBS-T to take away excess 
unbound 1° antibody after which the membrane was incubated with a goat anti-rabbit 
HRP-conjugated 2° antibody (Table 2.2) in 5% non-fat milk with TBS-T for a further 
1 h at room temperature with gentle agitation. This was followed by washing the 
membrane for 3 x 10 min in TBS-T to remove excess unbound 2° antibody. 
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2.8.5 Immunological detection 
In order to identify specific proteins blotted to membranes immunological detection 
systems are used.  
 
2.8.5.1 Materials 
Enhanced chemiluminescence (ECL) Western blotting detection reagent (GE 
Healthcare Life Sciences, Amersham ECL, PC - RPN2209), hyperfilm (GE 
Healthcare Life Sciences, Amersham Hyperfilm ECL, PC - 28-9068-39), developer 
(Sigma-Aldrich, Kodak autoradiography GBX developer, PC - P7042 - 1 gal), fixer 
(Sigma-Aldrich, Kodak autoradiography GBX fixer, PC - P7167 - 1 gal).  
 
2.8.5.2 Method 
Following the final washing step, the membrane was incubated with ECL substrate 
mixture (Reagent A and B were mixed to a ratio of 1:1) for 1 min at room temperature. 
The membrane was removed from the substrate and excess substrate was drained. The 
membrane was sandwiched between cellulose acetate sheets and taped inside a film 
cassette removing any air bubbles and exposed to the hyperfilm in the dark for variable 
exposure periods depending on the strength of the signals. The film was developed 
using appropriate developing solution and fixative. Subsequently, the film was 
washed, air dried and then scanned using a densitometer (GS-800, Bio-Rad) in 
grayscale using the quality one software version 4.6.5. Densitometry of the blots was 
conducted using ImageJ software (version 1.48). Mean area densities and the relative 
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incorporated ribonucleic acid (RNA) purification, reverse transcription and 
amplification of the complementary DNA (cDNA) by real time PCR using primers 
specific for the genes of interest. The real time signal is a measure of the fluorescence 
generated when the SYBR green dye intercalates into the minor groove of double 
stranded DNA following each PCR cycle.  
 
2.12.1 RNA purification 
2.12.1.1 Materials 
TRI reagent (Sigma-Aldrich, PC - T9424), chloroform (Sigma-Aldrich, PC - C2432 - 
25 ml), 2-propanol (Sigma-Aldrich, PC - I9516 - 25 ml), 75% ethanol (Sigma-Aldrich, 
PC - E7023 - 500 ml) (75 ml of ethanol was mixed with 25 ml of dH2O to make 75% 
ethanol). 
 
2.12.1.2 Method  
Cells were seeded at a density of 2 x 106 in 10 cm petri dishes and incubated for 24 h. 
Following treatment and the required exposure period, cells were then trypsinised and 
pelleted into microcentrifuge tubes. TRI reagent (1 ml) was added into each tube and 
the cell pellets were passed through a pipette several times to form homogenous cell 
lysates which were allowed to stand for 5 min at room temperature. Chloroform (200 
µl) was added and the samples were shaken vigorously for 15 sec and left at room 
temperature for 15 min. The resulting mixture was centrifuged at 12,000 rpm for 15 
min at 4 °C. Centrifugation separated the mixture into 3 phases and the colourless 
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upper aqueous phase which contained RNA was transferred to fresh tubes. Afterwards, 
0.5 ml of 2-propanol was added with mixing. Then the samples were allowed to stand 
for 10 min at room temperature and centrifuged at 12,000 rpm for 10 min at 4 °C. 
RNA was precipitated and a pellet was formed. The supernatant was removed and the 
RNA pellet was washed with 1 ml 75% ethanol. The samples were vortexed and then 
centrifuged at 7,500 rpm for 5 min at 4 °C. The RNA pellet was air-dried for 10 min 
and 20 µl of ddH2O was added to the pellet. RNA concentration was measured by a 
nanodrop (Thermo Scientific, NanoDrop, 1000) and stored at -80 °C.  
 
2.12.2  Reverse transcription (Preparation of cDNA) 
2.12.2.1 Materials 
SuperScript III reverse transcriptase kit stored at -20 °C (Life technologies, PC - 
18080-093). The kit contained SuperScript III RT (200 U/µl) 10 µl, 5 x first-strand 
buffer 1000 µl and 0.1 M dithiothreitol (DTT) 500 µl, Oligo (dT)20 primer (Life 
technologies, PC- 18418-020), deoxynucleotide solution (dNTP) mix (10 mM each) 
(Life technologies, PC - R0192) and RNaseOUT recombinant RNase inhibitor (Life 
technologies, PC   10777-019). 
 
2.12.2.2 Method 
Oligo (dT)20 (1 µl), 5 µg RNA, 1 µl dNTP mix and 13 µl ddH2O was added into a 
microcentrifuge tube and mixed. The mixture was heated up to 65 °C for 5 min and 
incubated on ice for 1 min. First-strand buffer (4 µl; 5 x), 1 µl 0.1 M DTT, 1 µl 
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RNaseOUT, 1 µl SuperScript III RT was added and mixed by pipetting. This mixture 
was incubated for 60 min at 50 °C and the reaction was inactivated by heating at 70 
°C for 15 min. cDNA was stored at -20 °C.  
 
2.12.3 Amplification of cDNA by real time PCR (QPCR) 
2.12.3.1 Materials 
Brilliant II SYBR green QPCR master mix stored at -20 °C (Agilent technologies, PC 
- 600828).  
Below mentioned primers  ✁✂✁ ✄✁☎✆✝✞✁✄ ✟✂✠✡ ☛☞✞✆✌✁✂☎✍✎ ✏✂✠✑✁ Library Assay Design 
✒✁✞✓✁✂✔ ✠✟ ✓✕✁ ✖✠✗✕✁  ✁✑☎✆✓✁ ✍✞✄ ✓✕✁✘  ✁✂✁ ✠✂✄✁✂✁✄ ✟✂✠✡ ✙✆✝✡✍-Aldrich. 
EGFR- ✚✠✂ ✍✂✄ ✛✜✔-✢✔✣- TTCCTCCCAGTGCCTGAA  
✖✁✌✁✂☎✁ ✛✜✔-✢✔✣- GGGTTCAGAGGCTGATTGTG 
CYP1A1- ✚✠✂ ✍✂✄ ✛✜✔-✢✔✣- AGTGGCAGATCAACCATGAC 
     ✖✁✌✁✂☎✁ ✛✜✔-✢✔✣- TTGTCGATAGCACCATCAGG 
GAPDH- ✚✠✂ ✍✂✄ ✛✜✔-✢✔✣- AGGTGAAGGTCGGAGTCAAC 
    ✖✁✌✁✂☎✁ ✛✜✔-✢✔✣- GATGACAAGCTTCCCGTTCT 
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2.13.1 Materials 
Nitrocellulose-coated glass slides (Grace-Bio-labs, PC - 305116), blocking solution - 
0.2% I-block (Applied biosystems, PC - T2015) and 0.1% tween in PBS, antibody 
diluent (Dako, PC - S080981-2). 
 
2.13.2 Method  
Cells were seeded at a density of 1 x 106 in 10 cm petri dishes and incubated for 24 h. 
Following treatment and the required exposure period, cell lysates were collected by 
adding NP40 lysis buffer with phosphatase and protease inhibitors. Lysates were 
solubilised in 4 x SDS sample buffer at a ratio of 1:3 respectively and heated for 5 min 
at 100 °C. Samples (10 µl) were loaded onto a 384 well plate (Life technologies, PC - 
AB-1055). Samples were robotically spotted in duplicates onto nitrocellulose-coated 
glass slides using a microarraying robot (MicroGrid 610, Digilab). Slides were 
incubated overnight in blocking solution at 4 °C with constant shaking. After washing 
3 x 5 min each in 1 x TBS-T, the slides were incubated with the 1° antibodies (Table 
2.2, except HER4, ER, CYP1A1, 4E-BP1, eIF4E and c-MET antibodies). 
Subsequently, antibodies were diluted in antibody diluent  ✁✂✁✄✄✄☎✆ ✝✞ ✟✠✠✡☛✡☞✞✌ ✍-
actin (diluted 1:1000 in the same diluent) was used as a protein loading control. Slides 
were incubated overnight at 4 °C while shaking.   
Following washing, as described above, the slides were incubated with diluted infrared 
Licor 2° antibodies (1:5000 in 1 x TBS-T) - 800 CW (green) anti-rabbit antibody for 
detection of rabbit 1° antibodies and 700 CW (red) anti-mouse antibody for detection 
☞
✎
✍
-actin, for 30 min at room temperature in the dark while shaking. Then slides were 
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dissolving the Gefitinib solution in 1ml of PBS (pH 7.2) (1:1 solution of DMSO:PBS) 
to make a final concentration of 1 mM. H- ✁✂ ✄✂ ✄ ☎✆✝☎✞✝✂✟✄✂✠✆✝ ✆✡ ☛☞✌ ✍✎✏✄✑ ✄✒✒✞✒
to this solution where the concentration of Gefitinib was ~ 40-fold in excess of H-AFt. 
The resulting solution was stirred overnight at 4 °C so that Gefitinib would be diffused 
into H-AFt. Afterwards, this solution was exhaustively dialysed for 48 h at 4 °C in 20 
mM Tris (pH 8.0) using a dialysis membrane (MW cut off 8,000 Da) to remove all 
molecules < 8,000 Da MW, and therefore to remove un-encapsulated Gefitinib. The 
solution was centrifuged at high speed (13,000 rpm, 12 min, 4 °C) to remove any 
impurities and the supernatant was transferred to a new tube and stored at -20 °C. The 
fluorescence of the resulting solution was visualised under UV. The protein 
concentration of the encapsulated agent was determined by Bradford assay. In order 
to avoid degradation of the prepared test agent, a fresh agent was prepared every 3 
months. 
 
2.14.2 Determining encapsulation efficiency  
2.14.2.1 Method 
Encapsulated Gefitinib was quantified by UV spectrometry after weighing and freeze-
drying the encapsulated NPs for 8 h and dissolving in DMSO. Afterwards, the 
absorbance of Gefitinib was read at 250 nm by Perkin Elmer precisely Lambda 25 
UV/VIS spectrometer. Results were analysed using Perkin Elmer UV WinLab 
software (version 6.0.4.0738). A standard curve for Gefitinib was assembled using 6 
serial dilutions in the range of 0.5 - 250 ✍✎✓ ✑✔✕✑✞✖✔✞✝✂✗✘, the amount of Gefitinib 
encapsulated within H-AFt was determined according to the Beer-Lambert law which 
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Figure 3.2: Densitometry plots of protein expression levels of (a) EGFR (b) HER2 
(c) HER3 (d) HER4 and (e) ER in the breast cancer cell line panel. Mean and SD 
of  ✁✂✄☎✆ ✝ ✞. 
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It was observed that MDA-MB 468 cell line expressed EGFR to the greatest extent, 
corroborating previous observations of EGFR overexpression on this cell line [34]. 
MDA-MB 231 also overexpressed EGFR. SKBR3, ZR-75-1 and T47D cell lines 
expressed moderate levels of EGFR. MCF7 expressed the least amount of EGFR. 
SKBR3 cell line overexpressed HER2 and the T47D cell line expressed moderate 
levels of HER2. Among the breast cancer cell lines, T47D expressed large levels of 
HER3 while MCF7 and MDA-MB 231 cell lines expressed moderate levels of HER3. 
SKBR3 expressed low levels of HER3 while MDA-MB 468 and ZR-75-1 barely 
expressed HER3. MCF7 cell line was the only cell line that expressed HER4 (Figure 
3.1) and (Figure 3.2 (a-d)). 
 
T47D expressed ER most abundantly among the 6 breast cancer cell lines, 
corroborating previous studies [166]. The MCF7 cell line expressed moderate levels 
of ER while ZR-75-1 expressed low levels of ER. MDA-MB 468, SKBR3 and MDA-
MB 231 cell lines did not express ER, as expected (Figure 3.1) and (Figure 3.2 (e)). 
These results corroborated previous literature as mentioned in chapter 1, section 1.3, 
with respect to HER family and ER protein expression confirming that these breast 
cancer cell lines have retained their established molecular phenotypes in the panel of 
cell lines used [27] [31] [166] [167].  
 
3.2.2 Cellular growth assay 
It has been shown that various steroid hormones, peptide hormones and growth factors 
are involved in the growth and regulation of breast cancer cells [168]. Thus, 
propagation of these cancerous cells in vitro requires specific culture conditions and 
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culture media. Various culture media have been developed in many laboratories to 
support the growth of breast cancer cells of different lineages. In general, the culture 
medium used has to provide all essential nutrients for cell metabolism, growth and 
proliferation. Commonly culture media are supplemented with animal serum, and 
most commonly with FBS to promote cell growth and proliferation. It has been 
demonstrated that animal serum is an extremely complex mixture of low and high 
weight biomolecules with diverse growth promoting and growth inhibiting activities 
[169] [170]. 
 
The main function of serum in culture media is to provide hormonal and growth 
stimulating factors that initiate cell growth and proliferation. However, in the tissue 
culture environment, the presence of hormones and growth factors in the serum at 
times complicates the demonstration of specific effects on growth of cells [168]. FBS 
is found to be of better quality than serum from adult animals because of its low 
gamma globulin content while a high content of antibodies from adult animal serum 
may inhibit growth and proliferation [169].  
 
In the current study, the effect of FBS on the proliferation of breast cancer cell types 
was studied. Previous studies have portrayed that growth of ER+ breast cancer cells is 
stimulated by both oestrogens and growth factors which enhance the production and 
secretion of a number of proteins, while cells which are ER- are only stimulated by 
growth factors [171]. Further, following long term oestrogen deprivation, breast 
cancer cell lines have shown an adaptive process with an increase in ER expression 
and high sensitivity to low levels of oestrogen. Furthermore, cancer cells have been 
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A typical growth curve will immediately show a lag phase lasting up to 48 h. 
Subsequently, the cells enter into an exponential growth phase termed as the log phase, 
in which the cell population doubles repeatedly. During the log phase the effects of 
pharmacological agents or chemical agents that stimulate or inhibit cell growth can be 
studied. After the log phase, when the cell population becomes very dense, cells enter 
into a stationary phase and the growth rate ceases. Finally the cells enter into a decline 
phase where cells die and the cell population declines [145].  
 
The MCF7 cell line showed a high growth rate in 2% FBS compared to all other cell 
lines. The growth curves for both FBS levels were not statistically different from each 
other, apart from days 5 and 9 in log phase and days 14 - 17 in stationary phase (Figure 
3.3 (a)) (P < 0.01). The cells showed a high exponential growth from days 8 - 14 in 
both growth curves. The population doubling time was 36 h for MCF7 cells that were 
in medium supplemented with 10% FBS. The population doubling time for cells in 
medium supplemented with 2% FBS was also ~ 36 h. The cell number reduced rapidly 
  ✁✂✄ ☎✆ ✝✞ ✟✠✁✝✡✟ ☛✡☞☞✌✠✟✠✞✍✠✁ ✝✞ ✎✏ ✑✒✓ ✔✕✠✞ ✖✗✟☞✂✘✠✁ ✍✗ ☎✙✏ ✑✒✓✚  
 
MCF7 cells are ER+ and express very low levels of EGFR [28] [173]. Oestrogens are 
well known to stimulate an array of biosynthetic processes in hormone responsive 
target cells. Studies have shown that MCF7 cells are able to convert oestrone sulfate 
which is a non-oestrogenic compound included in culture medium to oestrone and that 
these cells are able to stimulate growth even at low serum levels such as 0.05% FBS 
[174]. Further, it has been reported that these cells are able to produce growth factors 
☛✡✖✕ ✂☛
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in growth signals  [37] [175]. Another study has shown that phenol red the commonly 
used pH indicator in tissue culture medium has some structural resemblance to certain 
nonsteroidal oestrogens and that phenol red possesses oestrogenic properties. It 
stimulates cell proliferation in a dose dependent manner in oestrogen responsive cells. 
Thus, MCF7 cells grown in phenol red-containing medium may be oestrogen 
stimulated [176]. Further as outlined in chapter 1, it is reported that oestrogens are able 
to activate the RAS/MAPK pathway showing cross talk between ER and RAS/MAPK 
which plays a role in cell growth and differentiation thus, increasing cell growth in 
this cell line even in low serum levels [177]. In contrast a study done by Clark et al, 
2002, has shown that MCF7 cells show low levels of AKT phosphorylation due to 
wild type PTEN expression in medium supplemented with 10% FBS and in serum 
deprived medium implying that these cells do not hyperactivate the PI3K/AKT 
pathway. Thus, it can be suggested that oestrogen stimulation may play a key role in 
the growth of this cell line and that these cells are secreting their own growth factors 
that stimulate growth even in serum depleted medium.  
 
T47D cells grew rapidly in medium supplemented with 10% FBS from day 10 
onwards when compared to cells in medium supplemented with 2% FBS (P < 0.0001) 
(Figure 3.3 (b)). The doubling time for cells in medium supplemented with 10% FBS 
was 48 h. These results suggest that T47D cell proliferation heavily depends on the 
level of serum compared to MCF7 cells although, both cell lines are ER+ and 
categorised under the luminal A subtype.  
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Further, it implies that T47D cells are unable to secrete autocrine growth factors to 
stimulate growth unlike MCF7 cells although T47D expressed a higher level of ER. 
Indeed, it has been shown previously that MCF7 cells are able to produce more growth 
factors compared to T47D and ZR-75-1 cells [30]. On the other hand, T47D cells 
expressed higher levels of EGFR, HER2 and HER3 than MCF7 cells, suggesting that 
these cells may depend on exogenous growth factors for stimulation. Hence, in 2% 
FBS which had low levels of growth factors these cells demonstrated low growth.   
 
ZR-75-1 cells also demonstrated hindered growth in medium supplemented with 2% 
FBS with a short log phase whereas cells in medium supplemented with 10% FBS 
showed rapid growth during the log phase. There was a significant difference in the 
cell numbers between cells cultured in medium with 2% and 10% FBS during the 12th 
day and 19th day (P < 0.0001) (Figure 3.3 (c)). The cell doubling time in medium 
supplemented with 10% was ~ 48 h. This cell line is also ER+ and showed similar 
growth characteristics to the T47D cell line.  
 
SKBR3 cells did not show a high growth rate in medium supplemented 10% FBS and 
these cells had the shortest incubation period compared to the other cell lines as all 
cells detached and died at ~ day 16. Further, cells in medium with 2% FBS showed 
retarded growth and entered a quiescent state from day 3 which has been shown 
previously [178]. High cell numbers were observed in the log and stationary phases 
between days 10 - 14 in medium supplemented with 10% FBS compared to cells that 
were in medium with 2% FBS (P < 0.0001) (Figure 3.3 (d)). This cell line showed a 
doubling time of 24 h for cells in medium supplemented with 10% FBS. As these cells 
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are ER- and PR- their growth is not stimulated by hormones. Therefore, growth 
factors, receptors and activated signal transduction cascades may play a major role in 
SKBR3 cell proliferation [179]. It has been reported that serum starvation decreased 
AKT (Ser473) phosphorylation in SKBR3 cells, suggesting that this cell line depends 
on serum derived growth factors for AKT (Ser473) phosphorylation in the PI3K/AKT 
pathway when compared to other breast cancer cell lines which have also been serum 
starved. In contrast, these cells have shown AKT (Thr308) phosphorylation in 
response to serum starvation and that Thr308 phosphorylation may be associated with 
HER2 overexpression in this cell line [180]. However, for AKT to achieve full 
activation, phosphorylation is needed at both Ser473 and Thr308, upon growth factor 
and receptor binding [181]. Therefore, this may underpin the retarded growth in 
medium supplemented with 2% FBS.  
 
MDA-MB 468 cells showed excellent growth in medium supplemented with 2% FBS 
(Figure 3.3 (e)). However, there was a significant difference in the cell numbers 
between days 8 - 14 (P < 0.0001) and days 16 - 17 (P < 0.01) with a population 
doubling time of 24 h for cells that were in medium supplemented with 10% FBS and 
a population doubling time of ~ 48 h for cells that were in depleted medium. This cell 
line is PTEN deficient, thus, Clark et al, 2002, has demonstrated that even under serum 
starvation MDA-MB 468 cells have showed phosphorylation at both Ser473 and 
Thr308 residues of AKT [180] [182]. Further, the mTOR pathway is also highly 
activated in these cells which demonstrates the reason for somewhat large cell 
numbers in medium supplemented with 2% FBS [182].  
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The MDA-MB 231 cell line showed significantly reduced growth in medium 
supplemented with 2% FBS when compared to growth in medium supplemented with 
10% FBS during days 6 - 15 (P < 0.0001) (Figure 3.3 (f)). The doubling time for cells 
that were in medium with 10% FBS was 36 h. Clark et al, 2002, demonstrated that 
MDA-MB 231 cells showed low levels of phosphorylated AKT in medium 
supplemented with 10% FBS and serum deprived medium suggesting that these cells 
show reduced AKT activity [180]. In contrast, MDA-MB 231 cells harbour a mutant 
form of the RAS gene (K-RAS) [72]. Thus, the RAS/MAPK pathway is constitutively 
activated in these cells, which could be a reason for high cell numbers in medium 
supplemented with 10% FBS. Furthermore, Leong et al, 2010, reported that MDA-
MB 231 cell proliferation was inhibited when cells were subjected to prolonged serum 
starvation and that they entered an inactive state [183]. Interestingly, the same authors 
have shown that in serum starvation, MDA-MB 231 cells showed a loss of 
phosphorylated ERK although these cells exhibits a mutated form of RAS which may 
indicate another reason for hindered growth in medium supplemented with 2% FBS 
[183].  
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3.2.3 In vitro growth inhibitory effects of EGF, Gefitinib, Erlotinib and 
Raloxifene 
Using MTT viability assays the anti-proliferative effects of EGF, Gefitinib, Erlotinib 
and Raloxifene were investigated in all 6 breast cancer cell lines in the presence of 
medium supplemented with 2% FBS and 10% FBS. GI50 values were determined for 
all agents; results are summarised in the tables below.  
(a) EGF Mean GI50 ± SD (72 h MTT assays) 
Cell line Medium supplemented 
with 2% FBS 
Medium supplemented with 
10% FBS 
MCF7 >10 nM >10 nM 
T47D >10 nM >10 nM 
ZR-75-1 >10 nM >10 nM 
SKBR3 9.89 nM ± 2.97 0.50 nM ± 0.38 
MDA-MB 468 6.78 nM ± 3.40 7.78 nM ± 3.15 
MDA-MB 231 >10 nM >10 nM 
 
 
(b) Gefitinib Mean GI50 ± SD (72 h MTT assays) 
Cell line Medium supplemented 
with 2% FBS 
Medium supplemented with 
10% FBS 
MCF7 15.83 µM ± 10.34 >25 µM 
T47D 1.26 µM ± 0.88 4.12 µM ± 1.53 
ZR-75-1 1.77 µM ± 1.14 4.84 µM ± 2.07 
SKBR3 0.25 µM ± 0.15 0.94 µM ± 0.85 
MDA-MB 468 0.24 µM ± 0.15 2.01 µM ± 1.21 
MDA-MB 231 16.68 µM ± 1.40 21.80 µM ± 0.74 
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(c) Erlotinib Mean GI50 ± SD (72 h MTT assays)           
Cell line Medium supplemented 
with 2% FBS 
Medium supplemented with 
10% FBS 
MCF7 >25 µM >25 µM 
T47D 10.47 µM ± 4.29 12.96 µM ± 2.07 
ZR-75-1 10.95 µM ± 0.69 14.72 µM ± 4.11 
SKBR3 12.23 µM ± 1.36 17.34 µM ± 1.75 
MDA-MB 468 2.48 µM ± 2.20 13.90 µM ± 1.15 
MDA-MB 231 >25 µM >25 µM 
 
(d) Raloxifene Mean GI50 ± SD (72 h MTT assays) 
Cell line Medium supplemented 
with 2% FBS 
Medium supplemented with 
10% FBS 
MCF7 7.06 µM± 0.22 18.88 µM± 1.96 
T47D 6.59 µM ± 3.12 16.76 µM ± 1.42 
ZR-75-1 5.94 µM ± 0.83 15.75 µM ± 1.60 
SKBR3 13.64 µM ± 1.07 19.22 µM ± 0.71 
MDA-MB 468 6.95 µM ± 1.67 15.00 µM ± 0.87 
MDA-MB 231 7.37 µM ± 2.28 16.81 µM ± 0.90 
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Table 3.1: Mean GI50 ± SD values of (a) EGF, (b) Gefitinib, (c) Erlotinib, (d) 
Raloxifene and (e) DMSO (vehicle control). Pharmacological agents' activity was 
tested in cells grown in medium supplemented with 2% and 10% FBS. DMSO was 
used as the solvent for some pharmacological agents. The effect of DMSO was tested 
in medium supplemented with 10% FBS. Cells were seeded in 96 well plates at a 
density of 2.5 x 103 cells/well. After allowing time to adhere (24 h), cells were exposed 
to agents (72 h; n = 8 ✁ ✂✄☎✆ ☎✆✝ ✞✟ ✠✡ ☛☞✌☎✍✎ ✏ ✑✁ 
 
EGF is an important regulator of cell growth. It has been reported that EGF acts as a 
mitogen in some human breast cancer cell lines, suggesting that it may be an additional 
hormonal factor regulating growth of breast cancer in certain patients with this disease 
[120]. In contrast, EGF mediated apoptosis has also been reported in some tumour cell 
lines [34] [184]. However, the results of studies investigating the effect of EGF still 
remain controversial as conflicting results have been reported. Therefore, the effect of 
EGF was investigated on growth of all 6 breast cancer cell lines in medium 
supplemented with 10% and 2% FBS. It has been reported that > 1,000 proteins are 
(e) DMSO  Mean GI50 ± SD 
(72 h MTT assay) 
Cell line Medium supplemented 
with 10% FBS 
MCF7 >1% 
T47D 0.82% ± 0.11 
ZR-75-1 0.85% ± 0.03 
SKBR3 >1% 
MDA-MB 468 >1% 
MDA-MB 231 >1% 
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present in serum, thus EGF could be also present [170]. Hence, by using serum 
depleted medium the effect of EGF could be more readily observed.  
 
Out of the 6 cell lines, the HER2 overexpressing SKBR3 cell line appeared to be most 
sensitive to growth inhibitory properties of EGF showing a low GI50 value in medium 
supplemented with 10% FBS (GI50 = 0.50 nM) (Table 3.1 (a)). It has been found that 
there is an inverse relationship between the amount of EGFR and EGF induced 
mitogenesis. Thus, low expression of EGFR is associated with growth stimulation by 
EGF, while high EGFR expression is correlated with growth inhibition by EGF [34] 
[185]. In this study, MCF7, T47D and ZR-75-1 cell lines express low levels of EGFR, 
and are ER+ (Figure  3.1) and (Figure 3.2) and were not inhibited by EGF in neither 
medium supplemented with 2% nor 10% FBS. Fitzpatrick et al, 1984, revealed that 
EGF (10 nM) was able to stimulate cell proliferation in MCF7 and T47D cells and that 
it works as a mitogen [186]. In contrast to these results, the HER2 overexpressing 
SKBR3 cell line was inhibited by EGF in 10% FBS as outlined above. Previous studies 
have portrayed that cells which express high levels of both EGFR and HER2 
invariably undergo apoptosis rather than proliferation in response to EGF [178]. It has 
been suggested that ligand dependent apoptosis in cells that express high levels of 
EGFR and HER2 such as SKBR3 cells is a natural mechanism that protects cells from 
excessive proliferation in response to high amounts of EGF activated signalling [178]. 
However, in serum depleted medium, SKBR3 cells showed a GI50 value of 9.89 nM. 
The growth of this cell line was compromised heavily as shown in section 3.2.2, in 
2% FBS. As a consequence, EGF could be creating conflicting signals in 2% FBS 
since EGF is known to act as a mitogen and also an inhibitor. Although MDA-MB 
Chapter 3 
162 
 
468 and MDA-MB 231 cell lines expresses high levels of EGFR, this agent was not 
potent in these cells in both 2% and 10% FBS. It could be because both these cell lines 
express high levels of EGFR only. Further, MDA-MB 468 cells possess deficient 
PTEN and MDA-MB 231 cells harbour mutant K-RAS leading to constitutive 
activation of the PI3K/AKT and RAS/MAPK pathways [62] [180] [187].  
 
In medium supplemented with 2% FBS, increased Gefitinib potency was observed 
compared to medium supplemented with 10% FBS in all 6 breast cancer cell lines 
(Table 3.1 (b)). However, this could be due to growth of some cell lines being much 
reduced in serum depleted medium. Further, it has been shown that serum has an 
inhibitory effect and pharmacological agents are shown to bind to specific proteins of 
serum which partially prevents uptake of the agents by cells; thus reducing potency 
[188]. On the other hand, among all the cell lines tested in medium supplemented with 
10% FBS; SKBR3 cells showed the highest sensitivity to Gefitinib (GI50 = 0.94 µM). 
Amidst the cell lines expressing high levels of EGFR; the MDA-MB 468 cell line 
demonstrated a GI50 value of 2.01 µM and the MDA-MB 231 cell line did not show 
sensitivity (GI50 = 21.80 µM) in medium supplemented with 10% FBS. Of the ER+ 
cell lines both T47D and ZR-75-1 cell lines showed moderate sensitivity while the 
MCF7 cell line was unresponsive to Gefitinib.  
 
Previous research has demonstrated that efficacy of Gefitinib is not directly related to 
EGFR expression levels. In fact, high EGFR expression levels have not been shown 
sensitivity to Gefitinib due to molecular defects in downstream signalling pathways 
[189]. HER2 expression appeared to be important for the sensitivity of this agent. 
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Indeed, prior work has demonstrated that Gefitinib is extremely effective in inhibiting 
tumours that express high HER2; hence high sensitivity was observed in the HER2 
overexpressing SKBR3 cell line [189]. HER2 remains the preferred dimerisation 
partner of other HER receptors. Although both homo- and heterodimerisation activates 
the EGFR network, heterodimers are found to be more potently mitogenic and HER2 
heterodimers generate the strongest biological activity compared to other heterodimers 
[49] [189]. However, Gefitinib does not directly inactivate HER2 thus, the presence 
of EGFR is necessary for inactivation of HER2 signalling which explains the 
sensitivity of SKBR3 cells to Gefitinib [189] [190].  
 
Similar to Gefitinib the effect of Erlotinib was investigated by MTT assays using the 
6 breast cancer cell lines. All cell lines tested were resistant to this agent when 
compared to the results of Gefitinib (Table 3.1 (c)). Gefitinib and Erlotinib are 
structurally related, but distinct and possess different affinities towards EGFR [99]. 
Further, Guix et al, 2005, reported that treatment with Erlotinib before surgery in 14 
patients diagnosed with breast cancer resulted in significant down-regulation in the 
RAS/MAPK pathway with reduced cell proliferation. However, they did not see cell 
apoptosis and down-regulation of the PI3K/AKT pathway [191]. In fact, Normanno et 
al, 2006, indicated that anti-EGFR agents are effective only in tumours that 
demonstrate down-regulation of both RAS/MAPK and PI3K/AKT pathways, which 
may explain a reason for resistance towards this agent in this study [192].  
 
Research has shown cross talk between ER and EGFR pathways; thus membrane 
bound ER is able to activate EGFR, HER2, PI3K and Src. The Src family of protein 
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tyrosine kinases, plays a major role in regulating signal transduction by a diverse set 
of cell surface receptors including steroid receptors [88]. Further, ERK1/2 of the 
RAS/MAPK pathway also activate ER and the ER coactivator AIB1 (Src3) [60] [87]. 
Osborne et al, 2005 has shown that growth of the MCF7 xenografts in athymic mice 
is stimulated by oestrogen and inhibited by oestrogen deprivation either alone or in 
the presence of Tamoxifen. Tamoxifen is a pioneering SERM and used as an anti-
cancer targeted therapy for ER+ breast cancers. This agent is also used to prevent 
development of breast cancer in high risk women [115]. However, the anti-cancer 
effects of Tamoxifen is temporary because resistance emerges after several months of 
treatment in some patients [87] [89]. Indeed, in the presence of excessive levels of ER, 
AIB1 and HER2, Tamoxifen has shown to behave as an oestrogen agonist and 
stimulate tumour growth. These results imply that other SERMs might be more 
effective than Tamoxifen [87]. Raloxifene is a second generation SERM similar to 
Tamoxifen. Raloxifene has also been shown to possess mixed agonist and antagonist 
activity similar to Tamoxifen [193]. Nevertheless, Raloxifene is primarily used to treat 
postmenopausal osteoporosis and it is also used to reduce the risk of developing breast 
cancer in postmenopausal women but with fewer side effects compared to Tamoxifen 
[115]. Hormone replacement therapy has shown to reduce menopausal symptoms and 
protect postmenopausal women from osteoporosis. However, as outlined in chapter 1 
hormone replacement therapy is associated with an increased risk of breast cancer. 
This effect restricts the clinical use of hormone replacement therapy for long periods 
for the prevention of osteoporosis. Raloxifene has shown to act as an oestrogen agonist 
in the skeleton and it counteracts the effects of oestrogen in the breast and uterus [193]. 
The effect of Raloxifene was tested against the panel of breast cancer cell lines in this 
study to determine the effect of this agent on breast cancer, although it is not used as 
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a therapy currently for breast cancer. It was found that none of the cell lines tested 
were sensitive towards Raloxifene in both medium supplemented with 2% or 10% 
FBS (Table 3.1 (d)). However, this agent portrayed a dose dependent growth inhibitory 
effect at higher concentrations in the MTT assays with all tested breast cancer cell 
lines. Interestingly, Raloxifene was found to function as an AhR ligand [141]. Thus, 
its action as an AhR ligand was evaluated. These results are described in chapter 6.  
 
DMSO was used as a solvent to dissolve many pharmacological agents in this study. 
It is a chemical that dissolves both polar and nonpolar compounds and it is found to 
be miscible with a wide range of organic solvents and with H2O [194]. DMSO was 
tested in all 6 breast cancer cell lines to determine whether it contributed to the 
inhibition seen with the pharmacological agents. It was tested at a concentration range 
of 0.01% - 1%. MCF7, SKBR3, MDA-MB 468 and MDA-MB 231 cell lines were not 
influenced by DMSO vehicle control. However, a marginal effect was observed with 
T47D and ZR-75-1 cell lines between 0.5% and 1% concentrations of DMSO (Table 
3.1 (e)). Nevertheless, the final concentration of DMSO vehicle used within the agents 
never exceeded 0.05% which is a negligible concentration to impact cell viability.  
 
Out of the 4 pharmacological agents tested, EGF and Gefitinib were found to be potent 
in the HER2 overexpressing SKBR3 cell line. Thus, these 2 agents were selected for 
further investigations against this cell line. Although Gefitinib demonstrated a potent 
effect in SKBR3 cells in medium supplemented with 2% FBS, this cell line showed 
hindered growth with 2% FBS. Hence, only medium supplemented with 10% was used 
for further studies. Further, it has been shown that 10% FBS, would provide a more 
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natural context and the results found may be more physiologically relevant [184]. 
Below are representative MTT dose response curves of EGF and Gefitinib against the 
SKBR3 cell line in medium supplemented with 2% and 10% FBS (Figure 3.4). As it 
is seen in the graphs treatment with EGF and Gefitinib for 72 h resulted in dose 
dependent growth inhibition. An extremely significant growth inhibition was observed 
at higher concentrations (P < 0.0001).  
   
 
 
 
 
 
  
 
 
 
 
Figure 3.4: Growth inhibitory curves for EGF and Gefitinib against SKBR3 cells. 
(a) EGF in medium supplemented with 2% FBS, (b) EGF in medium supplemented 
with 10% FBS, (c) Gefitinib in medium supplemented with 2% FBS and (d) Gefitinib 
in medium supplemented with 10% FBS. Mean and SD of representative experiments 
 ✁✂ ✄☎✆✝✞ ✟✞ ✠ ✡ ☛✂✁ ☞✁✌ ✍✎✏ ☞✁✌ ✍✄ ✑ ✒✓ ✔ ✌✞✕✌✖ ☞✂✄ ✄✌✗✞✌✘✌✖ ✞☞ difference compared to 
control, * (P < 0.05), ** (P < 0.01), *** (P < 0.001), **** (P < 0.0001). 
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The mean SFs obtained indicated that both EGF (2x GI50) SF = 65.78%; P < 0.05) and 
Gefitinib (2x GI50) SF = 47.71%; P < 0.01) affected survival and proliferative capacity 
of SKBR3 cells significantly by reducing the number of colonies and also the size of 
the colonies formed compared to SKBR3 control within 14 days. These results 
corroborate with the results of the MTT assays and these results suggest that both 
agents exert a cytostatic as well as a moderate cytotoxic effect at the concentrations 
tested - 1x and 2x GI50.  
 
3.2.5 Effects of EGF and Gefitinib on SKBR3 cell cycle 
To determine the effect of EGF and Gefitinib on SKBR3 cell cycle progression, flow 
cytometry analysis was performed on cells treated with 2x GI50 concentrations of EGF 
and Gefitinib for 24, 48 and 72 h. As shown in figure 3.6, significant G1 arrests were 
caused by EGF (67.39%) (P < 0.01) and Gefitinib (80.67%) (P < 0.0001) compared to 
control (62.26%) after 24 h. This was followed by a corresponding decreased S phase 
(6.69%) which was extremely significant (P < 0.0001) and a significantly decreased 
G2/M phase (12.18%) (P < 0.05) in cells treated with Gefitinib compared to control 
cells (S phase - 15.25% and G2/M phase - 16.83%) in 24 h. In contrast, EGF caused a 
non-significant increased S phase (17.96%) compared to control cells whereas the 
G2/M phase (15.68%) was similar to control at 24 h.  
 
After 48 h, EGF maintained accumulated G1 events (67.20%) (P < 0.001) compared 
to control (62.72%). Unlike 24 h, after 48 h EGF treatment demonstrated decreased S 
(15.69%) and G2/M phases (16.81%); although they were not significant, compared 
to control. Gefitinib evoked an extremely significant G1 peak (72.45%) (P < 0.0001), 
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declined S phase (9.70%) and a reduced G2/M phase (13.70%); P < 0.0001 compared 
to control (S phase   17.01% and G2/M phase - 19.06%). 
 
After 72 h, EGF induced an increased G1 peak which was extremely significant 
(72.49%) (P < 0.0001) and this was followed by significantly reduced S (12.69%) (P 
< 0.001) and G2/M phases (12.14%) (P < 0.01) compared to control cells (G1 phase   
67.29%, S phase   16.11% and G2/M phase   15.10%). Gefitinib also elicited a 
significant G1 peak (73.46%) (P < 0.0001), reduced S (12.06%) (P < 0.0001) and 
G2/M phases (12.15%) (P < 0.05). Nevertheless, it was observed that the number of 
events had decreased for the G1 phase and correspondingly the number of events had 
somewhat increased for S and G2/M phases with time in Gefitinib treated cells. On 
the other hand, EGF showed a reversed response with time. It was also observed that 
there were no significant pre-G1 events observed at all 3 time points for both agents 
tested.  
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Figure 3.6: Cell cycle analysis following treatment of SKBR3 cells with EGF and 
Gefitinib. Cells were treated with 2x GI50 concentrations of these agents for 3 time 
points (a) 24, (b) 48 and (c) 72 h. Mean and SD of  ✁✂✄☎✆ ✝ ✞, (n = 2 per trial). * indicates 
significant difference compared to control, * (P < 0.05), ** (P < 0.01), *** (P < 0.001), 
**** (P < 0.0001). 
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An accumulation of a pre-G1 peak in the cell cycle, is suggestive of apoptosis. A 
previous report has shown that Gefitinib did not cause a pre-G1 peak in SKBR3 cells 
supporting the results of the current study. The same report has shown that Gefitinib 
caused a G1 accumulation in SKBR3 cells [195]. Further, 2 additional research groups 
have also reported that Gefitinib caused significant G1 accumulations with the same 
cell line [196] [197]. Cyclin D1 is required for the progression of the G1 to S phase 
and is shown to be an important target for proliferative signals in the G1 phase [198]. 
In addition, reduction in cyclin D1 synthesis in cells has been shown to be followed 
by a decrease in CDK activity. CDKs are a family of serine and threonine kinases that 
play a key role in controlling cell cycle progression as mentioned in chapter 1 [198] 
[199]. In actual fact, in the current study it was observed by Western blots that both 
EGF and Gefitinib (1x and 2x GI50 concentrations) abolished cyclin D1 protein levels 
completely in SKBR3 cells that were treated for 24 h compared to untreated cells 
(Figure 3.14) confirming the results of the cell cycle analysis. Researchers have shown 
that cell cycle progression is regulated through cycle regulatory proteins, such as 
cyclins, CDKs and CDK inhibitors [195]. However, cancer cells are insensitive to 
these regulatory proteins and are able to proliferate continuously as mentioned by the 
 ✁✂✄☎✂✄✁✆✁✝✁✆✞ ✆✟ ✠ntigrowth signals✡ ☛✠☞☞✌✠✍✎ [37]. These researchers mentioned above 
have shown that the G1 accumulation induced by Gefitinib is due to reduction in cyclin 
D1 and CDK2, CDK4 and CDK6 protein levels. Further, they have shown that 
Gefitinib induces high levels of p27kip1 and phosphorylated Rb levels which is 
associated with the G1 arrest; thereby explaining the effect of Gefitinib in the cell 
cycle [195] [200] [201].  
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Garcia et al, 2006 investigated the effect of EGF in MCF7 cells in serum deprived 
medium. They revealed an arrest in the G1 phase and a reduction in the S phase of the 
cell cycle that was associated with a loss of EGFR expression in the absence of other 
growth factors over a period of 6 days. However, these researchers observed increased 
cyclin D1 levels and they also observed an increase in p21cip1 protein levels which is 
associated with inhibition of the cell cycle. An increase in p21cip1 protein expression 
has found to inhibit cell cycle progression through the interaction with cyclin D1. They 
have also shown that p21cip1 levels could inhibit cyclin D1 levels with time and that 
EGFR activation via EGF in the absence of other growth factors causes G1 arrest and 
a reduction in MCF7 S phase cells [202]. It could be suggested that a similar effect is 
taking place in SKBR3 cells exposed to EGF. However, SKBR3 cells express high 
levels of HER2 and moderate levels of EGFR compared to MCF7 cells (Figure 3.1) 
and (Figure 3.2).  In the presence of a large amount of EGF, excessive ligand binding 
would result in homo- and heterodimerisation of EGFR and HER2 receptors. In fact, 
heterodimerisation is preferred in cells that express both EGFR and HER2 [203]. 
These heterodimers remain longer on the cell surface compared with EGFR 
homodimers and thus exaggerate signalling [203]. This results in loss of nutrients with 
time, which in turn reduces cellular proliferation.  At 72 h, the number of cells in the 
S phase and G2/M phase reduced significantly in this experiment, possibly due to a 
similar effect.  
 
3.2.6 Effects of EGF and Gefitinib on SKBR3 cellular apoptosis 
One of the major hallmarks of human cancers is acquired resistance to apoptosis as 
mentioned in chapter 1. Evasion of apoptosis contributes to tumour development, 
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invasion and also resistance to treatment [37]. Although there was no significant pre-
G1 phases suggestive of apoptosis observed in the cell cycle analysis, the clonogenic 
assay results demonstrated a moderate cytotoxic effect, thus it was investigated 
whether the agents induced cell death in SKBR3 cells using an apoptotic assay.   
 
Apoptosis and necrosis are 2 major cell death pathways. Characteristics of apoptosis 
include cell shrinkage, cell fragmentations, nuclear fragmentations and membrane 
blebbing [204] [205]. Necrosis is initiated by cellular accidents such as physical 
damage and energetic failure. Necrosis, or primary necrosis is characterised by loss of 
plasma membrane integrity, cell swelling and cell lysis [204] [205]. Further, secondary 
necrosis takes place when late stage apoptotic cells are not being recognised by 
phagocytes [206]. Furthermore, necroptosis is a programmed form of necrotic death 
and shares key processes with apoptosis [207]. However, there are many other 
mechanisms of cell death such as autophagy and paraptosis as well [208].  
 
SKBR3 cells were treated with 2x GI50 concentrations of these 2 agents for 24, 48 and 
72 h. To quantify apoptotic or necrotic populations; fluorescein isothiocyanate 
(FITC)-labelled annexin V was used. Early and late apoptotic populations were 
summed to determine the total apoptotic population in cells following treatment.    
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Figure 3.8: Apoptotic analysis of SKBR3 cells following exposure to EGF and 
Gefitinib. Cells were treated with 2 x GI50 concentrations of these agents for 3 time 
points 24, 48 and 72 h. Mean and SD of  ✁✂✄☎✆ ✝ ✞, (n = 2 per trial). * indicates 
significant difference compared to control, * (P < 0.05), ** (P < 0.01), *** (P < 0.001), 
**** (P < 0.0001). 
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There was no significant apoptosis or necrosis observed after 24 h exposure to either 
EGF or Gefitinib in SKBR3 cells. However, after 48 h, Gefitinib caused a small but 
significant total apoptotic population (13.38%) (P < 0.0001) relative to control 
(4.05%), in contrast EGF did not demonstrate apoptosis after 48 h. After 72 h both 
EGF (9.70%) (P < 0.05) and Gefitinib (16.98%) (P < 0.0001) induced apoptosis 
compared to control (4.62%). Even after 72 h, no significant necrotic population was 
observed for both agents (Figure 3.8). It was observed that Gefitinib evoked a ~ 4-fold 
increase in the total apoptotic population at 72 h. The increase in apoptotic population 
was time dependent, nevertheless there was no significant difference between the early 
and late apoptotic populations in cells exposed to Gefitinib. On the other hand, it was 
observed that EGF evoked an increased early apoptotic population relative to the late 
apoptotic population which was significant at 72 h (P < 0.01).  
 
From the results obtained, it was evident that EGF evoked an apoptotic population in 
SKBR3 cells only after 72 h, whereas Gefitinib caused a significant apoptotic effect 
in SKBR3 cells after 48 h. However, the apoptotic population observed was low for 
both EGF and Gefitinib. In fact, EGF has been shown to cause progressive cell death 
only with prolonged treatment (~ 144 h) in A431 epidermoid cancer cells that express 
high EGFR and HER2, which supports the current study results  [184].  
 
The small apoptotic populations indicates that these agents exert a cytostatic effect 
together with a moderate cytotoxic effect. Prior research has shown that Gefitinib acts 
as more of a cytostatic agent in sensitive cells but is able to induce a low or moderate 
level of apoptosis as well. This low or intermediate level ability to mediate apoptotic 
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signals have shown to be underlying the low regression rate observed in tumour 
xenografts treated with Gefitinib. Further, this type of response has shown to be 
associated with disease stability in contrast to standard chemotherapy which aims to 
kill tumour cells and achieve a partial response or a high regression rate [189]. Thus, 
the results of the present study corroborate with previous literature, and also with the 
results of the clonogenic assay within this chapter. 
 
Further, SKBR3 cells possess mutant TP53, and are able to inhibit apoptotic responses 
necessary for tumour suppression  [207] [209]. However, Tikhomirov and Carpenter, 
2004, reported  that SKBR3 cells with high levels of EGFR and HER2 do not depend 
on TP53 accumulation in response to EGF induced apoptosis [178]. Furthermore, it 
has been also shown that Gefitinib mediated anti-proliferative action does not require 
functional TP53 since TP53 and its downstream molecule p21cip1 were not regulated 
by this agent, demonstrating that this agent is effective in a range of tumour types 
[201]. Many researchers have reported that Gefitinib induces apoptosis by a variety of 
mechanisms including down-regulation of anti-apoptotic proteins and up-regulation 
of pro-apoptotic proteins of the Bcl-2 family. These proteins are found to be mediated 
by the TP53 protein [210]. As SKBR3 expresses mutant TP53, it was thought that Bcl-
2 family of proteins may not play a major role in SKBR3 cell death with EGF and 
Gefitinib treatment. Thus, it was evident that these effects were cell type- and dose-
dependent [184] [192] [201] [211] [212]. It has been shown that caspases initiate the 
execution phase of apoptosis where many substrates such as poly (ADP-ribose) 
polymerases (PARP) are cleaved [210]. Thus, PARP activity was investigated in the 
present study as a small level of apoptosis was observed by agent treatment. However, 
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no PARP cleavage was observed in these cells following both EGF and Gefitinib 
treatment after 24 h (Figure 3.14). Indeed no apoptosis was observed at 24 h in the 
apoptotic analysis assay in treated SKBR3 cells corroborating the findings of PARP. 
Gefitinib has also been shown to inhibit major cell survival and growth signalling 
pathways such as RAS/MAPK and PI3K/AKT pathways, as a consequence of 
inactivation of EGFR and HER2. In addition, EGF induced HER2 down-regulation 
has been reported. These effects were investigated subsequently in detail and the 
results are shown in section 3.2.7 where it was observed that both EGF and Gefitinib 
down-regulated EGFR and HER2 activated RAS/MAPK and PI3K/AKT pathways.  
 
3.2.7 Effects of EGF and Gefitinib on EGFR, HER2, RAS/MAPK, PI3K/AKT, 
JAK/STAT signalling pathways, PARP and cyclin D1 in SKBR3 cells by 
Western blotting 
SKBR3 cells were treated with 1x and 2x GI50 concentrations of EGF and Gefitinib 
for 24 h and the protein expression levels of EGFR, P-EGFR (Tyr1068), HER2 and P-
HER2 (Tyr1221/1222) were evaluated. It was observed that EGF increased the total 
EGFR protein expression levels at 24 h, however, the results were not significant. 
Gefitinib did not alter total EGFR protein levels significantly. In contrast, EGF down-
regulated P-EGFR levels extremely significantly at 1x and 2x GI50 concentrations (P 
< 0.0001) - P-EGFR (Tyr1068) ARD - 1x GI50 EGF   1.45% and 2x GI50   1.20%. 
Gefitinib also down-regulated P-EGFR levels, but the levels were not as low as EGF- 
1x GI50 - ARD   43.17% and 2x GI50   ARD   41.00% compared to SKBR3 control 
(P < 0.0001).  
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Figure 3.11: Adjusted relative density (ARD) levels of EGFR, P-EGFR, HER2 
and P-HER2 for EGF and Gefitinib. (a) EGFR, (b) P-EGFR, (c) HER2 and (d) P-
HER2 levels in SKBR3 cells. Cells were treated with EGF and Gefitinib for 24 h. 
 ✁✂✄ ✂✄☎ ✆✝ ✞✟ ✠✡☛✂☞✌ ✍ ✎✏ ✑ ☛✄☎☛✒✂✠✁✌ ✌☛✓✄☛✟☛✒✂✄✠ ☎☛✟✟✁✡✁✄✒✁ ✒✞✔✕✂✡✁☎ ✠✞ ✒✞✄✠✡✞☞✖ ✑ ✗✘
< 0.05), ** (P < 0.01), *** (P < 0.001), **** (P < 0.0001).  
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In the current study, the activity of EGF was investigated and it was found that EGF 
abolished EGFR phosphorylation (Tyr1068) at 24 h in SKBR3 cells suggesting that 
EGF would block downstream EGFR signalling in these cells. In contrast EGF caused 
enhanced up-regulation of basal levels of EGFR at 24 h. These results may infer that, 
when EGF is bound to EGFR and when it is being phosphorylated the phosphorylated 
form gets degraded with time. Subsequently, when phosphorylation of EGFR ceases, 
basal levels of EGFR may be enhanced to maintain receptor stabilisation after 24 h 
[213].  
 
EGF did not down-regulate P-HER2 (Tyr1221/1222) thus continued signalling 
through activated HER2 could persist in SKBR3 cells. In fact, the mechanism by 
which EGF inhibits SKBR3 proliferation is complex and controversial. Prior research 
has reported that EGF was able to reduce both EGFR and HER2 levels in a human 
mammary epithelial cell line due to accelerated degradation, as such it may be that the 
effect of EGF is cell type specific [214].  
 
As expected Gefitinib reduced both phosphorylated EGFR and HER2 in SKBR3 cells 
indicating that Gefitinib blocks EGFR and HER2 downstream events. In fact, 
mounting evidence suggests that Gefitinib blocks both the RAS/MAPK and 
PI3K/AKT pathways which are strictly regulated by either EGFR or HER2 in cancers 
[189] [213]. Thus, these pathways were explored with Gefitinib treated SKBR3 cells 
and also EGF treated cells.  
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It was observed that EGF lowered P-CRAF (Ser259) levels significantly at 2x GI50 
(ARD   60.58%) compared to control (P < 0.0001) and similarly reduced P-ERK 1/2 
levels at both 1x GI50 (ARD   55.92%) and 2x GI50 concentrations (ARD   48.55%) 
significantly (P < 0.0001). Further, EGF elicited an increase in the P-SAPK/JNK 
levels at 2x GI50 (ARD   135.09%) (P < 0.05). EGF did not alter any other protein 
expression levels investigated of this pathway nor total protein expression levels.  
 
It was noticed that Gefitinib treated SKBR3 cells expressed significantly lower levels 
of P-CRAF (Ser259) (1x GI50 - 51.42% and 2x GI50 ARD - 42.18%) (P < 0.0001), 
compared to control. Interestingly, Gefitinib diminished P-ERK1/2 levels, that is 
downstream of CRAF in SKBR3 cells showing that this agent inhibits the RAS/MAPK 
pathway effectively in these cells (1x GI50 concentration - ARD - 7.68% and 2x GI50 
concentration - ARD - 6.25%) (P < 0.0001). Further, Gefitinib induced increased 
phosphorylation in p38 (Thr180/Tyr182) significantly (1x GI50 concentration - ARD 
- 133% and 2x GI50 concentration - ARD - 123%) (P < 0.0001). In contrast, the same 
agent decreased P-SAPK/JNK (Thr183/Tyr185) protein expression levels 
significantly at both concentrations tested (1x GI50 concentration - ARD   60.40% (P 
< 0.01) and 2x GI50 concentration - ARD   45.30% (P < 0.001)). Gefitinib did not 
perturb total expression levels of the proteins investigated in this pathway (Figure 
3.12). Densitometry analysis with the ARD values for the significant results are shown 
in appendix I under section 9.1.1.1.  
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would eventually inhibit SKBR3 cell growth and proliferation. Previous research has 
shown that EGF could induce phosphorylation of p38 where EGF mediates apoptosis 
[178] [184]. However, in the current study this was not observed. On the contrary 
activation of P-SAPK/JNK by EGF was noticed in SKBR3 cells which has not been 
reported before. SAPK/JNK controls a spectrum of cellular processes including cell 
proliferation, differentiation and apoptosis as outlined in chapter 1 [65]. Further, 
SAPK/JNK activation has shown to trigger the mitochondria-dependent apoptotic 
pathway in response to many types of cell stress suggesting one of the mechanisms by 
which EGF inhibits cellular proliferation and apoptosis in SKBR3 cells [65]. 
However, further work is needed to verify the actual function of P-SAPK/JNK in EGF 
treated SKBR3 cells.  
 
The findings of Gefitinib are mostly consistent with previous reports where it has been 
shown that this agent is able to abolish P-ERK1/2 in SKBR3 cells at concentrations 
used in this study [189]. Further, Gefitinib evoked an increase in P-p38. p38 has been 
implicated in a variety of cellular responses such as cell cycle, cell death, cell 
differentiation and senescence according to cell type, indicating that Gefitinib may 
induce apoptosis through this pathway [67] [184] [215]. Intriguingly, this agent 
reduced the levels of P-SAPK/JNK. It has been also shown that SAPK/JNK activation 
depends on the nature of the stimulus or the activity of other pathways [65] [216].  
 
PI3K/AKT pathway activity was also reduced after SKBR3 cells were exposed to EGF 
and Gefitinib. It was observed that P-AKT (Ser473) activity was significantly down-
regulated by both 1x GI50 (ARD   46.55%) (P < 0.01) and 2x GI50 EGF (ARD   
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65.04%) (P < 0.05). It was noted that there was increased phosphorylation in cells 
exposed to 2x GI50 concentrations compared to 1x GI50. However the results were not 
significant. EGF also reduced P-AKT (Thr308) levels significantly - at 1x GI50 (ARD 
  53.97%) and 2x GI50 (ARD   52.88%); P < 0.01.  
 
Similarly, Gefitinib treated SKBR3 cells demonstrated reduced levels of P-AKT 
(Ser473) - 1x GI50 (ARD   48.28%) and 2x GI50 (ARD   25.24%); P < 0.01 and P-
AKT (Thr308) - 1x GI50 (ARD   66.62%); P < 0.05 and 2x GI50 (ARD   58.31%); P 
< 0.01 compared to control. Neither EGF nor Gefitinib altered total AKT levels. 
Further, no other protein expression levels tested in this pathway were significantly 
affected by these 2 agents (Figure 3.13). Densitometry analysis with the ARD values 
for the significant results are shown in appendix I under section 9.1.1.2. 
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EGF and Gefitinib showed potent growth inhibitory effects in the HER2 
overexpressing SKBR3 cell line. From the clonogenic assay it was found that both 
agents showed a cytostatic and also a moderate cytotoxic effect in SKBR3 cells. 
Further, both EGF and Gefitinib elicited a remarkable G1 arrest at all 3 time points in 
the cell cycle analysis and it was found that both agents abolished cyclin D1 levels 
which is important for the progression of G1 to S phase in the cell cycle. The agents 
also showed a small amount of apoptosis but a significant percentage of apoptosis was 
found only after 48 h of treatment for Gefitinib and 72 h of treatment for EGF. The 
apoptotic effect of EGF could be associated with up-regulation of P-SAPK/JNK 
pathway. EGF abolished P-EGFR whereas Gefitinib reduced P-EGFR levels. Only 
Gefitinib was found to lower P-HER2 levels. In addition, it was found that both 
RAS/MAPK and PI3K/AKT pathways are involved in the growth inhibition of EGF. 
Various mechanisms have been proposed for EGF activity in the literature, however, 
results within this chapter verify that these mechanisms are cell type specific. Gefitinib 
inhibition was associated with simultaneous down-regulation of RAS/MAPK, 
PI3K/AKT and the JAK/STAT pathways in this study, suggesting that breast cancer 
cells overexpressing activated EGFR/HER2 have high intrinsic sensitivity to EGF and 
Gefitinib via inhibition of simultaneous receptor signalling pathways. Nevertheless, it 
was also observed that both EGF and Gefitinib showed a slightly different spectrum 
of activity in SKBR3 cells. These results may prove useful for breast cancer patients 
who fall into the HER2 molecular subtype to receive maximum benefit from anti-
EGFR/HER2 therapy including EGF, which might be able to be used as an effective 
strategy to overcome EGFR/HER2 associated breast cancer proliferation, although, 
more research is warranted to determine whether EGF could be used as a therapy for 
HER2 overexpressing breast cancer.  
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site thereby increasing the therapeutic effect while minimising systemic toxicities 
[129]. When selecting a delivery system a major consideration is controlled release of 
the drug to the target site at a therapeutically optimal rate [104] [224]. As a promising 
targeted delivery system, the native iron storage protein ferritin was chosen. Ferritin 
is an ideal drug delivery carrier due its nanoscale structure, biocompatible, 
biodegradable, multifunctional, stable and non-toxic properties [105] [131] [225]. The 
internal cavity of ferritin stores iron atoms. When the iron is released AFt is formed 
with a hollow cavity. In this study, Gefitinib was encapsulated into the cavity of H-
AFt by diffusion. Prior research has shown that AFt has been used for many successful 
applications both in vitro and in vivo. For instance, iron oxide NPs have been 
encapsulated inside H-AFt to visualise tumour tissues in vitro [226]. Further, a 
gadolinium-loaded AFt displayed system has been used to visualise tumour 
endothelial cells that could be used for identifying angiogenic blood vessels both in 
vitro and in vivo. This system has displayed good in vivo stability and tolerability 
[227]. Liang et al, 2014 has shown that AFt-encapsulated Doxorubicin displayed an 
excellent safety profile which reduced toxicity in healthy organs in vivo murine models 
compared to free Doxorubicin and also Doxil which is the clinically approved 
liposomal Doxorubicin nanomedicine formulation which was discussed in chapter 1 
[228]. Furthermore, it has been shown that AFt-encapsulated lead sulphide (PbS) 
quantum dots can be used in anti-tumour activity in both in vitro and in vivo. In vitro 
breast and colon carcinoma cell growth has been inhibited effectively while in vivo 
this agent has shown to be well tolerated with no behavioural or weight changes in 
mice [229]. In addition, near-infrared of PbS quantum dots have been used for tumour 
imaging in the same study [131] [229]. These studies confirm that AFt is efficiently 
up taken by tissues in vivo and that it is a safe and efficient vehicle for Gefitinib drug 
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on the outer surface which eventually will damage the stability and drug delivery 
effectivity to cells, therefore a diffusion method was utilised [228].  
 
Gefitinib but not H-AFt is fluorescent. The fluorescence of Gefitinib was checked 
under UV. At the end of the encapsulation process of Gefitinib into H-AFt, the 
fluorescence of the resulting solution was visualised under UV and it was found that 
the resulting solution was fluorescent, but not as fluorescent as Gefitinib alone (Figure 
4.1 (b1 - b3)). This indicates that Gefitinib is encapsulated within H-AFt. In fact, it 
has been previously shown that attachment of drug molecules to the AFt surface is 
very low [232].  
 
Subsequently, the EE of the encapsulated test agent was determined. The EE was 
analysed using a UV spectrophotometer; 250 nm was chosen as the optimum 
wavelength to analyse the absorbance of Gefitinib [233]. An example of the spectrum 
is shown in Figure 4.1 (c). With the use of the Beer-Lambert law, encapsulated 
Gefitinib was quantified and an average maximum EE of ~ 54.90% was found. It was 
observed that even though the drug concentration was increased the EE did not 
increase. This might indicate that there is a maximum amount of drug molecules that 
the AFt cavity can hold. Protein determination by Bradford assay revealed an average 
of 1.25 mg H-AFt/ml which is equivalent to 50.58 µM. UV spectrophotometry 
determined a mean concentration of 604.70 µM Gefitinib. Thus, on average 1µM of 
H-AFt was equivalent to 11.96 µM of encapsulated Gefitinib.  
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4.2.1.2 Mass spectrometry (MALDI) 
Mass spectrometry measures the mass to charge ratio of charged particles which can 
be used to determine the purity and the molar mass of the particles of importance 
[234]. MALDI studies showed high intensity peaks for H-AFt and Gefitinib, which 
indicate high abundance of the drug and the protein in the mixture corresponding to a 
MW of 24,711.9 Da for H-AFt and a MW of 442.6 Da for Gefitinib which is 
comparable to expected standard values (Figure 4.1 (d)). The standard MW of H-AFt 
is 21,000 Da, however, the H-AFt which was used for the encapsulation procedure 
had additional his-and avidin tags and also linker sequences that made it slightly larger 
[130]. The standard MW of Gefitinib is 446.9 Da [108] [125]. The values obtained by 
MALDI demonstrate that there was an abundance of H-AFt and Gefitinib in the 
encapsulated test agent.  
 
4.2.1.3 Confirmation of encapsulation of Gefitinib in H-AFt 
In order to confirm whether Gefitinib was encapsulated within the H-AFt NPs, Astrios 
EQ flow cytometry (Beckman Coulter) analysis was employed. The area occupied by 
a molecule is proportional to the MW, thus particles more than a certain size could 
only be analysed by this method. The MW of H-AFt was found to be 24,711.8 Da 
compared to Gefitinib which has a much smaller MW (442.6 Da), beyond detection 
by flow cytometry. As Gefitinib is fluorescent under UV, H-AFt-encapsulated-
Gefitinib was observed using excitation and emission wavelengths of 355 and 385 nm 
respectively by the 405/30 band pass filter of the flow cytometer. Fluorescence was 
detected by the forward scatter and a marker was placed to detect the populations 
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positive (R3) and negative (R4) for fluorescence. Figure 4.1 (e1) shows a histogram 
of H-AFt which was not encapsulated, thus showing only a negative population on to 
the left with very little fluorescence. However, after encapsulation of Gefitinib within 
the H-AFt cavity, a large positive population, shifted to the right, was detected with a 
fluorescence population 180 x brighter than H-AFt alone. These data confirm 
encapsulation of Gefitinib within AFt NPs (Figure 4.1 (e2)).  
 
4.2.1.4 Determining stability and structural integrity 
Gefitinib was encapsulated in AFt adopting a dialysis method. In order to determine 
whether the stability and the structural integrity of H-AFt-encapsulated-Gefitinib were 
altered after encapsulation, SDS-PAGE was carried out (Figure 4.1 (f1)). As depicted, 
H-AFt-encapsulated-Gefitinib showed a band similar to that of H-AFt only, ~ 24,700 
Da. This indicates that AFt protein structure remains unchanged after encapsulation 
of Gefitinib. The amount of H-AFt was less in the encapsulated test agent which was 
expected (Figure 4.1 (f2)).  
 
4.2.1.5 TEM 
TEM images revealed that encapsulated Gefitinib molecules do not disrupt the 
structure of H-AFt NPs and confirm that the NPs possess and retain their spherical 
shape even after encapsulation. The mean outer diameter of the H-AFt NPs was 
measured to be 12.5 ± 0.46 nm which confirms that the size has not changed following 
encapsulation. However, specific Gefitinib molecules within the NP could not be 
determined from the TEM images; the electron density of Gefitinib molecules was 
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Figure 4.1: Characterisation of H-AFt-encapsulated-Gefitinib. (a) Schematic 
representation of preparation of H-AFt-encapsulated-Gefitinib NPs. (b) Fluorescence 
of (b1) H-AFt-encapsulated-Gefitinib, (b2) H-AFt only (b3) Gefitinib only, visualised 
under UV. (c) Spectrum of Gefitinib at 250 nm using UV spectrometry (d) MALDI 
spectrum with peaks for Gefitinib and H-AFt of the encapsulated test agent 
demonstrating the MWs of Gefitinib (442.9 Da) and H-AFt (24,711.9 Da) within the 
test agent. (e) Flow cytometry histograms confirming the encapsulation of Gefitinib 
in H-AFt. (e1) H-AFt only and (e2) H-AFt-encapsulated-Gefitinib. (f) Determining 
stability and structural integrity of H-AFt, (f1) SDS-PAGE - 1) Marker 2) H-AFt only 
and 3) H-AFt-encapsulated-Gefitinib and (f2) Densitometry analysis of SDS-PAGE. 
Mean and SD of  ✁✂✄☎✆ ✝ ✞. (g) TEM Images of H-AFt-encapsulated-Gefitinib (g1) and 
(g2).  
 
4.2.2 In vitro growth inhibitory effects of H-AFt-encapsulated-Gefitinib 
The effect of H-AFt-encapsulated-Gefitinib was assessed using the HER2 
overexpressing SKBR3 cell line and the MDA-MB 231 cell line that does not express 
HER2. The SKBR3 cell line expresses low levels of EGFR and the MDA-MB 231 cell 
line expresses high levels of EGFR [189]. Cells were incubated with H-AFt-
encapsulated-Gefitinib, Gefitinib alone and H-AFt alone for 72 h initially. Dose 
dependent growth inhibition was demonstrated (Table 4.1 (a)), (Figure 4.2 (a - c)). 
Interestingly, the SKBR3 cell line was sensitive to both Gefitinib alone (GI50 = 0.94 
✟M) and H-AFt-encapsulated-Gefitinib (GI50 = 1.44 ✟M). However, the GI50 value 
obtained with the SKBR3 cells treated with H-AFt-encapsulated-Gefitinib was 
(g1) (g2) 
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slightly higher compared to Gefitinib alone. This implies that encapsulated Gefitinib 
requires time to be released from the H-AFt cavity as it is processed by acidic 
endosomes and lysosome systems within the cell. At early time points, AFt has shown 
to be restricted in endosomes while with time, AFt is transferred to lysosomes. These 
systems will facilitate release of the drug and degrade cytosolic AFt by autophagy or 
proteasomal elimination [130]. Indeed Liang et al, 2014, has shown that Doxorubicin 
was gradually released from the AFt cavity which was located in the cytoplasm and 
transferred to acidic lysosomes of cancer cells at 24 h. Subsequently, majority of the 
encapsulated drug has been in lysosomes [228]. It has been portrayed that late 
endosomes could reach an acidity of pH 6.0 while lysosomes are highly acidic and can 
reach an acidic environment of pH 4.5 and 5.0 [235]. This is an ideal environment for 
AFt to release its cargo because it has been shown that the AFt cage starts to swell and 
the protein subunits separate at pH   5.0 [129].  
 
This observation was further confirmed by a MTT assay which was used to test the 
activity of H-AFt-encapsulated-Gefitinib and Gefitinib alone following 24 h exposure. 
H-AFt-encapsulated-Gefitinib demonstrated a GI50 value of 2.24 ✂M which was 
higher than the GI50 value obtained after 72 h. Gefitinib alone demonstrated a GI50 
value of 0.74 ✂M. The MDA-MB 231 cell line demonstrated low sensitivity to both 
Gefitinib alone (GI50 = 21.80 ✂M) and H-AFt-encapsulated-Gefitinib (GI50 > 25 ✂M) 
after 72 h exposure (Figure 4.2 (d ✁ f), and also after 24 h exposure where both agents 
showed a GI50 value > 25 µM. As it was outlined in the previous chapter, no correlation 
was observed between EGFR expression and cell sensitivity to Gefitinib alone and H-
AFt-encapsulated-Gefitinib although Gefitinib is an EGFR TKI [190]. Gefitinib 
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activity requires a phosphorylated form of EGFR whereas MDA-MB 231 cells express 
a non-phosphorylated form of EGFR, hence are not sensitive to this drug [189].  
 
In the current study, transferrin has been exploited for the delivery of H-AFt-
encapsulated-Gefitinib into cancer cells by transferrin receptors [220] [228]. Many 
studies have portrayed modified ferritin with recognition ligands to achieve tumour 
specific targeting, however, it was thought that it could abolish the intrinsic tumour 
specific binding and then disrupt the release of encapsulated cargo which will result 
in an interrupted in vivo performance [228] [236] [237].  
 
H-AFt is efficiently taken up by cells transported via the cardiovascular system by the 
use of TfR1[130] [238]. TfR1 receptors are expressed at high levels in cancer cells 
compared to normal human cells. It has been found that the expression of TfR1s is 
associated with tumour stage or cancer progression [218]. In fact, malignant breast 
tissue has been shown to have a 7-fold increase in cytosolic ferritin compared to 
benign lesions of the breast [237]. Iron is required by many cellular processes such as 
metabolism and DNA synthesis. Thus, cancer cells have more TfR1s than normal cells 
[234] [238]. These receptors reside on cell membranes and transport cargo into cells 
by receptor mediated endocytosis via clathrin-coated pits [126] [218]. Further, the 
EPR effect may enhance NP drug accumulation at tumour sites compared to normal 
tissues by passive targeting. Nevertheless the EPR effect would only be achieved in 
an in vivo environment [218]. Further, TfR1 receptors have also shown potential in 
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the delivery of anti-cancer agents into the brain by overcoming the blood-brain barrier 
[220]. This is quite important as breast cancer often metastasises into the brain [15].  
 
However, it has been shown that binding of H-AFt occurs in the absence of transferrin 
and that binding is significantly inhibited by transferrin although not completely since 
transferrin is the main transport system for iron atoms. Research has depicted that the 
binding sites for H-AFt and transferrin might not be identical but probably overlap or 
that transferrin alters TfR1 so that it reduces binding of H-ferritin which could be a 
limitation to this system. Nonetheless, it has also been shown that high concentrations 
of H-AFt partially block binding of transferrin to TfR1 [130]. Further, it has been 
demonstrated that ferritin/AFt binds to an inhibitor of angiogenesis with high affinity 
and antagonises the effects of this inhibitor thereby increasing cell viability in vivo 
which may suggest competition between endogenous ferritin and H-AFt uptake [239]. 
However, once again at high concentrations of H-AFt this function might be succeeded 
in vivo as successful delivery of agents encapsulated in AFt has been shown [228]. 
Another limitation to this delivery system would be that markedly high levels of TfR1 
are exhibited on haematopoietic stem cells. However, it is apparent that 
hyperexpression of TfR1s in haematopoietic stem cells is related to differentiation 
rather than proliferation. In vitro studies have shown that erythroid cells show 
markedly higher TfR1 levels compared to other progenitor cells at an early 
differentiation stage to maturation. Thus, H-AFt-encapsulated-Gefitinib may bind to 
haematopoietic stem cells including erythroid cells which may affect haematopoiesis 
in vivo [240].  Despite its limitations, TfR1 receptors were considered in this study as 
a targeting molecule due to high levels expressed in tumour cells. 
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Both SKBR3 and MDA-MB 231 cells express high levels of TfR1s which would assist 
H-AFt-encapsulated-Gefitinib uptake compared to normal cells [241] [242]. 
Nevertheless, the SKBR3 cell line showed a lower GI50 value to H-AFt alone 
compared to the MDA-MB 231 cell line (Table 4.1 (a)). The greater SKBR3 growth 
inhibition in the presence of H-AFt compared to MDA-MB 231 implies greater 
sequestration of H-AFt by SKBR3 cells. Indeed, it has been shown previously that 
ferritin was not taken up by MDA-MB 231 cells [243]. Intriguingly, it was observed 
that the GI50 value obtained for MDA-MB 231 with the exposure to H-AFt alone was 
lower compared to H-AFt-encapsulated-Gefitinib. This could be due to MDA-MB 231 
cells being resistant to Gefitinib and with the release of the drug these cells may 
demonstrate resistant mechanisms by increased proliferation.  
 
To determine whether a longer exposure time to encapsulated drug, will be more 
effective in cells, MTT assays were performed following 120 h cellular exposure to 
agents (Table 4.1 (b)) and (Figure 4.3 (a - f)). Interestingly, the GI50 value for H-AFt-
encapsulated-Gefitinib (GI50 = 0.52 ✂M) against the SKBR3 cell line was lower 
compared to the 72 h and 24 h assays and it was also lower than Gefitinib alone for 
120 h (GI50 = 1.66 ✂M). There was no apparent significant difference between the GI50 
values of Gefitinib alone after 72 and 120 h exposure periods (P > 0.05). However, 
from the results it is apparent that the GI50 values for Gefitinib alone increased with 
time, whereas the GI50 values for H-AFt-encapsulated-Gefitinib decreased with time 
for the SKBR3 cell line showing enhanced H-AFt-encapsulated-Gefitinib potency 
with increased time (Figure 4.4). Consistent with results following 72 h exposure, after 
120 h exposure, the MDA-MB 231 cell line did not show any sensitivity to H-AFt-
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encapsulated-Gefitinib. Once again the SKBR3 cell line showed a lower GI50 value 
for H-AFt alone compared to the MDA-MB 231 cell line at 120 h. It should be noted 
that at H-AFt-encapsulated-Gefitinib GI50 values of 1.44 ✂  (72 h) and 0.52 ✂  (120 
h), the concentrations of H-AFt were 0.11 ✂  and 0.04 ✂  respectively, 
concentrations which negligibly impacted SKBR3 growth inhibition. These results 
demonstrate that drug encapsulation enhances the activity of Gefitinib in SKBR3 cells 
and support the hypothesis that the H-AFt cage allows controlled release of the drug 
molecules. Sustained drug release is an attractive factor in a drug delivery system and 
may lead to extended exposure of tumour cells/tissue to therapeutic drug 
concentrations [104].  
 
Tumour microenvironments exhibit lower extracellular pH than normal tissues while 
the intracellular pH of cells within normal and tumour cells is similar [129]. The 
overall pH range within a tumour environment is 6.9 and 7.4 whereas normal cells will 
have a pH range between 7.2 and 7.6 [244] [245]. This slightly more acidic 
environment develops within tumour cells when increased glucose break down results 
in significant production of lactate and H+ which is transported to the extracellular 
environment. Therefore, due to the pH discrepancy, encapsulated drug may preferably 
be released within this slightly more acidic tumour microenvironment [129]. Hence, 
it was tested whether a more acidic in vitro environment would promote effective 
release of Gefitinib from its H-AFt cage. (Table 4.1 (c)) and (Figure 4.5). However, 
preliminary investigations revealed that SKBR3 cells cannot withstand environments 
< pH 7.0 for > 72 h. Lower GI50 values were observed at pH 7.0 following 72 h 
exposure compared to normal pH conditions (pH 7.5) for both Gefitinib and H-AFt-
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encapsulated-Gefitinib. This could be because Gefitinib ionises progressively as the 
pH drops, which increases solubility of Gefitinib [123]. It could be also a consequence 
of compromised cell growth.  
 
 
 
 
 
 
Table 4.1: Mean GI50 ± SD values of Gefitinib, H-AFt, and H-AFt-encapsulated-
Gefitinib. It should be noted that the GI50 values for H-AFt-encapsulated-Gefitinib 
refer to encapsulated Gefitinib concentrations. The amount of Gefitinib encapsulated 
per H-AFt cage impacts material potency and merits further detailed study. Cells were 
seeded in 96 well plates at a density of 2.5 x 103 cells/well. After allowing time to 
adhere (24 h), cells were exposed to Gefitinib alone, H-AFt-encapsulated-Gefitinib or 
H-AFt alone (n = 8 for either 72 h or 120 h at pH 7.5). SKBR3 cells were also seeded 
at a density of 2.5 x 103 cells/well in 96 well plates at pH 7.0 and treated with Gefitinib 
alone or H-AFt-encapsulated-Gefitinib. M ✁✂ ✁✂✄ ☎✆ ✝✞ ✟✠✡✁☛☞ ✌ ✍✎  
(a) Mean GI50 ± SD (72 h MTT assay) 
Cell line Gefitinib 
alone 
H-AFt-encapsulated-
Gefitinib 
H-AFt alone 
SKBR3 0.94 ✏M ± 0.85 ✑✎✒✒ ✏✓ ✔ ✑✎✕✖ ✒✎✗✒ ✏✓ ✔
4.80 
MDA-MB 
231 
21.80 ✏M ± 
0.74 
✘ ✕✙ ✏✓ ✑✚✎✒✛ ✏✓ ✔
1.39 
(b) Mean GI50 ± SD (120 h MTT assay) 
Cell line Gefitinib alone H-AFt-encapsulated-
Gefitinib 
H-AFt alone 
SKBR3 ✑✎✚✚ ✏✓ ✔ ✑✎✍✚ ✖✎✙✕ ✏✓ ✔ ✖✎✕✜ ✙✎✙✖ ✏✓ ✔ ✙✎✍✗ 
MDA-MB 231 ✑✜✎✙✚ ✏✓ ✔ ✖✎✜✑ ✘ ✕✙ ✏✓ ✑✜✎✗✙ ✏✓ ✔
0.21 
(c) Mean GI50 ± SD (72 h MTT assay at pH 7.0) 
Cell line  Gefitinib alone H-AFt-encapsulated-Gefitinib 
SKBR3 ✖✎✑✍ ✏✓ ✔ ✖✎✖✗ ✖✎✒✒ ✏✓ ✔ ✖✎✕✗ 
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Figure 4.2: Growth inhibitory curves for Gefitinib and H-AFt-encapsulated-
Gefitinib after 72 h exposure. (a, b, c) SKBR3 cell line and (d, e, f) MDA-MB 231 
cell line. Cells were treated after 24 h and exposed to agents for 72 h (n = 8) prior to 
MTT assay; (a, d) Gefitinib only, (b, e) H-AFt-encapsulated-Gefitinib and (c, f) H-
AFt only. Mean and SD of representative experiments are shown (n = 8 per trial); trials 
  3. * indicates significant difference compared to control, * (P < 0.05), ** (P < 0.01), 
*** (P < 0.001), **** (P < 0.0001).  
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Figure 4.3: Growth inhibitory curves for Gefitinib and H-AFt-encapsulated-
Gefitinib after 120 h exposure. (a, b, c) SKBR3 cell line and (d, e, f) MDA-MB 231 
cell line. Cells were treated after 24 h and exposed to agents for 120 h prior to MTT 
assay (n = 8); (a, d) Gefitinib only, (b, e) H-AFt-encapsulated-Gefitinib and (c, f) H-
AFt only. Mean and SD of representative trials are shown (n = 8 per trial); trials   3. 
* indicates significant difference compared to control, * (P < 0.05), ** (P < 0.01), *** 
(P < 0.001), **** (P < 0.0001). 
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Figure 4.4: GI50 values for Gefitinib alone and H-AFt-encapsulated-Gefitinib at 
each time point tested in the SKBR3 cell line. Mean and SD of each GI50 value is 
shown; trials   3.  
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Figure 4.5: Growth inhibitory curves after 72 h exposure at pH 7.0. (a) Gefitinib 
only and (b) H-AFt-encapsulated-Gefitinib. SKBR3 cells were seeded at a density of 
2.5 x 103 cells/well in 96 well plates at pH 7.0. Cells were treated after 24 h and 
exposed to agents for 72 h (n = 8) prior to MTT assay. Mean and SD of representative 
trials are shown (n = 8 per trial); trials   3. * indicates significant difference compared 
to control, * (P < 0.05), ** (P < 0.01), *** (P < 0.001), **** (P < 0.0001). 
 
 
4.2.3 Effects of H-AFt-encapsulated-Gefitinib on SKBR3 colony formation 
Clonogenic assays were performed to determine whether single SKBR3 cells were 
able to survive challenge with Gefitinib alone or H-AFt-encapsulated-Gefitinib (brief 
exposure of 24 h vs. continuous exposure to agents for 14 days) and subsequently form 
progeny colonies, indicative of tumour  repopulation [147]. Cells were treated with 1 
µM (equivalent to 1x GI50 of Gefitinib) and 5 µM (equivalent of 5x GI50 of Gefitinib) 
(Figure 4.6).  
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The clonogenic assay results concur with those of the MTT assays. H-AFt-
encapsulated-Gefitinib was less potent than Gefitinib alone after 24 h exposure. The 
SF of cells treated with H-AFt-encapsulated-Gefitinib was 34.40% (5 ✂M) compared 
to control whereas SF of cells treated with Gefitinib was 3.48% (5 ✂M) compared to 
control. It was noted that an increased concentration such as 5 ✂M which is equivalent 
to 5x GI50 of Gefitinib demonstrated a highly cytotoxic effect compared to 1x and 2x 
GI50 concentrations of the same agent which resulted in cytostatic and moderate 
cytotoxic effects showed in the previous chapter. Further, it was also observed in 
chapter 3, that 2x GI50 was more cytotoxic than 1x GI50 following a same trend to the 
results within this chapter. Interestingly, following continuous exposure to both 
agents, no colonies could be detected after 14 days, compared to control. Results infer 
that continuous exposure allows Gefitinib molecules to escape from the H-AFt cavity 
and endorse the premise of sustained drug release from an efficient drug delivery 
system.  
 
4.2.4 Release of Gefitinib from H-AFt  
The AFt NPs disassemble into protein subunits under acidic conditions and release the 
encapsulated cargo [129]. In order to verify this, a pH dependent drug release profile 
was carried out. The release of H-AFt-encapsulated-Gefitinib was examined over a 
period of 24 h by analysing the buffer released from the dialysis bags and buffer 
retained within the dialysis bags. UV spectrometry was adopted to compare Gefitinib 
release from H-AFt at pH 2, 4 and 7.5. At pH 2, the AFt cage completely disassembles, 
at pH 4, the AFt cage will swell and the protein subunits will separate, at pH 7.5, the 
AFt cage retains its assembled structure [129]. Release of Gefitinib alone was 
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observed only at pH 7.5. By analysing the buffer released from the dialysis bag it was 
observed that Gefitinib alone showed a rapid release profile with a higher percentage 
of drug release. Gefitinib release reached a plateau at 6 h. In comparison at pH 2, 4 
and 7.5, H-AFt-encapsulated-Gefitinib showed a slower cumulative release profile 
and a lower percentage of drug release due to being encapsulated in the AFt cavity. 
Among the pH levels the fastest cumulative release profile was observed for H-AFt-
encapsulated-Gefitinib at pH 2. This is consistent with the AFt cage disassembling 
completely and releasing more Gefitinib molecules to diffuse into the buffer. (Figure 
4.7 (a)).  
 
In figure 4.7, it was observed that only a low percentage of Gefitinib was detected as 
released, for all 4 release profiles. The buffer used was 20 mM Tris buffer and 
Gefitinib is not soluble in aqueous buffers such as Tris. Thus, Gefitinib would have 
been degraded or precipitated in the released buffer after 24 h as the samples were 
incubated for more than 24 h before analysing them with the UV spectrometry. 
Therefore only a maximum of 19% was detected in 24 h for Gefitinib alone as released 
and the rest which was released would have been degraded or reformed precipitates.   
 
The residual buffer with NPs remaining in the dialysis bags at all studied pH levels 
was analysed by flow cytometry and compared to H-AFt only (control), also placed in 
a dialysis bag (Figure 4.7 (c)). At pH 2 and 4, residual dialysis bag buffer revealed 
only 2 negative (R4) populations exposing no fluorescence in the histograms relative 
to control. This implies that there was no Gefitinib left in the dialysis bags; drug had 
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been released over the 24 h period (Figure 4.7 (d and e). However at pH 7.5, a small 
population positive for fluorescence remained (R3): 18.0 ± 3.1 x brighter fluorescence 
was detected compared to H-AFt alone, which corroborated with the results obtained 
by UV spectrometry examining Gefitinib released from the H-AFt-capsule (Figure 4.7 
(f)). These results further confirm sustained release of Gefitinib from H-AFt which 
maximises the efficacy of the drug, especially at physiological pH levels. 
Nevertheless,  in an acidic environment such as stomach cancers where the pH reaches 
as low as pH 1.5, a higher percentage of drug might be observed [228] [245] [246] 
(Figure 4.7 (b)).  
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Figure 4.7: Detection of Gefitinib release from the H-AFt cavity. (a) Cumulative 
release of Gefitinib alone at pH 7.5 and from H-AFt-encapsulated-Gefitinib at pH 2, 
4 and 7.5 at 2, 6, 12 and 24 h observed by UV spectrometry. (b) Relative total 
fluorescence emitted by Gefitinib retained within the dialysis bags at pH 2, 4 and 7.5 
after a period of 24 h detected by flow cytometry. (c - f): Representative histograms 
representing fluorescence emitted by Gefitinib. A marker was placed to detect the 
positive (R3) and the negative (R4) populations for fluorescence. (c) Residual H-AFt 
alone, (d) Residual H-AFt-encapsulated-Gefitinib (pH 2), (e) Residual H-AFt-
encapsulated-Gefitinib (pH 4) and (f) Residual H-AFt-encapsulated-Gefitinib (pH 
7.5). Mean and SD of  ✁✂✄☎✆ ✝ ✞, (n = 3 per trial). * indicates significant difference 
compared to control, *** (P < 0.001). 
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4.2.5 Cellular uptake of H-AFt-encapsulated-Gefitinib by confocal microscopy 
Cellular uptake and internalisation of H-AFt-encapsulated-Gefitinib or Gefitinib alone 
was measured by confocal microscopy. SKBR3 and MDA-MB 231 cells were treated 
with H-AFt-encapsulated-Gefitinib (5 ✂M), or Gefitinib alone (5 ✂M) for 24 h. The 
fluorescence of Gefitinib is environmentally sensitive   peak excitation and emission 
depends upon environment polarity and is intense in nonpolar solvents [153]. 
Intracellular fluorescence was punctuate and was localised in cytoplasmic vesicles 
such as acidic lysosomes and endosomes. Fluorescence was excluded from nuclei 
[153]. It was evident from the bright fluorescence within the cytoplasm of H-AFt-
encapsulated-Gefitinib and Gefitinib treated cells that H-AFt-encapsulated-Gefitinib 
was internalised in a manner similar to Gefitinib alone. However, the punctuate 
fluorescence pattern was slightly less within the cells treated with H-AFt-
encapsulated-Gefitinib compared to Gefitinib alone (Figure 4.8 (b - e)). SKBR3 cells 
that were treated with 5 ✂M H-AFt alone (Figure 4.8 (f)) appeared to be identical to 
control cells (Figure 4.8 (a)) and did not show bright fluorescence as expected. The 
MDA-MB 231 cells that were treated with (5 ✂M)
 
H-AFt-encapsulated-Gefitinib did 
not show visible cellular uptake compared to MDA-MB 231 cells that were treated 
with Gefitinib alone indicating negligible uptake in these cells (Figure 4.8 (h - k)). 
Further, neither MDA-MB 231 control (Figure 4.8 (g)) nor MDA-MB 231 cells treated 
with 5 ✂M H-AFt alone (Figure 4.8 (l)) fluoresced.  
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4.2.6 Cellular uptake of H-AFt-encapsulated-Gefitinib by flow cytometry 
Cellular uptake of H-AFt-encapsulated-Gefitinib was measured quantitatively using 
flow cytometry. SKBR3 and MDA-MB 231 cells were treated with H-AFt-
encapsulated- Gefitinib or Gefitinib alone (5 ✂M) for 24 h and compared to control. 
Mean fluorescence was used as a measure of Gefitinib uptake by cells and compared 
to control (Figure 4.9). The uptake of Gefitinib alone by SKBR3 cells (P < 0.001) and 
MDA-MB 231 cells (P < 0.0001) was extremely significant compared to control. The 
uptake of H-AFt-encapsulated-Gefitinib by SKBR3 cells was also significant (P < 
0.05) compared to control. However, uptake of H-AFt-encapsulated-Gefitinib by 
MDA-MB 231 cells was not significant compared to control corroborating confocal 
microscopy results. Thus, the qualitative observations of confocal microscopy were 
reinforced by flow cytometry analyses. Together, results suggest that H-AFt-
encapsulated-Gefitinib is internalised by HER2 overexpressing SKBR3 cells 
successfully.  
 
 
 
 
 
Figure 4.9: Mean fluorescence uptake by SKBR3 and MDA-MB 231 cells using 
flow cytometry. Mean and SD of  ✁✄☎✆✝ ✞ ✟, (n = 2 per trial). * indicates significant 
difference compared to control, * (P < 0.05), ** (P < 0.01), *** (P < 0.001), **** (P 
< 0.0001). 
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Figure 5.1: Growth inhibitory curves of H and L-AFt-fusion proteins, 
Trastuzumab, targeting protein, H and L-AFt only. (a, b, c, d, e and f) SKBR3 and 
(g, h, i, j, k and l) MDA-MB 231 cells; (a, g) H-AFt-fusion protein, (b, h) L-AFt-fusion 
protein, (c, i) Trastuzumab, (d, j) targeting protein, (e, k) H-AFt only and (f, l) L-AFt 
 ✁✂✄☎ ✆✝✞✁ ✞✁✟ ✠✡  ☛ ☞✝✌☞✝✍✝✁✎✞✎✏✑✝ ✝✒✌✝☞✏✓✝✁✎✍ ✞☞✝ ✍✔ ✕✁ ✖✁ ✗ ✘ ✌✝☞ ✎☞✏✞✂✙✚ ✎☞✏✞✂✍ ✛
3. * indicates significant difference compared to control, * (P < 0.05), ** (P < 0.01), 
*** (P < 0.001), **** (P < 0.0001). 
 
From the results obtained it was observed that the novel HER2 targeting H-AFt-fusion 
protein was the most potent agent among all agents tested against the SKBR3 cell line 
(GI50 = 18.26 nM). The L-AFt-fusion protein was less potent (✜ 5-fold) (GI50 = 103.60 
nM) than the H-AFt-fusion protein against the same cell line. Both agents elicited dose 
dependent growth inhibition and all concentrations tested showed a significant growth 
inhibitory effect compared to untreated SKBR3 cells (P < 0.0001). The difference in 
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the potency of H and L-AFt-fusion proteins could be a consequence of the high uptake 
of H-AFt by the SKBR3 cells which expresses high levels of TfR1. As it was outlined 
in chapter 4, binding of ferritin to TfR1s consists only of H ferritins illustrating that 
binding of ferritin to cells is facilitated by the H chain but not by the L chain [130].  
 
Interestingly, the HER2 targeting protein alone displayed potency against the SKBR3 
cell line (GI50 = 34.69 nM). These results showed that the HER2 targeting protein 
elicited potent activity against the SKBR3 cell line, which was higher than that for the 
L-AFt-fusion protein. This may be because the targeting protein has very high affinity 
for the HER2 receptor which would facilitate immediate binding to the cell surface of 
HER2 receptors of SKBR3 cells, which would decrease hetrodimerisation and thereby 
induce cell death [53]. This could also happen particularly in the absence of other 
required growth factors and nutrients during an incubation period of 72 h, thus 
inducing cell death [34] [132].  
 
Each AFt subunit is fused to a targeting protein in a 1:1 ratio to develop the H-AFt-
fusion protein. However the toxicity profile of different combinations of H-AFt alone 
with H-AFt-fusion proteins were determined against the SKBR3 and MDA-MB 231 
cell lines as the H-AFt-fusion protein was quite toxic. This experiment was carried out 
in collaboration with a PhD student M. Zygouropoulou under the supervision of the 
author. Results are shown in appendix II.  
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From the results obtained it was observed that the different combinations of H-AFt 
alone with H-AFt-fusion proteins were not as potent compared to the H-AFt-fusion 
protein which comprises a targeting protein fused to each subunit of the H-AFt, against 
the SKBR3 cell line. Hence, all experiments were carried out with the H-AFt-fusion 
protein which had targeting proteins fused to each subunit of H-AFt.  
 
As expected, H-AFt and L-AFt by themselves did not show good potency against the 
SKBR3 cell line. H-AFt only was slightly more potent than L-AFt possibly as a 
consequence of H-AFt being up taken more readily by the cells compared to L-AFt. 
Trastuzumab demonstrated potency against the SKBR3 cell line (GI50 = 27.00 nM), 
however, compared to the H-AFt-fusion protein it was slightly less potent illustrating 
that the H-AFt-fusion protein is more effective in the SKBR3 cell line (GI50 = 18.26 
nM) (P < 0.05), (Figure 5.1 (a - f)). Enhanced potency of H-AFt-fusion protein relative 
to Trastuzumab may be related to the size of the proteins where H-AFt-fusion protein 
is smaller than Trastuzumab. In addition, excellent cell penetration and high affinity 
binding characteristics of the H-AFt-fusion protein would have been beneficial [249] 
[250]. Furthermore, H-AFt-fusion protein binds to a different epitope of the HER2 
receptor in contrast to Trastuzumab [249]. Thus, the activity of the 2 agents could be 
distinct. None of the agents were highly potent against the MDA-MB 231 cell line 
which lacks HER2 expression compared to the SKBR3 cell line (Figure 5.1 (g-l)). 
Although, the MDA-MB 231 cell line was not sensitive to the fusion proteins, the H-
AFt-fusion protein was slightly more potent against the MDA-MB-231 cell line 
compared to the L-AFt-fusion protein, a probable consequence of high expression of 
TfR1s on the cell surface of these cells [241]. Further, the MDA-MB 231 cell line 
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showed moderate levels of sensitivity towards the HER2 targeting protein compared 
to all other agents tested on this cell line. In contrast, MDA-MB 231 cell growth was 
unaffected by Trastuzumab at all observed concentrations. It should be noted that the 
MTT assays were carried out using different batches of the agents; hence, the GI50 
values for each agent were slightly inconsistent which is reflected on the SDs. 
 
5.2.2 Effects of H and L-AFt-fusion proteins, targeting protein and 
Trastuzumab on SKBR3 and MDA-MB 231 colony formation 
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Figure 5.2: Effects of H and L-AFt-fusion proteins, targeting protein and 
Trastuzumab on colony formation. (a) SKBR3 (b) MDA-MB 231. (c) 
Representative images of colony formation after exposure to agents. Mean SF as % 
plating efficiency of control represented as the mean ± SD of  ✁✂✄☎✆ ✝ 3, (n = 3 per 
trial). * indicates significant difference compared to control, * (P < 0.05), ** (P < 
0.01), *** (P < 0.001), **** (P < 0.0001). 
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To analyse whether individual SKBR3 and MDA-MB 231 cells were able to retain 
their ability to reproduce after a short exposure (24 h) to H and L-AFt-fusion proteins, 
HER2 targeting protein and Trastuzumab, clonogenic assays were carried out. The 
results of H and L-AFt-fusion proteins were remarkable showing that SKBR3 cells 
were not able to meet the challenge of both H and L-AFt-fusion proteins. The SF of 
SKBR3 cells after exposed to 1x GI50 and 2x GI50 of the H-AFt-fusion protein showed 
no colonies after 14 days (P < 0.0001). Similarly, SKBR3 cells failed to form colonies 
after exposure to 1x and 2x GI50 concentrations of L-AFt-fusion protein (P < 0.0001) 
suggesting that these agents are highly cytotoxic and that the effect is irreversible. The 
results for both agents against the MDA-MB 231 cell line corroborated the results of 
the MTT assays; H-AFt-fusion protein showed a lower SF than the L-AFt-fusion 
protein probably due to uptake of H-AFt by the TfR1 receptors of MDA-MB 231 cells 
(Figure 5.2).  
 
 
Following treatment of SKBR3 cells with 1x and 2x GI50 concentrations of the HER2 
targeting protein, SFs of 75.44% and 61.84% respectively were obtained (compared 
to control; P < 0.0001). Although the targeting protein showed potent activity (GI50 = 
34.69 nM) against the SKBR3 cell line in MTT assays, it is apparent that the SKBR3 
cells were able to resume growth after a brief exposure to the agent, suggesting that 
the HER2 targeting protein is nontoxic to cells compared to the fusion proteins. 
Previous research done by Lee et al, 2008, has shown similar results. They have shown 
that the targeting protein did not significantly affect the clonogenic survival in SKBR3 
cells and that it is not toxic  [249].  
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Interestingly Trastuzumab resulted in SFs of 85.87% and 53.57% with 1x and 2x GI50 
concentrations respectively (compared to control; P < 0.0001) indicating that the 
SKBR3 cells survived the brief exposure compared to the fusion proteins. MDA-MB 
231 colony formation was uninhibited after exposure of cells to Trastuzumab. These 
results suggests that Trastuzumab is more of a cytostatic agent with moderate 
cytotoxic effects and also that it is highly selective to the HER2 overexpressing 
SKBR3 cell line. These results are consistent with in vivo data [55] [252].  
 
5.2.3 Confocal microscopy imaging of SKBR3 cells treated with H-AFt-fusion 
protein  
The H-AFt-fusion protein was shown to be the most potent agent among the 2 fusion 
proteins hence, the uptake of H-AFt-fusion protein by SKBR3 cells was visualised by 
fluorescence confocal microscopy. Strong fluorescence was observed in treated 
SKBR3 cells compared to control cells (Figure 5.3 (b)). After a 2 h time period, 
localisation of the agent was observed (Figure 5.3 (c)). After 6 h exposure, a sufficient 
amount of H-AFt-fusion protein had been internalised into SKBR3 cells. This could 
be most likely by receptor mediated endocytosis according to previous literature [131]  
[222] [253]. Taken together these results indicate that a short exposure period (2 to 6 
h) is sufficient for H-AFt-fusion protein to recognise and bind to HER2 receptors on 
the surface of SKBR3 cells and to be internalised (Figure 5.3 (d)). It was observed that 
fluorescence was present in both the cytoplasm and nuclei by the superimposition of 
green (H-AFt-fusion protein) on blue (DAPI) staining. These results may suggest that 
the H-AFt-fusion protein is accessing the DNA within the nucleus. The internalisation 
of the agent was still detectable at 24 h (Figure 5.3 (f)). This experiment was carried 
out in collaboration with Dr. Lei Zhang and the author extends her appreciation.  
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protein induced a higher accumulation in the G1 phase (75.90%) (P < 0.001) compared 
to L-AFt-fusion protein (71.79%) (P < 0.01). Trastuzumab also caused a significant 
accumulation of the G1 phase (70.08%) relative to SKBR3 control after 24 h (P < 
0.05), which was consistent with previous research [55] (Figure 5.4 (a)).  
 
Interestingly, 48 h exposure of SKBR3 cells to both H and L-AFt-fusion proteins, 
resulted in a significant increase in the G1 phase, and resulted in depleted S and G2/M 
phases. Moreover, the H-AFt-fusion protein induced a significant pre-G1 
accumulation which is indicative of apoptotic cells (6.00%) compared to control 
(2.00%) (P < 0.05). It was observed that the H-AFt-fusion protein demonstrated a 
much greater effect compared to the L-AFt-fusion protein at all 3 phases at 48 h in 
SKBR3 cells, although the difference was not significant (Figure 5.4 (b)).  
 
Following 72 h exposure, it was found that both H and L-AFt-fusion proteins caused 
significant pre-G1 accumulations (H-AFt-fusion protein 11.10% (P < 0.01), L-AFt-
fusion protein 14.80% (P < 0.001) and SKBR3 control, 2.60%. Further, both fusion 
proteins caused an enhanced G1 peak (H-AFt-fusion protein   74.80%; P < 0.0001 
and L-AFt-fusion protein   65.00%; P < 0.01) and reduced cell populations in S phase 
(H-AFt-fusion protein   5.30%; P < 0.01 and L-AFt-fusion protein   6.50%; P < 0.05) 
and G2/M phase (H-AFt-fusion protein 
 
 5.70%; P < 0.001 and L-AFt-fusion protein 
 
 8.50%; P < 0.01) significantly compared to SKBR3 control (G1 phase 
 
 55.40%, S 
phase 
 
 13.70% and G2/M 
 
 17.20%)  (Figure 5.4 (c)) and (Figure 5.5 (a)). It was 
observed that the H-AFt-fusion protein demonstrated a much greater significant effect 
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at the G1 phase P < 0.0001 and G2/M phase P < 0.05 compared to the L-AFt-fusion 
protein at 72 h. 
 
In contrast, MDA-MB 231 cells were resistant to both H and L-AFt-fusion proteins 
and did not display cell cycle perturbations compared to the untreated cells at all 3 
time points (Figure 5.4 (d, e and f)) and (Figure 5.5 (b)). Trastuzumab did not 
demonstrate a significant accumulation of the pre-G1 phase or a significant depleted 
S and G2/M phase compared to the H-AFt and L-AFt fusion proteins at all investigated 
time points against the SKBR3 cell line (Figure 5.4 (a, b and c)) and (Figure 5.5 (a)). 
Similar to the results obtained for the fusion proteins, the MDA-MB 231 cell line was 
mostly resistant towards Trastuzumab, however this agent showed a significant 
enhanced G1 peak in MDA-MB 231 cells at 24 h (P < 0.01) and 48 h (P < 0.05). 
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Figure 5.4: Effects of H-AFt-fusion protein, L-AFt-fusion protein and 
Trastuzumab on SKBR3 and MDA-MB 231 cell cycle. (a, b, c)- SKBR3 and (d, e, 
f)- MDA-MB 231 cells were treated with 2x GI50 concentrations of these agents for 3 
time points 24, 48 and 72 h. Mean and SD of trials   ✁, (n = 2 per trial). * indicates 
significant difference compared to control, * (P < 0.05), ** (P < 0.01), *** (P < 0.001), 
**** (P < 0.0001). 
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From the results obtained it is evident that the H-AFt-fusion protein induced 
significant SKBR3 G1 accumulations at all 3 time points investigated. In addition, this 
agent showed a depleted S and a G2/M phase at 48 and 72 h. The L-AFt-fusion protein 
also showed similar results although not as significant as the H-AFt-fusion protein. 
This effect may suggest that the H-AFt-fusion protein blocks cells in the G1 phase or 
in the G1/S transition phase and selectively inhibits cells that are actively proliferating 
in the S phase probably by manipulating their DNA since it was observed that the H-
AFt-fusion protein was stained within the nucleus in the confocal microscopy images. 
Previous literature has shown that cytosolic signalling activates different genes and 
how small differences in signal strength can generate qualitative differences in gene 
expression. Thus, inhibition of signalling pathways may inhibit gene transcription 
[254]. Indeed, as discussed in section 5.2.6, it was observed that the H-AFt-fusion 
protein inhibited signalling pathways that would have resulted in a reduced 
orchestration of cell cycle events that causes reduced cell proliferation. Further, the 
results reveal that both fusion proteins were able to induce a marked increase in pre-
G1 phase events. The pre-G1 phase is indicative of apoptosis and it shows that SKBR3 
cells are susceptible to H-AFt-fusion protein induced cytotoxicity [255]. Furthermore, 
the SKBR3 cell line expresses mutant TP53, which may allow abnormal proliferation 
[209] [256]. Thus, these results suggest that H-AFt-fusion protein is able to overcome 
TP53 mutant mechanisms in SKBR3 cells by inhibiting abnormal proliferation in 
SKBR3 cells. Trastuzumab was only able to cause G1 accumulations in cells and it  is 
shown to be associated with increased p27kip1 levels [55]. It has been demonstrated 
previously that anti-HER2 monoclonal antibodies exert inhibitory effects on HER2 
overexpressing breast cancers by enhancing levels of p27kip1 causing proliferating cells 
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to exit from the cell cycle [257]. Further, investigations are warranted to determine 
whether the H-AFt-fusion protein possesses a similar mechanism within the cell cycle.  
 
5.2.5 Effects of H and L-AFt fusion proteins, targeting protein and 
Trastuzumab on SKBR3 and MDA-MB 231 cellular apoptosis 
In order to identify whether the agents described in this chapter induced cell death 
following treatment, an annexin V-FITC/PI assay was carried out.  
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Figure 5.6: Effects of H-AFt-fusion protein, L-AFt-fusion protein and 
Trastuzumab on SKBR3 and MDA-MB 231 cellular apoptosis. (a, b, c)- SKBR3 
and (d, e, f)- MDA-MB 231 cells were treated with 2 x GI50 concentrations of these 
agents for 3 time points 24, 48 and 72 h. Mean and SD of  ✁✂✄☎✆ ✝ ✞✟ (n = 2 per trial). * 
indicates significant difference compared to control, * (P < 0.05), ** (P < 0.01), *** 
(P < 0.001), **** (P < 0.0001). 
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SKBR3 and MDA-MB 231 cells were treated with 2x GI50 concentrations of the H 
and L-AFt-fusion proteins for a time course of 24, 48 and 72 h. Early and late apoptotic 
populations were summed to determine the total apoptotic population in cells 
following treatment.  The results obtained were then compared to results obtained with 
Trastuzumab treatment.  
 
H-AFt-fusion protein induced a significant apoptotic population relative to control 
SKBR3 cells at 24 h (P < 0.05). On the contrary, L-AFt-fusion protein did not induce 
a significant apoptotic population in SKBR3 cells in 24 h. Trastuzumab caused a 
significant apoptotic population in 24 h (P < 0.001), (Figure 5.6 (a)). After 48 h, the 
H-AFt-fusion protein caused an increased apoptotic population relative to control (P 
< 0.01). All agents induced significant necrotic populations compared to control at 48 
h (Figure 5.6 (b)). Interestingly, after 72 h there was a dramatic increase in the total 
apoptotic population in SKBR3 cells after treatment with H-AFt-fusion protein 
(40.30%) and L-AFt-fusion protein (31.70%) compared to control SKBR3 cells 
(3.75%). Out of the total apoptotic population the late apoptotic population was 
increased compared to the early apoptotic population (P < 0.0001). When SKBR3 cells 
were visualised microscopically following 72 h, it was observed that cells treated with 
these 2 novel agents showed morphological changes indicative of apoptosis. Cells 
were shrunk and showed cell fragmentations. At 72 h in contrast, Trastuzumab, 
induced a smaller apoptotic population (14.10%) compared to control SKBR3 cells (P 
< 0.01). All agents at 72 h, also caused significant necrotic populations, H-AFt-fusion 
protein (12.00%), L-AFt-fusion protein (12.60%), Trastuzumab (11.60%) compared 
to SKBR3 control (1.50%),  (P < 0.01), (Figure 5.6 (c)) and (Figure 5.7(a)). MDA-
MB 231 cells were extremely resistant to treatment and no significant apoptosis was 
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observed in all 3 time points with all tested agents (Figure 5.6 (d, e and f)) and (Figure 
5.7 (b)).  
 
From the results, it was observed that H and L-AFt-fusion proteins induced apoptosis 
and necrosis and that the H-AFt-fusion protein was more toxic than the L-AFt-fusion 
protein causing increased apoptosis. SKBR3 cells progressed to apoptosis and also 
necrosis at 72 h. These results confirmed the results of the cell cycle analysis which 
showed a stark pre-G1 accumulation at 72 h which is indicative of apoptotic cells.  
 
In the current study, it was observed by Western blots that SKBR3 cells treated with 
2x GI50 of H-AFt-fusion protein down-regulated total PARP at 24 h (Figure 5.12). In 
addition, protein microarray analyses (section 5.2.7) following 24, 48 and 72 h 
exposure of SKBR3 cells to H-AFt-fusion protein confirmed these results obtained for 
PARP expression levels. These results may imply that the H-AFt-fusion protein may 
activate apoptotic pathways at an earlier time point than 24 h and the level of PARP 
may be reduced due to post-apoptotic degradation; and activating secondary necrosis 
afterwards [258]. Certainly, it has been shown that cell death occurs by alternative 
methods and more than one apoptotic cascade may be activated at the same time [208]. 
One of the main methods of cell death in the case of H-AFt-fusion proteins is necrosis, 
as a high percentage of necrosis was observed in this investigation. This could be 
secondary necrosis taking place. However, it has been shown that programmed 
necrosis can also participate in cell killing when apoptotic pathways are abrogated 
[259]. Furthermore, it was observed by Western blotting that the H-AFt-fusion protein 
is able to down-regulate proteins of the RAS/MAPK, PI3K/AKT and JAK/STAT 
pathways by direct blockade of the HER2 receptor. Inhibition of proteins of these anti-
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apoptotic pathways sensitises SKBR3 cells to apoptosis [248]. Trastuzumab also 
caused apoptosis in SKBR3 cells and it has been previously shown that Trastuzumab 
is able to mediate apoptosis by inhibiting the PI3K/AKT signalling pathway. Further, 
Trastuzumab is able to mediate apoptosis by inhibiting cellular DNA repair 
mechanisms and by antibody dependent cellular cytotoxicity in vivo [55]. As future 
studies, it would be interesting to determine whether the H-AFt-fusion protein 
possesses a similar mechanism.  
 
5.2.6 Effects of H-AFt-fusion protein, targeting protein and Trastuzumab on 
HER2/P-HER2, RAS/MAPK, PI3K/AKT and JAK/STAT signalling 
pathways and PARP in SKBR3 and MDA-MB 231 cells by Western 
blotting 
SKBR3 and the MDA-MB 231 cells had been treated with H-AFt-fusion protein, 
targeting protein and Trastuzumab for 24 h by 1x and 2x GI50 concentrations. 
Following treatment both cell lines were examined for protein expression levels of 
HER2, P-HER2 and for the expression levels of key proteins of RAS/MAPK, 
PI3K/AKT and JAK/STAT pathways. Initially, it was found that HER2 and P-HER2 
expression was significantly reduced in SKBR3 cells after treating the cells with H-
AFt-fusion protein (P < 0.0001) (HER2 - ARD - 1x GI50   22.88% and 2x GI50   
8.99% and P-HER2 - ARD - 1x GI50   76.41% and 2x GI50   19.02% compared to 
SKBR3 control). In contrast, it was observed that the targeting protein was not able to 
decrease HER2 or P-HER2 protein expression levels in SKBR3 cells. Further, HER2 
expression levels were not decreased in response to Trastuzumab, however P-HER2 
expression levels were slightly reduced (P < 0.05) (Figure 5.8) and (Figure 5.9 (a) and 
(b)). 
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Figure 5.9: ARD levels for HER2 and P-HER2 of HER2 targeting agents. (a) 
HER2 and (b) P-HER2 expression levels in SKBR3 and MDA-MB 231 cells. Cells 
were treated with H-AFt-fusion protein, targeting protein or Trastuzumab for 24 h. 
Mean and SD of trials   ✁✂ * indicates significant difference compared to control, * (P 
< 0.05), ** (P < 0.01), *** (P < 0.001), **** (P < 0.0001).  
 
 
Previous research has shown that some anti-HER2 monoclonal antibodies are able to 
reduce the amount of total HER2 receptor expressed on the cell surface [260]. H-AFt-
fusion protein decreased the levels of total HER2. This may be a result of accelerated 
internalisation of the H-AFt-fusion protein after binding to cell surface HER2 
receptors by endocytosis followed by intracellular routing to lysosomes where 
degradation occurs [261]. Further, suppression of HER2 receptor levels will further 
reduce homodimerisation and heterodimerisation of HER receptors which in turn will 
reduce phosphorylation levels [49]. However, the amount of phosphorylation 
observed in this study was not as low as the amount of total HER2 in response to H-
AFt-fusion protein treatment. This could be due to certain amount of dimerisation and 
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subsequent autophosphorylation. Nevertheless, down-regulation of downstream 
pathways were observed in SKBR3 cells after exposure to H-AFt-fusion protein which 
is discussed below.  
 
In contrary, the targeting protein did not show any alterations of total and 
phosphorylated HER2 levels which was expected as it was merely used as a targeting 
molecule. Further, complying with the results of this study, previously it has been 
shown that total HER2 receptor levels were unchanged in SKBR3 cells and that 
phosphorylation of HER2 was inhibited slightly by Trastuzumab treatment and the 
efficacy of this agent is largely related to down-regulation of the PI3K/AKT pathway 
and inducing an immune response [103] [262]. 
 
Next, the protein expression levels of some of the key proteins of the RAS/MAPK 
pathway was investigated following exposure with the agents mentioned above. It was 
observed that both total CRAF (ARD   50.95%) and P-CRAF (Ser259) (ARD - 
10.88%) and similarly total ERK1/2 (ARD - 76.99%) and P-ERK1/2 (ARD   51.60%) 
of the RAS/MAPK pathway were extremely suppressed in SKBR3 cells following 
treatment with 2x GI50 of H-AFt-fusion protein compared to SKBR3 control (P < 
0.0001). Phosphorylation at Ser259 of CRAF (ARD   14.54%) and ERK 1/2 (ARD   
65.61%) was significantly reduced with 1x GI50 of H-AFt-fusion protein as well (P < 
0.0001). In comparison, the targeting protein did not cause significant perturbations in 
the phosphorylated forms of the same proteins. Nonetheless, significant down-
regulation of total CRAF after exposure to 2x GI50 targeting protein was observed 
(ARD 
 
 42.43%) (P < 0.0001). Trastuzumab (2x GI50) showed similar results to the 
H-AFt-fusion protein, where all 4 proteins of the RAS/MAPK pathway investigated 
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showed significant depletion. Conversely, a lower concentration of Trastuzumab (1x 
GI50) did not cause significant down-regulation compared to H-AFt-fusion protein. 
Protein expression in MDA-MB 231 cells was not significantly affected other than 
total CRAF following exposure to 2x GI50 H-AFt-fusion protein (P < 0.001).  
 
 
It was also found that H-AFt-fusion protein (2x GI50 concentrations) down-regulated 
phosphorylated levels of p38 (Thr180/Tyr182) (ARD   55.02%) (P < 0.0001). 
Furthermore, it down-modulated P-SAPK/JNK (Thr183/Tyr185) at both 1x and 2x 
GI50 concentrations in SKBR3 cells (ARD   44.61% and 37.55% respectively) (P < 
0.001). Trastuzumab did not perturb P-p38 (Thr180/Tyr182) but inhibited P-
SAPK/JNK (Thr183/Tyr185) significantly in SKBR3 cells (P < 0.01). Targeting 
protein alone did not cause any perturbations in these proteins (Figure 5.10). 
Densitometry analysis with the ARD values for the significant results are shown in 
appendix I under section 9.1.2.1. 
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reduced active form. It was also observed that protein expression levels of ERK1/2 
which in turn is phosphorylated by MEK were also down-modulated in this study, 
nevertheless the measured levels of total and phosphorylated ERK1/2 were higher than 
that observed for CRAF and P-CRAF. Although the RAF MEK ERK cascade is 
typically drawn as a linear cascade of protein kinases, it is actually a key core 
component of a complex signalling network, with many other interactions as 
mentioned before. As such, different alternations of protein expression levels could be 
expected. Further, in line with previous research it was found that Trastuzumab 
inhibited phosphorylation of CRAF and ERK at 2x GI50 concentrations [116] [135].  
 
H-AFt-fusion protein caused suppression of phosphorylation of p38 and SAPK/JNK 
but not the total protein expression levels. Donnelly et al, 2014, has shown increased 
phosphorylation of p38 in the RAS/MAPK pathway was associated with acquired 
resistance to Trastuzumab and that inhibition of p38 rescued Trastuzumab sensitivity 
in cells with acquired resistance. Thus, reduction in phosphorylation of p38 may 
enhance the effect of the H-AFt-fusion protein. However, controversies exist 
regarding the activity of this pathway and regulation of this pathway may involve 
many upstream and downstream signals that will coordinate cellular processes such as 
cell growth, apoptosis and survival [67]. Thus, more investigations are warranted to 
find out the exact function of p38 in cells treated with H-AFt-fusion protein.  
 
As far as the role of SAPK/JNK is concerned, debates exist over its precise function 
in cell proliferation and apoptosis. Thus, this pathway has been shown to have a pro-
apoptotic and an anti-apoptotic role or a neutral role depending on the stimuli [65] 
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[66]. In the current investigation, inhibition of P-SAPK/JNK was observed in SKBR3 
cells exposed to H-AFt-fusion protein. Similar results were observed in response to 
Trastuzumab as well. Previously, Dokmanovic et al, 2009, has shown that a 
Trastuzumab resistant SKBR3 cell line was restored by down-regulating P-ERK1/2 
and P-SAPK/JNK by a Rac1 inhibitor [264]. Hence, it could be suggested that these 
agents are enhancing the pro-apoptotic role of SAPK/JNK in SKBR3 cells in the 
current study. Nevertheless, further investigations are needed to confirm the exact 
mechanism. The targeting protein did not affect these protein expression levels.  
 
It was further examined whether the H-AFt-fusion protein is able to abolish protein 
expression levels of the PI3K/AKT pathway. It was found that P-AKT (Thr308) (ARD 
  65.68%) was significantly supressed by 2x GI50 H-AFt-fusion protein (P < 0.05) 
compared to SKBR3 control. Although the same agent (2x GI50) showed reduction in 
P-AKT (Ser473) and total AKT, the results were not significant. The targeting protein 
did not show alterations in these proteins in SKBR3 cells. However, Trastuzumab (2x 
GI50) demonstrated significant depletion of total AKT (P < 0.05), P-AKT (Ser473) (P 
< 0.05) and P-AKT (Thr308) (P < 0.001) compared to SKBR3 control. 
Phosphorylation of PTEN (Ser380) was slightly reduced by 1x and 2x GI50 
concentrations of H-AFt-fusion protein (P < 0.01). Nevertheless, total PTEN protein 
expression was unaffected. Targeting protein did not affect the PTEN expression 
levels, however, it was observed that Trastuzumab also caused reduction in 
phosphorylated PTEN (Ser380) protein expression levels (P < 0.001). Further, total 
✁✂✄ ☎✆✝ ✞-✁✂✄ ☎✆ ✟✂✠✡☛☞ ✌✍✎ ✞-PDK1 (Ser241) protein levels were unaffected in 
SKBR3 cells by the effect of H-AFt-fusion protein and Trastuzumab. Thus, the effect 
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both P-AKT (Thr308) and (Ser473) levels. It has been reported that as a result 
Trastuzumab causes accumulation of cells in the G1 phase of the cell cycle, which was 
observed in this study [262].  
 
 
PTEN negatively regulates the PI3K/AKT pathway. Intriguingly, previous literature 
has shown that reduction of total PTEN and increased phosphorylation of the PTEN 
protein especially at Ser380 causes to lose its tumour suppressor function which is 
controversial to some of the other published reports [266]. Multiple phosphorylation 
sites of the PTEN protein has been identified such as Ser380, Thr382, and Thr383, 
that leads to loss of phosphatase activities or a gain of PTEN stability which may in 
turn result in loss of tumour suppressor function and increased cancer susceptibility. 
However, out of the phosphorylation sites of the PTEN protein, according to previous 
reports, Ser380 is the most critical for regulation of PTEN function, and this form was 
investigated in the current study [266]. Further, it has been shown that 
unphosphorylated forms of PTEN can act to down-regulate AKT activity, rather than 
the phosphorylated forms which may also demonstrate a suppressed form. Thus, in 
this regard, reduction of phosphorylation by the H-AFt-fusion protein in SKBR3 cells 
may be advantageous and promotes AKT down-regulation [267] [268]. P-PTEN was 
down-regulated significantly in SKBR3 cells after Trastuzumab treatment as well. 
However, prior reports have shown that loss or reduced PTEN activity caused blocked 
Trastuzumab mediated growth inhibition due to continuous activation of the 
PI3K/AKT pathway which results in resistance to the agent [55] [103]. Therefore, 
more investigations are warranted to state the exact mechanism of the H-AFt-fusion 
protein and Trastuzumab in SKBR3 cells with regards to the PTEN status in the 
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current study as it was observed that both agents down-regulated phosphorylated 
AKT.  
 
Interestingly, 1x and 2x GI50 concentrations of H-AFt-fusion protein degraded 
phosphorylated STAT5 (Tyr694) significantly compared to SKBR3 control (ARD   
1x GI50 - 46.84% and 2x GI50 - 17.42%) (P < 0.0001). However, phosphorylation of 
JAK2 (Tyr1007) in the JAK/STAT pathway was not inhibited by the H-AFt-fusion 
protein. Trastuzumab also evoked slight down-regulation of P-STAT5 in SKBR3 cells 
(P < 0.001) but did not deplete the protein expression levels of P-JAK2.  
 
P-STAT5 was not detected in MDA-MB 231 cells and no significant change in the 
protein expression levels of MDA-MB 231 cells was detected for P-JAK2. 
Furthermore, it was observed that protein expression levels of PARP were depleted by 
both 1x (P < 0.001) and 2x GI50 concentrations (P < 0.0001) of H-AFt-fusion protein 
and Trastuzumab (P < 0.0001) in SKBR3 cells. No cleaved PARP was observed in 
this experiment. Likewise, 2x GI50 concentrations of H-AFt-fusion protein also caused 
down-regulation of PARP in MDA-MB 231 cells (P < 0.0001). Trastuzumab also 
induced a slight effect in MDA-MB 231 cells (P < 0.05). Further, the targeting protein 
did not cause an effect in the protein expression levels of P-STAT5 and PARP (Figure 
5.12). Densitometry analysis with the ARD values for the significant results are shown 
in appendix I under section 9.1.2.3. 
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Studies have shown that STAT5 is activated via JAK2 within the JAK/STAT pathway. 
STAT5 has been shown a prominent role in breast cancer. However, this role is found 
to be controversial depending on the breast cancer subtype. Thus, determining the 
activity of JAK2/STAT5 in HER2 overexpressing SKBR3 cells after exposure to the 
3 agents was thought to be interesting [84]. It has been shown that STAT5 activity 
restores phosphorylated AKT and blocks cellular apoptosis, thereby off-setting the 
impact of cell viability [83]. Thus, reduction of P-STAT5 by the H-AFt-fusion protein 
and Trastuzumab may cause reduction in phosphorylated AKT thereby increasing 
apoptosis in SKBR3 cells. Further, as mentioned above SKBR3 cells treated with H-
AFt-fusion protein and Trastuzumab showed depleted PARP activity, with no cleaved 
PARP identified. TP53 loss in SKBR3 cells has shown to cause non-apoptotic cell 
death by impairing PARP activity. However, depleted PARP activity observed in the 
current study could be because of post-apoptotic degradation and secondary necrosis 
taking place in SKBR3 cells after exposure to H-AFt-fusion protein [258] [269].  
 
Taken together the results of the Western blots suggest that the novel H-AFt-fusion 
protein is able to down-regulate most of the key proteins of all 3 pathways investigated 
in this study. Nonetheless, the protein expression levels tested are not isolated proteins 
and they all exist in the presence of other proteins and among a plethora of many 
signalling pathways. As such, cross talk may influence the results of this study largely.  
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5.2.7 Effects of H-AFt-fusion protein, targeting protein and Trastuzumab on 
EGFR/P-EGFR, HER2/P-HER2, HER3/P-HER3, RAS/MAPK, 
PI3K/AKT and JAK/STAT signalling pathways and PARP in SKBR3 and 
MDA-MB 231 cells by reverse phase protein microarray (RPMA) 
The results of the protein microarray (RPMA) strongly corroborated with the results 
of the Western blots. As in the above Western blot experiments, 2x GI50 concentrations 
of H-AFt-fusion protein, targeting protein and Trastuzumab were evaluated for all 
protein expression levels tested in the Western blots by RPMA against SKBR3 and 
MDA-MB 231 cells. A time course of 24, 48 and 72 h was adopted to test the ability 
of all 3 agents to perturb signal transduction cascades. H-AFt-fusion protein down-
regulated total HER2 and P-HER2 in SKBR3 cells significantly during the time course 
(P < 0.0001) (Figure 5.13). Protein expression levels of other HER family members; 
EGFR and HER3 and their phosphorylated forms were also tested after SKBR3 cells 
had been treated with H-AFt-fusion protein. Extremely significant down-regulation of 
the expression levels of P-EGFR was observed with H-AFt-fusion protein treatment 
at all 3 time points (P < 0.0001). However, total EGFR was not down-regulated. 
Further, both total HER3 and P-HER3 were inhibited significantly by the H-AFt-
fusion protein (P < 0.01).  
 
 
Total CRAF and P-CRAF were also down-regulated by H-AFt-fusion protein at all 3 
time points in SKBR3 cells (P < 0.05). However, the H-AFt-fusion protein showed 
slight down-regulation of total and phosphorylated ERK1/2 in 24 h but surprisingly 
did not show inhibition of total and phosphorylated ERK1/2 in 48 and 72 h in SKBR3 
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cells. In fact, it showed up-regulation of P-ERK1/2 at 48 and 72 h (P < 0.01). In 
contrast, the same agent down-regulated P-p38, total SAPK/JNK and P-SAPK/JNK in 
SKBR3 cells at all 3 time points (P < 0.05). H-AFt-fusion protein was also able to 
perturb the PI3K/AKT pathway significantly. Total AKT, P-AKT (Thr308) and P-
AKT (Ser473) were down-regulated significantly at 24 and 72 h (P < 0.01). However, 
no significance was observed at 48 h. This could be due to the large variances in the 
results obtained. Further, the same agent inhibited protein expression levels of P-
STAT5 and PARP in SKBR3 cells significantly at all 3 time points (P < 0.0001). 
Trastuzumab elicited similar results to the H-AFt-fusion protein, however, showed 
significant up-regulation of HER2 and P-HER2 in 48 h, while the protein expression 
levels dropped at 72 h significantly (P < 0.0001). Trastuzumab did not cause down-
regulation in HER3 and P-HER3 but showed slight down-regulation in EGFR and P-
EGFR (P < 0.05). Further, the targeting protein was unable to cause a significant effect 
in this experiment. Furthermore, MDA-MB 231 cells were unaffected significantly 
with all tested proteins. This experiment was conducted in collaboration with Dr. Lei 
Zhang, Dr. Ola Negm and Dr. Paddy Tighe, and the author extends her appreciation.  
 
 
EGFR, HER2 and HER3 are all implicated in the development and progression of 
breast cancer [270]. Indeed, it has been shown that HER receptor family members 
interact with each other as a highly interactive signalling group [49]. As such, these 
results elicit that the H-AFt-fusion protein is able to bind to HER2 and suppress its 
signalling capability, and in addition inhibit the function of EGFR and HER3 as well. 
Further, HER2/HER3 heterodimer is considered the most potent HER receptor pair 
with respect to strength of interaction [270]. Thus, down-regulation of HER3 and also 
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extremely significant G1 accumulation phase at all 3 time points investigated. 
Furthermore, the H-AFt-fusion protein induced a large apoptotic population in SKBR3 
cells corroborating the cytotoxic effect it demonstrated in the clonogenic assay and 
also with the pre-G1 phases of the cell cycle. It has been shown that therapies leading 
to HER2 receptor down-regulation of its total and phosphorylation forms improve 
sensitivity in breast cancer cells. As such, the H-AFt-fusion protein evoked remarkable 
down-regulation of HER2 and P-HER2 proteins in SKBR3 cells. Protein microarray 
studies revealed, that the H-AFt-fusion protein is also able to down-regulate P-EGFR, 
HER3 and P-HER3 which may inhibit mitogenic receptor heterodimerisation. 
Inhibition of these receptors resulted in down-regulation of RAS/MAPK, PI3K/AKT 
and JAK/STAT pathways significantly thereby ultimately leading to SKBR3 
apoptosis. However, further studies are warranted to understand the mechanism by 
which H-AFt-fusion protein alters some of the protein levels in the studied signalling 
pathways. Nevertheless, this agent could be a promising nanodrug for the treatment of 
HER2 overexpressing breast cancer in the future.  
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CGP57380, Raloxifene and 5F 203, Gefitinib and 5F 203 and novel dual PI3K/mTOR 
inhibitors alone and in combination with 5F 203 have been investigated.   
 
Agent interactions were evaluated as, synergistic, additive or antagonistic according 
to the Chou and Talalay method [273] [274]. Synergism can be concluded if agent 
combinations demonstrate greater than the additive activity expected from each agent 
alone. Antagonism can be concluded if agent combination results in activity that is 
less than the additive activity of each agent alone [275]. The combination index (CI) 
theorem of Chou and Talalay quantitatively depicts synergism as CI < 0.9, additivity 
as 0.9 > CI < 1.1, and antagonism as CI > 1.1 of the agent combinations. The CI values 
were evaluated for each cell line tested with the 2 agent combinations using the 
equation below. The mutually nonexclusive model was used based on the assumption 
that the 2 agents act through entirely different mechanisms. [Agent1] and [Agent2] 
were 50% inhibitory concentrations (IC50) of agent 1 and agent 2 in combination. 
[Agent1]x and [Agent2]x were IC50 concentrations of agent 1 and agent 2 alone. IC50 
concentrations were used for calculation purposes as mentioned in the Chou and 
Talalay, CI method [273] [274].  
CI = [Agent1]
 
/ [Agent1]x + [Agent2] / [Agent2]x + [Agent1] x [Agent2] /    
[Agent1]x x [Agent2]x 
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MDA-MB 231 cell lines were resistant to Sirolimus alone. Once again T47D showed 
highest sensitivity to CGP57380 while SKBR3 also demonstrated somewhat high 
sensitivity to this agent. ZR-75-1, MCF7 and MDA-MB 468 depicted moderate 
sensitivity to CGP57380. MDA-MB 231 cell line was resistant to CGP57380 with a ~ 
10-fold higher GI50 value compared to the T47D cell line (Table 6.1). Sirolimus 
showed a dose dependent growth inhibitory effect that appeared cytostatic in the MTT 
experiments with all cell lines tested. CGP57380 also showed dose dependent growth 
inhibition in all cell lines tested.  
 
One of the main downstream effectors of the mTOR pathway is known to be 4E-BP1. 
Hyperphosphorylated 4E-BP1 is shown to dissociate from eIF4E thereby increasing 
the amount of functional eIF4E. Thus, Sirolimus inhibits mTOR signalling by 
suppressing mainly 4E-BP1 phosphorylation [276] [277]. Further, p70S6K1 is also 
phosphorylated by mTOR which is also inhibited by Sirolimus [276]. Previous 
observations on potency of Sirolimus have been contentious. Some researchers have 
reported various factors that are required for Sirolimus inhibition such as high levels 
of total p70S6K1 or loss of PTEN [117] [278]. In contrast, some have reported that 
loss of PTEN can facilitate a negative feedback loop leading to activation of the 
PI3K/AKT pathway in response to Sirolimus treatment and thereby resistance to this 
agent as mentioned in chapter 1 [279]. MDA-MB 468 cells are PTEN deficient, and 
in the present study, this cell line showed moderate sensitivity to Sirolimus compared 
to ZR-75-1 which is also PTEN deficient. ZR-75-1 cells showed high sensitivity, 
compared to MDA-MB 468 cells to Sirolimus (P < 0.01) [72] [117] [183]. 
Nevertheless, T47D was the most sensitive to Sirolimus in this study (GI50 = 0.62 nM). 
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T47D cells harbour wildtype PTEN and demonstrate a mutated PIK3CA gene [72]. 
According to previous observations, breast cancer cells that have a mutant PIK3CA 
gene are selectively sensitive to mTOR inhibitors such as Sirolimus [73]. In addition, 
it has been also shown previously that T47D and ZR-75-1 cell lines show high levels 
of total and phosphorylated p70S6K1 which could be the reason for high sensitivity 
to Sirolimus in this study [117].  
 
Further, cells expressing aberrant HER2 which regulates mTOR signalling have also 
shown sensitivity to mTOR inhibition thus, SKBR3 cells that fall into the HER2 
molecular subtype showed sensitivity to Sirolimus. On the other hand, MDA-MB 231 
cells were resistant. These cells express wild type PTEN and low levels of p70S6K1 
[117]. Further, MDA-MB 231 cells consists of a mutant form of the RAS gene (K-
RAS) [72]. Thus, the RAS/MAPK pathway is constitutively activated in these cells as 
well. Although, many reports have shown that MCF7 cells are sensitive to this agent 
due to having high levels of phosphorylated p70S6K1, a mutant PIK3CA gene and low 
levels of phosphorylated AKT, this cell line showed resistance to this agent in this 
study  [72] [117] [183].  
 
Existing research has shown that although Sirolimus reduces phosphorylation of 4E-
BP1 and p70S6K1, paradoxically it increases phosphorylation of eIF4E and AKT [79]. 
In fact, it has been revealed that Sirolimus only blocks mTORC1 but not mTORC2 
which mediates AKT phosphorylation [77]. However, it has been also shown that 
phosphorylated AKT levels are not increased in cell lines with wild type PTEN [279]. 
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Further, it has been portrayed that enhanced eIF4E phosphorylation is independent of 
p70S6K1 inhibition [277]. Some researchers have shown that Sirolimus treatment can 
up-regulate the RAS/MAPK pathway in certain cell lines [280] [281]. Thus, these 
factors could contribute to different levels of sensitivity to Sirolimus in the breast 
cancer cell line panel.  
 
eIF4E also targets the RAS/MAPK pathway. ERK and p38 phosphorylate MNK1 
leading to eIF4E phosphorylation which can be inhibited by CGP57380. This agent is 
in fact a potent inhibitor of both MNK1 and MNK2 [78]. Interestingly, T47D was the 
most sensitive cell line to CGP57380 as well (GI50 = 9.22 µM). The HER2 
overexpressing SKBR3 cell line also depicted high sensitivity to CGP57380. These 
cells have portrayed high levels of MNK1 and MNK2 activity and additionally high 
levels of basal and phosphorylated eIF4E, and are therefore sensitive to CGP57380 
[187] [282]. Further, Wheater et al, 2010, has shown that T47D, ZR-75-1 and MDA-
MB 231 cell lines were inhibited by CGP57380 due to high or moderate levels of 
phosphorylated eIF4E. Nevertheless, these researchers have shown differential 
phosphorylated eIF4E levels by CGP57380 within these cell lines and that it is most 
likely to reflect variations of metabolism of the agent or up-regulation of agent 
insensitive kinases [187]. Further, it has been also shown that MCF7 and MDA-MB 
468 cell lines depict low amounts of phosphorylated eIF4E which makes it less 
sensitive to CGP57380 [187] [283].  
 
Chapter 6 
269 
 
Interestingly, it has been found that enhanced eIF4E phosphorylation induced by 
Sirolimus is dependent on the MNK activation [79] [277]. As outlined above MNK1 
regulates eIF4E activation. Wang et al, 2007, has shown that knocking down MNK1 
activation reduced phosphorylated eIF4E levels but could not prevent its 
phosphorylation being increased by Sirolimus treatment. This suggests that MNK1 
silencing is not sufficient to prevent eIF4E phosphorylation by Sirolimus. Thus, it may 
imply that both MNK1 and MNK2 may be responsible for Sirolimus induced eIF4E 
phosphorylation because loss of MNK1 function may be compensating for MNK2 
[277]. Thus, it was hypothesised that combining both Sirolimus and CGP57380 would 
lead to reduced eIF4E phosphorylation thereby inhibition of mRNA translation.  
 
In order to determine the effect of the agent combination, 3 concentrations were 
selected from each agent depending on how effective the agents were in the cell line 
panel. The concentrations selected for CGP57380 were 1 µM, 5 µM and 10 µM while 
the concentrations for Sirolimus were selected as 0.1 nM, 0.5 nM and 1 nM for T47D, 
ZR-75-1, SKBR3 and MDA-MB 468 cell lines and 100 nM, 500 nM and 1 µM for 
MCF7 and MDA-MB 231 cell lines.  
 
Unexpectedly, it was found that all 6 cell lines with the agent combination showed a 
CI value of > 1.1 which indicated an antagonistic effect. These findings could be due 
to up-regulation of AKT of the PI3K/AKT pathway. Further, mTOR exerts influence 
on PI3K/AKT signalling through the mTOR-p70S6K1-insulin receptor substrate 
feedback loop in normal cells. However, it has been shown that inhibition of mTORC1 
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by mTOR inhibitors, relieves this negative feedback, by activating AKT. It has been 
reported that activated AKT extends a direct effect on pro-apoptotic and anti-apoptotic 
proteins of the Bcl-2 family which enhances cell survival [77] [284]. These findings 
can also be due to up-regulation of the RAS/MAPK pathway in the breast cancer cell 
lines. Upstream effectors of MNK such as ERK1/2 could be playing a role in these 
cell lines since it has been shown that CGP57380 does not affect the phosphorylated 
levels of ERK [285]. Further, prolonged treatment with Sirolimus has shown to add 
complexity to the extensive signal transduction cross talk by increasing ERK1/2 
signalling in certain cancer cells by a feedback activation [286]. 
 
In parallel to this study, an undergraduate student H. K. Sin supervised by the author 
carried out a study with Sirolimus and CGP57380 alone and in combination using 
pancreatic Mia PaCa-2 cells. Mia PaCa-2 cells represents a type of pancreatic ductal 
adenocarcinoma which is very aggressive [287]. Results were similar to the present 
study with antagonistic results. The results are shown in appendix III.  
 
Despite the efficacy of mTOR inhibitors, these agents have shown to induce eIF4E 
phosphorylation in a PI3K dependent mechanism. Intriguingly, Wang et al, 2007, has 
demonstrated that a PI3K inhibitor (LY294002) was able to block Sirolimus induced 
eIF4E phosphorylation in lung cancer cells. Furthermore, the same research group has 
depicted that mTOR inhibitors activate PI3K leading to an increase in eIF4E 
phosphorylation [277]. Therefore, it was investigated whether dual PI3K/mTOR 
inhibitors would be more effective in the panel of breast cancer cell lines.  
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6.2.2 Effects of dual PI3K/mTOR inhibitors 
6.2.2.1 In vitro growth inhibitory effects of dual PI3K/mTOR inhibitors 
Dual PI3K/mTOR inhibitors have an advantage over single target inhibitors since they 
are able to target PI3K, AKT and mTOR simultaneously. It has been shown previously 
that agents which fall into dual PI3K/mTOR inhibitors target both mTORC1 and 
mTORC2 which will inhibit negative feedback activation of PI3K/AKT signalling in 
cancer cells. This may completely abrogate PI3K/AKT and mTOR pathways which is 
beneficial but as a shortcoming these agents could be highly toxic [77].  
 
In the current study, 3 dual PI3K/mTOR inhibitors - MS-73, MS-74 and MS-76 have 
been tested in the panel of breast cancer cell lines. MS-74 and MS-76 are novel 
analogues of MS-73 as mentioned in chapter 1 [140]. MS-73 has been shown to be a 
 ✁✂ ✄☎✆✝ ✞✂✟✞✠✞✡☛☞  ☛☞✡☞✁✌✞✂✍  ☛✡✎✂✏✌ ✁✍✁✞✂✑✡ ✄☎✆✝ ✞✑☛✒☛☞✓✑ ✔ ✕✕✖✗✘  ✕✕✖✙✘  ✕✕✖✚✘
✁✂✛  ✕✕✖✜✢ [70]. Among the isoforms, ✡✟✎ ✍✎✂✎ ✎✂✏☛✛✞✂✍ ✡✟✎  ✕✕✖✗ ✞✑☛✒☛☞✓✘ ✣✟✞✏✟ ✞✑
PIK3CA is mostly mutated in breast cancer [70] [140]. As outlined in chapter 1, the 2 
novel analogues MS-74 and MS-76 have been developed to investigate the structural 
activity relationships with MS-73 and to increase solubility, because MS-73 is found 
to be poorly soluble. The MTT results for the 3 agents tested are summarised in Table 
6.2. 
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Table 6.2: Mean GI50 ± SD values of MS agents. Cells were seeded in 96 well plates 
at a density of 2.5 x 103 cells/well. After allowing time to adhere (24 h), cells were 
 ✁✂✄☎ ✆ ✝✄ ✞✟ ✠✝☎ ✡☛☞ ✌✍ ✠ ✎ ✏✑✒ ✓ ✞✠ ✞✠✆ ✔✕ ✄✖ ✝✗✘✞✙☎ ✚ ✛✒ 
 
MS-73 had the highest potency across all the cell lines and MS-76 had the least 
potency. It was observed that MDA-MB 468 which is the PTEN deficient cell line was 
the most sensitive towards all 3 agents. Interestingly, it was observed that there was a 
15-fold decrease in the potency of MS-74 compared to MS-73 (P < 0.0001) while there 
was a 5-fold decrease in the potency of MS-76 compared to MS-74 (P < 0.01) in the 
activity against the MDA-MB 468 cell line.  
 
ZR-75-1 also showed high sensitivity towards MS-73 and MS-74 while this cell line 
showed less sensitivity to MS-76 compared to MDA-MB 468 cells. T47D and SKBR3 
cell lines portrayed moderate sensitivity to MS-73, MS-74 and MS-76. MCF7 also 
showed moderate sensitivity to MS-73, however, this cell line showed less sensitivity 
Mean GI50 ± SD (72 h MTT assays) 
Cell line MS-73 MS-74 MS-76 
MCF7 36.53 nM ± 0.37 458.65 nM ± 13.13 5.16 µM ± 0.85 
T47D 25.16 nM ± 1.35 277.92 nM ± 8.38 2.77 µM ± 0.49 
ZR-75-1 16.94 nM ± 2.12 229.21 nM ± 5.46 2.13 µM ± 1.15 
SKBR3 29.70 nM ± 2.34 283.95 nM ± 20.99 2.80 µM ± 0.73 
MDA-MB 468 15.97 nM ± 1.64 233.03 nM ± 9.48 1.31 µM ± 0.41 
MDA-MB 231 52.14 nM ± 1.07 823.72 nM ± 16.86 7.32 µM ± 0.70 
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to MS-74 and MS-76. In contrast, the MDA-MB 231 cell line was resistant to all 3 
agents. 
 
According to prior literature, loss of the tumour suppressor gene PTEN and also 
mutations of the PIK3CA oncogene results in dysregulated PI3K/mTOR signalling 
[288]. In the current study 2 cell lines that are PTEN deficient; MDA-MB 468 and ZR-
75-1 portrayed similar sensitivity to MS-73 and MS-74. However, the MDA-MB 468 
cell line was the most sensitive to MS-76 as mentioned above.  
 
In contrast, an earlier study has reported that dual PI3K/mTOR inhibitors are potent 
in ER+ and HER2 overexpressing cell lines [288]. In fact, a study performed 
previously on MS-73 revealed that this agent showed enhanced potency with a HER2+ 
and ER+ breast cancer cell line - MDA-MB 361 [140]. However, HER2 
overexpressing SKBR3 cell line exhibited moderate sensitivity towards these agents 
in the present study. It could be due to SKBR3 harbouring wild type PTEN and PI3K 
[73] [288]. Moreover, T47D also showed moderate sensitivity. The reasons for the 
sensitivity could be; T47D harbouring a mutant PIK3CA gene and being HER2+ as 
depicted in chapter 3, figure 3.1 and figure 3.2 [73] [117]. Further, ligand independent 
ER activation has been shown by the mTOR pathway through phosphorylation of 4E-
BP1 and p70S6K1 [142]. T47D demonstrated high levels of ER as depicted in chapter 
3, figure 3.1 and figure 3.2. Thus, inhibition of T47D and ZR-75-1 cell growth by 
these novel agents would be beneficial. MCF7 which also harbours a mutated PIK3CA 
gene, did not show sensitivity to these agents compared to T47D [72]. Conversely, 
MCF7 cells did not express HER2 as shown in chapter 3, figure 3.1 and figure 3.2, 
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unlike T47D cells which could be the reason for reduced sensitivity. MDA-MA 231 
was resistant to these agents. These cells are shown to harbour wildtype PTEN and 
mutant RAS [72] [117]. Further, these cells do not harbour a mutated PIK3CA gene or 
have HER2 as depicted in chapter 3, figure 3.1 and figure 3.2 [72]. Thus, not sensitive 
to these agents. A significant dose dependent reduction of viable cell numbers was 
observed in MDA-MB 468, ZR-75-1, SKBR3 and T47D cell lines with the 3 agents. 
As depicted in the dose response curves, MS-73 and MS-74 showed cytotoxicity at 
higher concentrations while MS-76 showed cytotoxicity only at the highest 
concentration tested which was 10 µM (Figure 6.1).  
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MDA MB 468 cell line portrayed a strikingly low SF compared to control at all tested 
concentrations of the 3 agents. Interestingly, it was observed that at 150 nM MS-73, 
the number of colonies were less and the size of the colonies were reduced compared 
to control. At 1500 nM (~ 94 fold GI50), MS-73 completely abolished colony 
formation (P < 0.0001). The results for ZR-75-1 were very similar to MDA-MB 468 
and showed a very low SF (P < 0.0001).  
 
Remarkably, both 150 nM and 1500 nM of MS-73 completely eradicated survival of 
SKBR3 cells (P < 0.0001). It was noticed that, SFs of SKBR3 colonies were 
significantly reduced at 1500 nM MS-74 (10.27%) and MS-76 (71.12%) compared to 
MDA-MB 468 cells (MS-74 - 30.30% and MS-76 - 87.66%) which was remarkable 
(P < 0.0001). Similarly, SKBR3 cells at the highest concentration (1500 nM) of MS-
74 showed significantly less survival compared to ZR-75-1 cells (49.40%) (P < 
0.0001).  
 
Hence, it can be stated that the results of the clonogenic assay corroborates with the 
results of the MTT assay by demonstrating that MS-73 was the most potent while MS-
74 was moderately potent and MS-76 was the least potent among the tested agents. 
Further, evidence presented herein suggests that all 3 agents, especially MS-73 and 
MS-74 were highly cytotoxic in these cell lines at high concentrations. Interestingly, 
these results depict that the HER2 overexpressing SKBR3 cell line was unable to 
reproduce and form many colonies in the presence of the novel analogue - MS-74 at 
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the highest concentration which is 1500 nM. Therefore, SKBR3 and the MDA-MB 
468 cells lines were chosen to further investigate the activity of these 3 agents.  
 
6.2.2.3 Effects of dual PI3K/mTOR inhibitors on MDA-MB 468 and SKBR3 
cell cycle 
To further examine the effect of the 3 agents on cell cycling; flow cytometric analysis 
were carried out. Cells were treated with 15 nM, 150 nM and 1500 nM of the agents 
for 24 and 72 h. The highest 2 concentrations; 150 nM and 1500 nM of MS-73 and 
1500 nM of the new analogue MS-74 showed extremely significant pre-G1 
accumulations against the MDA-MB 468 cell line compared to control at 24 and 72 h 
(P < 0.0001) which is indicative of apoptosis. Interestingly, the pre-G1 accumulations 
in the SKBR3 cell line was stark. The results at 1500 nM of MS-73 (81.35%) and MS-
74 (80.45%) were remarkably high at 72 h in the SKBR3 cell line compared to control 
(9.90%) (P < 0.0001). These results corroborated the results of the clonogenic assay, 
although in this experiment, cells were exposed to agents for a period of 72 h. On the 
contrary, MS-76 did not evoke a significant pre-G1 population at all tested 
concentrations against both cell lines (Figure 6.3) and (Figure 6.4).  
 
Further, it was found that MS-73 caused a significant G1 phase arrest at all 3 
concentrations tested at 24 h and also at 15 and 150 nM at 72 h in the MDA-MB 468 
cell line (P < 0.0001) with corresponding diminished S and G2/M phases (P < 0.0001). 
However, 1500 nM MS-73, at 72 h showed a decreased G1 phase compared to control, 
due to a high apoptotic population (pre-G1) (P < 0.0001). The novel analogues, MS-
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74 (1500 nM) and MS-76 (1500 nM) also caused a G1 accumulation at both 24 h and 
72 h together with reduced S and G2/M phases in MDA-MB 468 cells compared to 
control cells (P < 0.0001). 
 
SKBR3 cells were significantly arrested in the G1 phase after treatment with all 3 
concentrations of MS-73 which was followed with decreased S and G2/M phases at 
24 h (P < 0.0001). In contrast, only 1500 nM MS-74 induced a G1 arrest at 24 h, which 
again resulted in reduced S and G2/M populations (P < 0.0001). Contrariwise, MS-76 
did not cause significant alterations in the cell cycle at 24 h in SKBR3 cells although 
this agent caused significant G1 accumulations in the MDA-MB 468 cell line.  
 
However, at 72 h the SKBR3 cell line portrayed reduced G1 populations with all 3 
agents compared to untreated cells (P < 0.0001). Among these results the highest 
concentrations of MS-73 and MS-74 caused an enhanced pre-G1 population which 
would have caused the reduced G1 phase at 72 h. MS-76 did not induce a discernible 
pre-G1 accumulation compared to MS-73 and MS-74 but still portrayed a reduced G1 
phase (P < 0.0001) that was followed by an increased G2/M phase (P < 0.0001) 
compared to control at 72 h. These results suggested that MS-76 did not perturb the 
cell cycle distribution in SKBR3 cells (Figure 6.3).  
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TP53 plays a prominent role as a checkpoint protein in cells at the transition from G1 
to S phase in the cell cycle. However, this function is defective in SKBR3 cells, thus 
at the concentration tested (1500 nM), MS-76 would have failed to inhibit cycling 
SKBR3 cells [41]. Subsequently, the effect of apoptosis in cells by these agents were 
evaluated, in order to confirm whether the pre-G1 phases observed were actually due 
to apoptosis. 
 
6.2.2.4 Effects of dual PI3K/mTOR inhibitors on MDA-MB 468 and SKBR3 
cellular apoptosis 
Induction of apoptosis by the 3 agents was analysed by flow cytometry. The early and 
late apoptotic populations were summed to determine the total apoptotic population. 
It was found that MS-73 caused a small significant apoptotic population with 150 nM 
and 1500 nM at 24 h and with 150 nM at 72 h (P < 0.01) in MDA-MB 468 cells. 
Nevertheless, at 72 h this agent caused a large total apoptotic population (23.33%) 
which was extremely significant compared to control (0.60%) (P < 0.0001). The early 
apoptotic population (19.73%) was higher than the late apoptotic population (3.60%) 
(P < 0.0001). MS-74 caused a small significant apoptotic populations at 150 nM (P < 
0.05) and 1500 nM (P < 0.01) at 24 h in MDA-MB 468 cells. However, no significant 
apoptosis was observed following treatment of cells with 150 nM at 72 h but only with 
1500 nM (P < 0.0001) at the same time point. These results corroborated with the 
results of cell cycle analysis of MDA-MB 468 cells, and the results may suggest that 
MDA-MB 468 cells would be able to resume growth after a longer incubation period 
at low concentrations such as 150 nM MS-74, due to being PTEN deficient [117]. MS-
76 did not induce prominent apoptosis in this cell line which again corroborated results 
Chapter 6 
285 
 
of the cell cycle analysis and the clonogenic assay where MS-76 showed reduced 
activity. 
 
None of the agents were found to cause apoptosis at 24 h in SKBR3 cells, although 
cell cycling results in the same cell line showed small significant pre-G1 populations 
with 1500 nM MS-73. In contrast at 72 h, 150 nM (37.27%) and 1500 nM (57.37%) 
MS-73 induced stark extremely significant apoptotic populations compared to SKBR3 
control (10%) (P < 0.0001) which corroborated the cell cycle results. It was observed 
that at 1500 nM of MS-73, there was no significant difference between the early 
(28.43%) and late (28.93%) apoptotic populations in SKBR3 cells. In addition, a small 
significant necrotic population (7.53%) was also observed compared to untreated 
SKBR3 cells (0.30%) with 1500 nM of MS-73 (P < 0.0001) at 72 h. There was no 
other significant necrotic populations identified in this experiment. MS-74 (1500 nM) 
at 72 h caused an extremely significant apoptotic population (33.05%) compared to 
SKBR3 control (8.63%) (P < 0.0001) which again was consistent with the cell cycle 
results. Interestingly, MS-76 (1500 nM) portrayed a slight but significant apoptotic 
population (12.70%) compared to SKBR3 control cells (10.60%) (P < 0.05), which 
was not apparent with the cell cycle results. However, the results obtained for SKBR3 
cells treated with 1500 nM of MS-76 corresponded with the clonogenic results where 
these cells depicted less survival of colonies at the same concentration compared to 
MDA-MB 468 cells.  
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apoptotic population at 1500 nM in SKBR3 cells. This could be secondary necrosis 
taking place when a large late apoptotic population is induced [206].  
 
6.2.2.5 Effects of dual PI3K/mTOR inhibitors on PI3K/AKT and mTOR 
pathways in MDA-MB 468 and SKBR3 cells by Western blotting 
The described effects on cell cycling and apoptosis in MDA-MB 468 and SKBR3 cells 
by the 3 agents, prompted an investigation into the key proteins which these agents 
would target within the PI3K/AKT and mTOR pathway. The effect of 1x and 2x GI50 
concentrations of the 3 agents within the MDA-MB 468 cell line was used to assess 
the activity of the proteins in the PI3K/AKT and mTOR pathways. Thus, both MDA-
MB 468 and SKBR3 cells were exposed for 24 h to 1x and 2x GI50 concentrations of 
the agents. As it has been shown that phosphorylation of 4E-BP1 results in eIF4E 
release which increases cap dependent translation, the effect of the agents on these 2 
proteins of the mTOR pathway were investigated. Further, phosphorylation of AKT 
of the PI3K/AKT pathway was also investigated [117] [276] [277].  
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It was found that all 3 agents down-regulated phosphorylated 4E-BP1 (Ser65) 
extremely significantly at all concentrations tested in MDA-MB 468 cells (P < 
0.0001). Interestingly, as shown by figure 6.7, the novel analogue MS-74 (1x GI50   
ARD - 9.89% and 2x GI50   ARD - 1.92%) showed a similar effect to MS-73 (1x GI50 
- ARD - 8.33% and 2x GI50   ARD - 2.00%). MS-76 also exhibited down-regulation 
(1x GI50   ARD - 33.32% and 2x GI50   ARD - 11.78%), although the effect was not 
as apparent as MS-74.  
 
The SKBR3 cell line also portrayed significant down-regulation of P-4E-BP1 (P < 
0.0001). Nevertheless, it was observed that the down-regulation was not as low 
compared to MDA-MB 468 cells (P < 0.001) except for 2x GI50 MS-73 where it was 
not significantly different compared to MDA-MB 468 cells (MDA-MB 468 - 2x GI50 
MS-73 - ARD - 2.00% and SKBR3 - 7.82%). Moreover, in SKBR3 cells, MS-74 did 
not cause a similar down-regulation of P-4E-BP1 compared to MS-73, unlike in 
MDA-MB 468 cells (SKBR3 - MS-73-1x GI50   ARD - 39.48% and 2x GI50   ARD - 
7.82%, MS-74 - 1x GI50 - ARD - 58.12% and 2x GI50   ARD   33.56% and MS-76 - 
1x GI50   ARD - 71.77% and 2x GI50   ARD - 59.99%).  
 
As shown in figure 6.7, MS-73 and similarly MS-74 down-regulated P-eIF4E (Ser209) 
significantly in MDA-MB 468 cells (P < 0.0001). On the contrary, the down-
regulation of eIF4E phosphorylation was not as efficient as P-4E-PB1 in MDA-MB 
468 cells. Interestingly, SKBR3 cells did not show any significant down-regulation of 
P-eIF4E. In contrast, SKBR3 cells after exposure to 2x GI50 concentrations of MS-73 
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down-regulated P-AKT (Ser473) (P < 0.01) and P-AKT (Thr308) (P < 0.01) which 
was the only alternation observed for phosphorylated AKT with the agents and their 
concentrations tested in this study. Densitometry analysis with the ARD values for the 
significant results are shown in appendix I under section 9.1.3.1. 
 
A parallel study carried out by 3 undergraduate students under the supervision of the 
author, found that a higher concentration of MS-73 (10 µM), completely abolished P-
AKT (Ser473) and P-AKT (Thr308) in MCF7 and HCT116 colon cancer cells. 
Additionally, the same agent at 10 µM down-regulated P-AKT (Ser473) and P-AKT 
(Thr308) levels significantly in MDA-MB 468 cells but failed to completely abolish 
P-AKT levels due to these cells being PTEN deficient. These results are shown in 
appendix IV. 
 
All 3 agents did not affect the total expression levels of AKT, 4E-BP1 and eIF4E 
within the current study. It has been shown earlier that MS-73 did not affect the total 
protein expression levels of AKT [26]. 
 
These results indicate that MS-73 and MS-74 inhibited the mTOR pathway 
significantly by down-regulating phosphorylation of 4E-BP1 and eIF4E in MDA-MB 
468 cells and also down-regulating P-4E-BP1 in SKBR3 cells. In fact, it was 
interesting to observe that all agents inhibited P-4E-BP1 in the PTEN deficient MDA-
MB 468 cell line which has been shown to have high levels of P-4E-BP1 [283]. This 
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is an interesting finding as it has been shown that Sirolimus decreases P-4E-BP1 and 
paradoxically increases eIF4E phosphorylation [277]. This increase of P-eIF4E has 
been shown to be PI3K dependent through MNK activation. In fact, Wang et al, 2007 
has shown that LY294002 which is a PI3K inhibitor was able to block Sirolimus 
induced eIF4E phosphorylation [277]. Thus, it was interesting to observe that there 
was no increase of eIF4E phosphorylation in MDA-MB 468 and SKBR3 cells after 
exposure to all 3 MS agents. These results suggest that there may be no or insignificant 
MNK activation in these cells with MS agent treatment. Further, this implies that these 
MS agents are in fact functioning as dual PI3K/mTOR inhibitors. Yet, the P-eIF4E 
expression levels did not correspond to P-4E-BP1 levels, which could suggest low 
activity of mRNA translation. These results may indicate that MS agent treatment is 
generating conflicting signals to cap dependent protein translation. This could be due 
to cross talk with compensatory and alternative signalling pathways involving P-eIF4E 
in breast cancer cells. Previously, it has been shown that ERK signalling is associated 
with enhanced eIF4E activation by feedback activity with the treatment of a 
mTORC1/2 inhibitor which could be one of the mechanisms for higher P-eIF4E 
expression [289]. Indeed, a previous study has shown that MS-73 does not inhibit the 
RAS/MAPK pathway [290]. However, more investigations are warranted to find the 
exact mechanism of these agents.  
 
Further, it was observed that all 3 agents failed to down-regulate the PI3K/AKT 
pathway in the MDA-MB 468 cell line at the tested concentrations. This could be due 
to PTEN deficiency in this cell line and the inability to inhibit AKT phosphorylation 
[77] [283]. Thus, these results may suggest that mTORC2 is not completely inhibited 
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by these agents at the tested concentrations in MDA-MB 468 cells [77]. mTORC2 is 
shown to contribute to complete AKT activation by phosphorylation of AKT (Ser473), 
therefore no inhibition of phosphorylated AKT was observed in MDA-MB 468 cells 
[291]. It has been shown that Sirolimus increases P-AKT (Ser473) by inhibiting 
mTORC1, but interestingly there was no increase of P-AKT (Ser473) observed in both 
cell lines tested following exposure to MS agents [292] [293]. Nevertheless, as 
outlined above, if higher concentrations of these agents were used, then down-
regulation of P-AKT would have been observed in MDA-MB 468 cells, as it was 
shown that 10 µM of MS-73 down-regulated P-AKT levels in MDA-MB 468 cells.  
 
In fact, HER2 overexpressing SKBR3 cells after exposure to MS-73 (2x GI50) 
inhibited P-AKT (Ser473) slightly which coincided with previous results in MDA-MB 
361 cells which is also HER2+ [140]. This could be the reason this cell line completely 
eradicated survival of SKBR3 cells preventing colony formation at 150 nM and 1500 
nM (P < 0.0001). Prior studies have also shown that MS-73 has little effect on 
upstream elements such as AKT in most cell lines although this agent down-regulated 
P-AKT (Ser473) and P-AKT (Thr308) in the MDA-MB 361 cell line [294]. The 
MDA-MB 361 cell line may show high sensitivity because it is PIK3CA mutant and 
also HER2+ [290]. This could be the reason less potent MS-74 and MS-76 did not 
demonstrate significant P-AKT inhibition in the SKBR3 cell line compared to MS-73.  
Once again, if higher concentrations were used down-regulation of this pathway would 
have been observed. Nevertheless, sensitivity of PTEN deficient cells and HER2 
overexpressing cells to dual PI3K/mTOR inhibitors may be dependent on interactions 
between other survival pathways such as the RAS/MAPK pathway [286]. Previously, 
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MS-73 has been shown to inhibit P-P70S6K1 which is also a downstream target of 
mTOR that is mainly responsible of phosphorylating 40S ribosomal protein S6 leading 
to mRNA translation that encodes for ribosomal proteins and elongation factor-1 
[140]. However, the expression of P70S6K1 was not investigated in this study, as it 
has been shown that eIF4E phosphorylation was independent P70S6K1 [277].  
 
Thus, taken together these results would suggest that MS agents, do function as dual 
PI3K/mTOR inhibitors and they would be more therapeutically effective in breast 
tumours lacking PTEN or breast tumours which are HER2 overexpressing if used at 
higher concentrations or combined with a different class of inhibitors. For instance, 
previously MS-73 has portrayed enhanced potency in resistant head and neck cancer 
models with the combination of Cetuximab an EGFR inhibitor [295]. Furthermore, 
MS-73 in combination with PD0325901 which is a MEK inhibitor has shown 
enhanced growth inhibition in a HCT116 model [290].  
 
6.2.3 In vitro growth inhibitory effects of AhR ligand - 5F 203 
The underlying anti-tumour mechanism of action of potent benzothiazoles (AhR 
ligands) in breast cancer has been previously explored by Dr. Tracey D. Bradshaw and 
her group [92] [94] [296]. Many signal transduction pathways such as the EGFR, ER 
and RAS/MAPK pathways have shown cross talk with the AhR pathway [297]. 
Further, signalling molecules downstream of EGFR such as PI3K, cross talks with 
pathways such as RAS/MAPK. Thus, PI3K may be responsive to AhR [61]. 
Furthermore, the AhR pathway influences a variety of cellular processes such as 
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mitogenesis, hypoxia response and vascularisation as mentioned in chapter 1 [92] [94]. 
AhR has been shown to be expressed in both ER+ and ER- cell lines [141]. Thus, 
studies were performed following combination of MS agents with a potent AhR 
ligand. 
 
5F 203, which is an AhR ligand, binds to cytosolic AhR which is translocated to the 
nucleus, followed by dimerisation with ARNT. Consequently, xenobiotic response 
elements on the CYP1A1 promoter is induced by driving gene transcription [296]. 
Induction of CYP1A1 gene expression is reflected as one of the most sensitive 
indicators of exposure to AhR ligands. Subsequently, CYP1A1 metabolises 5F 203 to 
a reactive electrophilic species which binds to nucleophilic regions of DNA that results 
in formation of DNA adducts and DNA strand breaks, ultimately causing cell death 
[92] [138] [296]. It has been previously shown that this agent is able to cause anti-
cancer effects in certain breast cancer cells (ER+ and ER-), thus the effect of this agent 
was tested in the panel of breast cancer cell lines [296] (Table 6.3).  
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Table 6.3: Mean GI50 ± SD values of 5F 203. Cells were seeded in 96 well plates at 
a density of 2.5 x 103 cells/well. After allowing time to adhere (24 h), cells were 
exposed to 5F 203 (72 h; (n = 8)). Mean and SD of tria ✁ ✂ ✄. 
 
Interestingly, it was found that the HER2 overexpressing SKBR3 cell line was the 
most sensitive towards 5F 203, out of the panel of breast cancer cell lines tested (GI50 
= 20.41 nM). MDA-MB 468 and T47D cell lines were also sensitive. It has been 
shown previously that this agent is very active in ER+ cell lines and also in TNBC 
MDA-MB 468 cells [92] [95] [141]. In contrast, TNBC MDA-MB 231 was resistant 
to 5F 203 and similar insensitivity to benzothiazoles has been shown by this cell line 
previously [95]. However, the sensitivity of all cell lines is shown to be based on 
cytosolic AhR expression levels [141]. Further, mutations in the CYP1A1 promoter 
may also lead to agent insensitivity [92]. As SKBR3 and MDA-MB 468 cell lines were 
highly sensitive to 5F 203, these cell lines were selected to analyse the combination 
effect of 5F 203 with MS agents.  
Cell line Mean GI50 ± SD 
(72 h MTT assay) 
MCF7 31.30 nM ± 2.72 
T47D 22.15 nM ± 1.35 
ZR-75-1 40.87 nM ± 0.01 
SKBR3 20.41 nM ± 0.90 
MDA-MB 468 22.94 nM ± 2.75 
MDA-MB 231 > 10  µM   
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6.2.4 Effects of 5F 203 and MS agents in combination 
6.2.4.1 In vitro growth inhibitory effects of 5F 203 and MS agents in 
combination 
All 3 MS agents were combined with 5F 203 and 3 concentrations were selected of 
each agent according to activity in the most sensitive cell line. The concentrations 
selected for 5F 203 were 4 nM, 10 nM and 20 nM equivalent to 0.2, 0.5 and 1x GI50 
concentrations respectively in the SKBR3 cell line.   
 
Concentrations for MS-73 were selected as 6 nM, 15 nM and 30 nM. Concentrations 
for MS-74 were selected as 60 nM, 150 nM and 300 nM while for MS-76 were selected 
as 600 nM, 1500 nM and 3000 nM equivalent to GI50 values in the MDA-MB 468 cell 
line. It was determined that both MDA-MB 468 and SKBR3 cell lines with the agent 
combinations showed a CI value of > 1.1 which indicated an antagonistic result.  
 
It has been shown that AhR ligands are able to stimulate ERK activity via the 
RAS/MAPK pathway [297] [298]. Further RAS/MAPK family members such as 
SAPK/JNK and p38 are also activated by AhR ligands [97]. Both SAPK/JNK and p38 
have been implicated in many cellular processes including apoptosis. However, their 
role is shown to be cell type specific [65] [67]. Indeed, it has been demonstrated that 
5F 203 is able to increase phosphorylation of ERK, JNK and p38 in ovarian cancer 
cells [137]. Moreover, MS agents do not inhibit the RAS/MAPK pathway [290]. 
Although both 5F 203 and MS agents were potent as single agents in both MDA-MB 
468 and SKBR3 cells; in combination it could be suggested that an alternative pathway 
such as RAS/MAPK may be highly activated in these cells which would have 
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increased their proliferation and survival. Nonetheless, it has been found clinically that 
multi kinase blockade may lead to increased toxicity, therefore dual PI3K/mTOR 
inhibitors may not be well suited for combination therapy [299].  
 
6.2.5 Effects of 5F 203 and Raloxifene in combination 
6.2.5.1 In vitro growth inhibitory effects of 5F 203 and Raloxifene in 
combination 
Raloxifene, a SERM has found to be an AhR ligand as mentioned before [115]. 
Raloxifene has been shown to activate AhR and induce apoptosis in MDA-MB 231 
cells compared to non-transformed mammary epithelial cells, implying that AhR is a 
molecular target of Raloxifene which helps this agent to induce apoptosis in the 
absence of ER. Further, the induction of apoptosis in MDA-MB 231 cells has shown 
to be dependent upon the AhR expression levels within the cells and the levels of 
sensitivity to Raloxifene [141]. The activity of Raloxifene was tested in the panel of 
breast cancer cell lines (Chapter 3, table 3.1). All cell lines tested showed similar GI50 
values in medium supplemented with 10% FBS (MCF7 - 18.88 µM, T47D - 16.76 
µM, ZR-75-1 - 15.75 µM, SKBR3 - 19.22 µM, MDA-MB 468 - 15.00 µM and MDA-
MB 231 - 16.81 µM).  
 
AhR, unlike most ligand-dependent transcription factors can be bound and activated 
by structurally varied ligands and these differences contribute to a variety of responses. 
These different responses elicited by the ligands have been linked to alterations in gene 
expression [300]. Thus, Raloxifene was combined with 5F 203 to determine activity 
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in ER- cell lines. Therefore, MDA-MB 468 and SKBR3 cell lines were chosen to 
determine the combined effect.  
 
As before, the concentrations selected for 5F 203 were 4 nM, 10 nM and 20 nM 
equivalent to 0.2, 0.5 and 1x GI50 concentrations respectively in the SKBR3 cell line. 
The concentrations selected for Raloxifene were 4 µM, 10 µM and 20 µM equivalent 
to 0.2, 0.5 and 1x GI50 concentrations respectively in the SKBR3 cell line. The 
concentrations selected for Raloxifene were based on the effectiveness of the agent in 
the entire cell line panel, as all cell lines showed a similar sensitivity profile in medium 
supplemented with 10% FBS. It was found that both MDA-MB 468 and SKBR3 with 
the agent combination showed a CI value of > 1.1 which indicated an antagonistic 
result.  
 
As both 5F 203 and Raloxifene are AhR ligands, it was postulated that there may be 
competitive binding to the AhR ligand binding pocket [300]. It has been shown that 
5F 203 is a high affinity ligand to AhR [138]. One of the most high affinity AhR 
ligands is found to be TCDD [138]. Interestingly, the affinity of 5F 203 is similar to 
TCDD and the difference between 5F 203 and TCDD for AhR affinity is shown to be 
within 10-fold. [92] [138]. However, Raloxifene has shown a lower binding affinity 
compared to TCDD and high concentrations of Raloxifene are shown to be needed to 
activate AhR which suggests that 5F 203 is a higher affinity AhR ligand than 
Raloxifene [141].  
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The antagonistic effect of the combination of 5F 203 and Raloxifene could be due to 
Raloxifene exhibiting an antagonistic activity in the presence of a full agonist such as 
5F 203, as Raloxifene is shown to have a low binding affinity to AhR [300]. Bazzi et 
al, 2009, has shown that TCDD in the presence of 5F 203 showed reduced potency for 
AhR compared to TCDD alone [138]. Further, they showed that in the presence of 
TCDD, 5F 203 acted as a partial agonist and showed decreased bioavailability [138]. 
A similar scenario could have taken place with the combination of 5F 203 and 
Raloxifene due to competition and perhaps the effect of Raloxifene is blocked after 
being competed out in the ER- cell lines tested.  
 
6.2.6 Effects of 5F 203 and Gefitinib in combination 
Cross talk between AhR and EGFR pathways has been identified [61] [301]. The AhR 
ligand, TCDD has shown to activate EGFR in certain cells that overexpress EGFR 
[61]. In addition, Sutter et al, 2009, has shown that EGFR ligands such as EGF could 
block AhR signalling by decreasing TCDD-induced CYP1A1 levels to basal levels in 
human keratinocytes by preventing recruitment of p300 (A histone acetyltransferase) 
coactivator [96]. Studies have shown that p300 which interacts with a variety of 
transcription factors, binds to ARNT in the AhR-ARNT complex and it plays a role in 
control of gene transcription [96]. In contrast, the EGFR inhibitor, Gefitinib that 
blocks EGFR expression is shown to activate p300 in skin carcinoma cells and is able 
to induce cell death [301]. However, these effects of TCDD, EGF and Gefitinib and 
the associated ability of induction of CYP1A1 could be cell type specific [61] [96]. 
CYP1A1 has shown to play a role in breast cancer. It has been found as a candidate 
gene for low penetrance of breast cancer susceptibility as CYP1A1 metabolises 
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xenobiotics, carcinogens and as well as oestrogen [61] [302]. Further, around 8 genetic 
polymorphisms of CYP1A1 have been identified [303]. It has been reported that these 
CYP1A1 polymorphisms function as predictors of the clinical outcome to EGFR 
inhibitors in patients with advanced lung cancer. Therefore, these genetic 
polymorphisms could be associated with CYP1A1 inducibility which would 
determine the outcome of the metabolised agent [301] [303].  
 
Interestingly, it has been shown that Gefitinib induces CYP1A1 activity which is 
associated with bioactivation of the drug through drug metabolism in Gefitinib 
sensitive cells [301]. Other EGFR inhibitors such as Erlotinib, Cetuximab and 
Lapatinib have also shown induction of CYP1A1 activity, however, Gefitinib has 
shown much higher induction than the other EGFR inhibitors in sensitive cells [301]. 
Although, Gefitinib and Erlotinib share similar chemical structures, it has been shown 
that these agents are metabolised by slightly different CYP enzymes [304]. For 
instance CYP1A2 and CYP1B1 are not shown to be involved in Gefitinib metabolism 
whereas CYP1A2 has shown to have a slight impact on Erlotinib metabolism [301] 
[304]. Further, MEK inhibitors of the RAS/MAPK pathway have demonstrated 
induction of high levels of CYP1A1 activity whereas PI3K/AKT/mTOR inhibitors 
have not shown any CYP1A1 induction in drug metabolism which could further 
explain the reason for antagonistic results of the MS agents and 5F 203 in combination 
[301].  
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It has been implied that induction of CYP1A1 expression by Gefitinib may be 
associated with inhibition of downstream EGFR signalling such as RAS/MAPK signal 
transduction, because agents inhibiting the RAS/MAPK pathway have been shown to 
induce high levels of CYP1A1. This is not the case for inhibitors of the 
PI3K/AKT/mTOR pathway. Indeed it was found that 1x and 2x GI50 concentrations 
of Gefitinib abolished phosphorylated ERK1/2 in SKBR3 cells and this was described 
in chapter 3 which would be a good indicator that this agent may induce CYP activity 
(Chapter 3, figure 3.12). In this context inhibition of the RAS/MAPK pathway might 
represent an association between EGFR inhibition and induction of CYP1A1 [301]. 
Further, as it was outlined before hypoxia increases ERK activation which thereby 
suppresses CYP1A1 activity. Hypoxia is mediated through HIF-1. HIF-1 helps 
hypoxic tumour cells to maintain energy production [305]. Moreover, HIF-1 has 
shown a strong correlation between elevated levels of tumour metastasis, angiogenesis 
and poor patient prognosis and resistance to anti-cancer therapy. HIF-1 is a 
hetrodimeric transcription factor composed of HIF- ✁ ✂✄☎ ✆✝✞- ✟ [305]. HIF- ✟
which is also known as ARNT is an important AhR binding partner [92] [298]. As 
such, under hypoxia, HIF- ✟ ✠✂✡✂ ☛☞✌✍✎ ✏✑ ☎✏✒✓✔✏✑✓☎ ✕✖ ✆✝F- ✁ ✂✄☎ ✗✔✓✑✘✒✂✙✚✛ ✄✖✕
available for dimerisation with AhR [305]. Inhibition of ERK will reverse this effect. 
Furthermore, 5F 203 is shown to induce CYP1A1 activity and promote anti-tumour 
activity [94]. Thus, Gefitinib and 5F 203 were combined to determine their activity. 
To carry out this task, 2 sensitive cell lines to both Gefitinib and 5F 203 were selected 
- SKBR3 and MDA-MB 468. In addition a cell line which was sensitive to 5F 203 but 
resistant to Gefitinib was selected, which was MCF7 and another cell line that was 
resistant to both agents were also selected - MDA-MB 231.  
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6.2.6.1 In vitro growth inhibitory effects of 5F 203 and Gefitinib in 
combination 
Initially, in vitro growth inhibitory activity was determined. For combination studies, 
the concentrations selected for 5F 203 were 4 nM, 10 nM and 20 nM and the 
concentrations selected for Gefitinib were 0.2 µM, 0.5 µM and 1 µM. The selected 
concentrations were based on 0.2x, 0.5x and 1x GI50 concentrations of both agents 
against the SKBR3 cell line, since it was the most sensitive cell line to 5F 203 and 
Gefitinib alone among the cell lines tested.  
 
Interestingly, it was found that both agents in combination showed a CI value of 0.64 
± 0.08 in SKBR3 cells, which is indicative of synergism according to the Chou and 
Talalay theorem [273]. In contrast, MDA-MB 468, MCF7 and MDA-MB 231 cell 
lines showed a CI value of > 1.1 which was antagonistic. SKBR3 cells demonstrated 
extremely significant sensitivity to the agents alone at the 2 highest concentrations 
tested of 5F 203 (20 nM) and Gefitinib (1 µM) (P < 0.0001). Further, agents in 
combination resulted in extremely significant growth inhibition of SKBR3 cells 
(observed growth) compared to the expected growth inhibition with all tested 
concentrations of the agent combination (P < 0.0001). Further in combination, 5F 203 
and Gefitinib demonstrated a dose dependent growth inhibition where increasing 
concentrations of the 2 agents resulted in increased growth inhibition in sensitive 
SKBR3 cells. (Figure 6.8 (a) and (b)).  
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Gefitinib alone at 0.5 µM demonstrated a SF of 91.11% and 1 µM of the same agent 
demonstrated a SF of 64.44% compared to control (P < 0.0001). In contrast 5F 203 
alone at 10 nM (SF = 8%) and 20 nM (SF = 2.67%) demonstrated very potent cytotoxic 
effects compared to control (P < 0.0001). Agents in combination showed a significant 
reduction in SKBR3 colony formation at the tested concentrations compared to 
Gefitinib alone (both 0.5 µM and 1 µM) (P < 0.0001). Surprisingly agents in 
combination of 0.5 µM Gefitinib and 10 nM 5F 203 (SF = 39.56%) and also 1 µM 
Gefitinib and 10 nM 5F 203 (SF = 33.78%) did not demonstrate a reduction in colony 
formation compared to 10 nM of 5F 203 alone, which illustrated antagonistic results 
(P < 0.0001). Similarly, 0.5 µM Gefitinib and 20 nM of 5F 203 (SF = 36%) failed to 
demonstrate a reduction in colony formation compared to 20 nM 5F 203 alone (P < 
0.0001), once again showing an antagonistic result. However, there was no significant 
difference seen between the colony formation of 20 nM 5F 203 alone and the 
combination of 1 µM Gefitinib and 20 nM 5F 203 (SF = 8.44%). Thus, among the 
combinations tested, 1 µM Gefitinib and 20 nM of 5F 203 were selected for further 
investigations as this combination also showed high potency in the MTT assay as well. 
Although, it was anticipated, synergism was not observed with this assay as 5F 203 
alone was extremely potent in SKBR3 colony inhibition. However, colony formation 
at all tested concentrations were significantly reduced compared to SKBR3 control (P 
< 0.0001). 
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6.2.6.3 Effects of 5F 203 and Gefitinib alone and in combination on SKBR3 
cellular apoptosis 
To determine the cytotoxic effect in detail, flow cytometric analysis was carried out 
using an annexin V-FITC/PI assay with 24 h and 72 h exposure points which coincides 
with the exposure times of the clonogenic and MTT assays respectively. It was found 
that at 24 h, Gefitinib alone (17.27%) and 5F 203 alone (20.70%) showed a greater 
apoptotic population compared to SKBR3 control (12.73%) (P < 0.0001). 
Interestingly, it was found that at 24 h the agents combination (1x GI50 of both agents, 
equivalent to 1 µM Gefitinib and 20 nM 5F 203) showed an extremely significant total 
apoptotic population (46.83%) compared to both agents alone and SKBR3 control (P 
< 0.0001). Intriguingly, at 24 h the expected apoptotic population was 25.24% while 
the observed was 46.83% endorsing the synergistic effect observed within the in vitro 
growth inhibitory MTT assays. At 72 h, Gefitinib alone demonstrated a significant 
apoptotic population (25.33%) compared to SKBR3 control (16.90%) (P < 0.001). 
Interestingly, 5F 203 alone demonstrated a high apoptotic population (63.93%) 
compared to control (P < 0.0001). Agents in combination also showed a high apoptotic 
population (67.95%) compared to control and Gefitinib alone (P < 0.0001). However 
there was no significant observed difference between the apoptotic populations evoked 
by 5F 203 alone and agents in combination at 72 h. Further, it was found that the 
expected apoptotic population for the agent combination was 72.36% while the 
observed was only 67.95% which is suggestive of an antagonistic apoptotic effect at 
72 h. In addition, there was no significant necrosis identified at both time points tested 
(Figure 6.10).  
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Figure 6.10: Apoptosis analysis of SKBR3 cells following exposure to 5F 203 and 
Gefitinib alone and in combination. (a) 24 h and (b) 72 h. Mean and SD of trials  
3, (n = 2 per trial). * indicates significant difference compared to control and agents 
alone, * (P < 0.05), ** (P < 0.01), *** (P < 0.001), **** (P < 0.0001). (c) and (d) are 
representative quadrant plots of control and agent combination, 10,000 events were 
analysed in each experiment. 
SKBR3 control- 72 h 
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These results confirm that 5F 203 alone and in combination evoked apoptosis in 
SKBR3 cells synergistically at 24 h. However, at 72 h the observed levels were less 
than expected for the agent combination. It was found that the effect of 1x and 2x GI50 
values of Gefitinib evoked a largely cytostatic and a moderate cytotoxic response in 
sensitive SKBR3 cells in chapter 3. Only at 48 h, a small significant apoptotic 
population was emerging with a 9.33% increase compared to control by Gefitinib 
alone as described in chapter 3. Further, at 72 h, a 12.93% increase was observed than 
control in Gefitinib treated SKBR3 cells. Results described within this chapter 
corroborate with these results, although, there is a slight difference which could be due 
to different passage numbers of SKBR3 cells used. At 24 h, 1x GI50 Gefitinib evoked 
only 4.54% greater apoptosis than control, and at 72 h, Gefitinib evoked an increase 
of 8.43% in apoptosis. Thus, these results demonstrate that the effect of Gefitinib was 
potentiated by combining 5F 203 with it in the apoptotic assay. Indeed, it has been 
demonstrated that activation of the AhR signalling pathway by 5F 203 triggers 
metabolic transformation of the drug through CYP1A1 into reactive species damaging 
DNA that ultimately results in apoptosis in sensitive cells [92] [93]. This was an 
interesting finding because it has been portrayed that TP53 mutant cells such as 
SKBR3 cells show greater resistance against DNA manipulating agents [209] [269] 
[306]. Nevertheless, it was noted that 5F 203 activity is independent of TP53 status 
since this agent has demonstrated its potent activity in TP53 mutant MDA-MB 468 
cells [137].  
 
As it was mentioned above induction of CYP1A1 by 5F 203 can lead to generation of 
ROS which results in DNA damage and then successively apoptosis in sensitive cells 
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[137]. On the other hand as outlined in chapter 3, it was shown that Gefitinib is able 
to down-regulate EGFR and RAS/MAPK pathways, thereby inhibiting cellular 
proliferation and causing apoptosis in SKBR3 cells. Therefore, the mechanism of 
action of the agents in combination was examined in detail as the agent combination 
evoked a high level of apoptosis in SKBR3 cells. Thus, the level of mRNA translation 
(CYP1A1 and EGFR), the effects of ROS generation, induction of DNA damage and 
protein expression levels of the main targets of EGFR and RAS/MAPK signalling, in 
agent combination treated SKBR3 cells were investigated.  
 
6.2.6.4 Effects of 5F 203 and Gefitinib alone and in combination on CYP1A1 
and EGFR mRNA translation  
It has been shown that CYP1A1 protein inducibility is strongly associated with its 
genetic expression [301]. Thus, QPCR was incorporated to produce quantitative data 
of the gene expression levels of CYP1A1. Further, because Gefitinib was responsible 
of inhibition of EGFR, the genetic expression of EGFR was also determined by QPCR. 
SKBR3 cells were treated with agents alone (1x GI50) and in combination (1x GI50 of 
each agent) prior to QPCR analysis (Figure 6.11).  
 
 
 
 
Chapter 6 
313 
 
 
 
 
 
 
 
 
 
 
Figure 6.11: mRNA expression levels of CYP1A1 and EGFR after exposure to 5F 
203 and Gefitinib alone and in combination for 24 h in SKBR3 cells. Fluorescence 
was recorded and normalised to the expression of GAPDH and the relative expression 
 ✁ ✂✄☎✆ ✝✂✞✂✟✠ mean and SD was calculated; trials ✡ ☛, (n = 3 per trial). * indicates 
significant difference compared to control and agents alone, * (P < 0.05), ** (P < 
0.01), *** (P < 0.001), **** (P < 0.0001). 
 
It was observed that Gefitinib caused a slight increase in CYP1A1 mRNA expression 
(~ 5-fold higher than control) although not significant. These results were interesting 
and confirmed that Gefitinib induces CYP1A1 activity in relation to drug metabolism 
in Gefitinib sensitive SKBR3 cells [301]. For 5F 203 alone, CYP1A1 mRNA 
translation was increased by ~ 24-fold relative to control. On the other hand, the agents 
in combination enhanced CYP1A1 mRNA translation remarkably with ~ 1385-fold 
relative to SKBR3 control (P < 0.0001). Further, agents in combination also showed 
enhanced CYP1A1 mRNA translation compared to agents alone (P < 0.0001). On the 
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contrary, mRNA levels of EGFR among treated SKBR3 cells were not significantly 
different compared to control. Protein expression levels of CYP1A1 and EGFR were 
also investigated by Western blotting to determine the correlation between mRNA and 
protein expression levels. These results are shown in section 6.2.6.7.  
 
These results strongly confirm that the synergism observed with Gefitinib and 5F 203 
in combination was possibly due to the induction of CYP1A1 expression in SKBR3 
cells. This observation would propose that monitoring CYP1A1 induction in HER2 
overexpressed breast tumours may provide a biomarker for identification of sensitive 
tumour phenotypes to 5F 203 inhibition in the clinic. 
 
6.2.6.5 Effects of 5F 203 and Gefitinib alone and in combination on induction 
of ROS 
As it was outlined before, 5F 203 has shown to generate ROS in sensitive cells by 
induction of CYP1A1 [137]. Thus, the effects of ROS generation was determined. A 
moderate increase of ROS is known to evoke malignant transformation of cells, but 
the development of cancer may depend on many more factors including the extent of 
DNA damage [307]. Nevertheless, ROS can act as a double edged sword in a 
malignant state where very high levels of ROS is shown to be therapeutically 
beneficial by inducing cancer cell apoptosis [269] [308]. For instance, Paclitaxel 
induces ROS in breast cancer cells [309]. Hence, the induction of ROS was 
investigated by 1x GI50 of Gefitinib and 5F 203 alone and in combination (Figure 
6.12).  
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Figure 6.12: Induction of ROS following exposure to 5F 203 and Gefitinib alone 
and in combination for 24 h in SKBR3 cells. Mean luminescence was recorded in 
relative light units (RLU) and relative ratios were calculated. SD were also calculated 
of trials   ✁, (n = 4 per trial). * indicates significant difference compared to control 
and agents alone, * (P < 0.05), ** (P < 0.01), *** (P < 0.001), **** (P < 0.0001). 
 
As shown in figure 6.12, agents in combination generated a larger level of ROS 
(166%) compared to control after 24 h which was significant (P < 0.0001). As stated 
in previous literature, it was observed that 1x GI50 of 5F 203 also generated ROS 
(137%) significantly (P < 0.0001) compared to control [137]. There was no significant 
ROS generation was observed for Gefitinib (110%) compared to control. Further, it 
was observed that agents in combination showed significant generation of ROS 
compared to Gefitinib alone and 5F 203 alone at 24 h (P < 0.0001) confirming the 
synergy observed within the MTT assay and the apoptosis assay. Subsequently, it was 
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determined whether the agents alone and in combination induced DNA damage in 
SKBR3 cells.  
 
6.2.6.6 Effects of 5F 203 and Gefitinib alone and in combination on induction 
 ✁ ✂-H2AX positive populations 
It was investigated whether the agents alone and in combination would cause DDSBs. 
✄☎✆✝✞ ✟-H2AX expression was measured in SKBR3 cells following exposure to 1x 
GI50 concentrations of Gefitinib and 5F 203 alone and in combination for 24 h and 72 
h (Figure 6.13).  
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As shown in figure 6.13, 5F 203 alone showed an increased positive population for 
DDSBs at 24 h (~ 6-fold) and 72 h (~ 4-fold) relative to control (P < 0.0001). Gefitinib 
alone also showed a slight increase in DNA damage relative to control at both 24 h (~ 
2.6-fold) and 72 h (~ 2.7-fold) in SKBR3 cells. Agents in combination demonstrated 
an enhanced positive population for DDSBs at 24 h (~ 8.5-fold) and 72 h (~ 5.8-fold) 
relative to SKBR3 control (P < 0.0001). However, these findings show that the agents 
in combination induced a slightly higher level of DNA damage at 24 h which would 
have led to high level of SKBR3 cell death at 24 h. Agents in combination showed 
significant DNA damage compared to Gefitinib at both time points (P < 0.0001). 
Further, the agents in combination showed a significant difference between the levels 
of DDSBs compared to 5F 203 alone only at 24 h (P < 0.01) and not at 72 h which 
validates the results observed with the apoptosis assay.  
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6.2.6.7 Effects of 5F 203 and Gefitinib alone and in combination on EGFR, 
HER2, RAS/MAPK and c-MET signalling pathways by Western 
blotting 
The effect of Gefitinib and 5F 203 (1x GI50 concentrations) alone and in combination 
(1x GI50 concentrations of each agent) on protein expression of EGFR, RAS/MAPK 
and c-MET signalling pathways were investigated further through Western blot 
analysis. As it was demonstrated in chapter 3, Gefitinib is extremely active in 
inhibiting the SKBR3 cell line that overexpresses HER2, with the presence of EGFR. 
In addition it was also found that AhR ligands could enhance the activity of EGFR. 
Thus, the effect of the agents in combination were investigated on the protein 
expression of EGFR and HER2 levels [61] [189]. Further, the protein expression of 
CYP1A1 was evaluated. These protein expression results helped to validate the 
mRNA expression levels of the QPCR analysis.  Protein expression levels of ERK1/2 
of the RAS/MAPK pathway was also investigated as ERK1/2 was shown to be 
associated with the induction of CYP1A1 expression [301].  
 
Furthermore, there has been evidence of cross talk between EGFR and c-MET. EGFR 
ligands are found to activate c-MET which results in synergistic activation of EGFR 
and c-MET pathways [310]. In addition c-MET and HER2 have also shown to 
synergise in promoting tumour growth. Overexpression and activation of c-MET is an 
independent predictor of poor prognosis in breast cancer [75] [310]. From a 
therapeutic point, inhibition of EGFR and HER2 by Gefitinib could provide cancer 
cells to shift their growth dependence to alternative receptor mediated pathways such 
as c-MET and demonstrate resistant mechanisms [75]. In actual fact, amplification of 
Chapter 6 
321 
 
c-MET has found to lead to Gefitinib resistance [101]. Furthermore, previous research 
has shown that hypoxic conditions can induce c-MET expression in many cancer cells 
which is mediated through HIF-1. In fact, 2 different binding sites for HIF-1 have been 
identified on the promoter of c-MET [311]. This demonstrates the association of c-
MET and AhR signalling since HIF- ✁ ✂✄ ☎✆✄✝ ✞✟✝✠✟ ☎✄ ✡☛☞✌ [305]. Moreover, 
hypoxia is shown to induce ERK activation as well [298]. Therefore, the effect of 
agents alone and in combination on these modulators were investigated by Western 
blots (Figure 6.14). Densitometry analysis with the ARD values for the significant 
results are shown in appendix I under section 9.1.3.2. 
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It was observed that Gefitinib alone decreased P-EGFR levels (ARD   57.49%) (P < 
0.0001) whereas 5F 203 alone slightly increased P-EGFR levels (ARD   115.89%) 
compared to control (P < 0.05). Interestingly, there was a remarkable reduction in P-
EGFR levels (ARD   5.36%) by the agents in combination compared to agents alone 
and control (P < 0.0001). Further, agents alone did not demonstrate a significant 
reduction in P-HER2 levels, in stark contrast the agents in combination portrayed a 
remarkable reduction in P-HER2 levels (ARD   5.25%) compared to SKBR3 control 
(P < 0.0001). However, there was no significant difference observed in the protein 
expression levels of total EGFR and HER2 by agents alone or by the combination.  
 
As expected CYP1A1 protein expression was increased with exposure of cells to 5F 
203 (1x GI50 concentration) compared to control (ARD   141.82%) (P < 0.05). In 
contrast, Gefitinib did not show a significant increase of CYP1A1 expression levels 
compared to control cells in the Western blot analysis, compared to QPCR analysis. 
Agents in combination, remarkably enhanced the CYP1A1 protein expression levels 
(ARD   385.40%) compared to control (P < 0.0001). It has been stated that the 
quantification of both mRNA and protein levels are complementary and is not 
redundant; measurements taken from both are necessary for a complete understanding 
of how the cell works [312]. Although mRNA is eventually translated into protein, 
and it can be assumed that there should be an association between the level of mRNA 
and that of protein, it has been depicted that, complicated and varied 
posttranscriptional mechanisms are most often involved in turning mRNA into 
protein, and there can be differences between mRNA translation and protein 
expression [312]. In fact, although, these results correspond with the results of the 
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mRNA expression levels of CYP1A1 confirming that the mRNA levels have been 
transferred into proteins, there is a slight difference between the 2 levels. For instance, 
there was no difference between the CYP1A1 protein expression levels for Gefitinib 
treatment and control.  
 
As portrayed in chapter 3, results within this chapter showed that Gefitinib alone 
completely abolished P-ERK1/2 expression (ARD   1.40%) in relative to control (P < 
0.0001). Although the results are not significant, it was also observed that 5F 203 alone 
reduced P-ERK1/2 expression very faintly (ARD   89.15%) compared to control. 
Intriguingly, the agents in combination almost abolished P-ERK1/2 expression levels 
(ARD   1.18%) (P < 0.0001). Total ERK1/2 levels were not altered.  
 
In addition, it was found that 5F 203 alone was able to extremely significantly decrease 
the expression levels of c-MET in SKBR3 cells compared to control (ARD   16.77%) 
(P < 0.0001) and the agents in combination also reduced c-MET levels compared to 
control but the reduction was not as low as 5F 203 alone (ARD   37.61%) (P < 
0.0001). In contrast, Gefitinib alone was not able to alter c-MET levels in SKBR3 
cells.  
 
These findings were extremely interesting, as outlined before induction of CYP1A1 
by Gefitinib is shown to be associated with increased drug metabolism. However, this 
increased metabolism has been shown to reduce the level of intracellular Gefitinib in 
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sensitive cells [301]. Hence, from the results of this study it can be suggested that in 
the presence of 5F 203 which induces CYP1A1 activity, the rate of Gefitinib 
metabolism increases to a level where Gefitinib could persist for a longer period of 
time within the cells and increase Gefitinib ✁ pharmacological action. Indeed, this 
strategy leads to enhanced inhibition of phosphorylation of EGFR and HER2 in 
SKBR3 cells by the agents in combination which works synergistically compared to 
Gefitinib alone [101]. These results add to a body of data which suggests synergism 
between 5F 203 and Gefitinib. 
 
In addition, it was interesting to observe that 5F 203 alone slightly increased P-EGFR 
that corroborates with previous literature, which describes that AhR ligands enhances 
EGFR expression levels [61]. Thus, these results demonstrate the importance of the 
combination of Gefitinib and 5F 203 which could work synergistically to inhibit cross 
talk between EGFR and AhR. Further, an association was stated between inhibition of 
this RAS/MAPK pathway and CYP1A1 induction [301]. Thus, inhibition of P-
ERK1/2 by Gefitinib would induce CYP1A1 expression which would synergistically 
work together with 5F 203 which also induces expression of CYP1A1 that ultimately 
leads to apoptosis of SKBR3 cells.  
 
Western blot results showed that 5F 203 alone down-regulated c-MET expression in 
SKBR3 cells significantly. These results suggest that 5F 203 treatment may be 
✂✄☎✆☎✝✞✟✝✠ ✡☛☞✌ ✁ ✍✎✞✟✆✟✞✏ ✍✁ ✑✒✓-✔✕ [305]. Depletion of ARNT impedes HIF-1 
composition which is induced by hypoxic conditions, increasing expression and 
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Although, Sirolimus and CGP57380 as single agents have shown to be effective in 
breast cancer, Sirolimus together with CGP57380 showed an antagonistic result in the 
panel of breast cancer cell lines [117] [187]. In order to obtain a better effect of 
Sirolimus or CGP57380 it could be combined with another PI3K/AKT or RAS/MAPK 
inhibitor.  
 
MS agents showed potent inhibitory effects both in PTEN deficient MDA-MB 468 
and HER2 overexpressing SKBR3 cells. MS-73 was the most potent, while MS-74 
was moderately potent and MS-76 was the least potent. It was found that all 3 agents 
tested significantly inhibited P-4E-BP1 of the mTOR pathway but was not able to 
inhibit the PI3K/AKT pathway in MDA-MB 468 cells at the tested concentrations. In 
contrast MS-73 down-regulated P-AKT while all 3 agents down-regulated P-4E-BP1 
in SKBR3 cells. 
 
An abundance of evidence demonstrates the importance of AhR in dictating 
tumorigenic outcomes, suggesting that therapeutic manipulation of AhR in human 
cancer is on the horizon [91]. For instance, aminoflavone an AhR ligand has shown 
potent inhibitory effects in breast cancer cell lines and these agents have reached 
clinical trials [313]. In the current study the AhR ligand, 5F 203 was tested in the panel 
of breast cancer cell lines and it was found to be potent in the HER2 overexpressing 
SKBR3 cell line. This agent was combined with MS agents, Raloxifene and Gefitinib. 
MS agents together with 5F 203 and Raloxifene together with 5F 203 showed an 
antagonistic effect in MDA-MB 468 and SKBR3 cell lines. In contrast, the 
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combination of 5F 203 and Gefitinib elicited synergy in SKBR3 growth inhibition, 
mainly by 5F 203 potentiating the effect of Gefitinib. The mechanism involved 
enhanced induction of CYP1A1 mRNA and protein expression. Subsequently it was 
observed that the agents in combination generated ROS which led to DNA damage 
(DDSB) in SKBR3 cells at 24 h. This ultimately resulted in a large apoptotic response 
in SKBR3 cells which inhibited SKBR3 cell growth at 24 h. Thus, 5F 203 in 
combination with Gefitinib may offer a potential novel treatment for HER2 
overexpressing breast cancer.  
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previously that certain cancer cells, invariably demonstrate a reduced dependence on 
exogenous mitogenic growth factors since they are able to generate many of their own 
mitogenic growth stimulatory signals [172]. Therefore, initially the effect of medium 
supplemented with depleted (2%) and normal (10%) levels of FBS on the breast cancer 
cell line panel were evaluated to understand how each cell line would behave in 
culture. MCF7 (ER+) and MDA-MB 468 (ER-) cell lines showed significant growth 
in serum depleted (2% FBS) medium suggesting no correlation with ER status and 
that these cells are able to stimulate their own growth factors even in a harsh 
environment compared to the rest of the cell lines. Out of all the cell lines tested, the 
HER2 overexpressing, TP53 deficient SKBR3 cell line which is categorised under the 
HER2 molecular subtype appeared to be the most sensitive to EGF in medium 
supplemented with 10% FBS. Further, the SKBR3 cell line was found to be the most 
sensitive to the EGFR TKI, Gefitinib in medium supplemented with 10% FBS. 
However, Erlotinib which is also an EGFR TKI, was not effective in any of the cell 
lines tested in the current study, although both Gefitinib and Erlotinib share similar 
chemical structures [304]. There is evidence of cross talk between the HER family and 
ER [87]. Thus, the effect of Raloxifene which is a second generation SERM which 
has shown to have fewer side effects than Tamoxifen was evaluated against the panel 
of breast cancer cell lines [115]. However, it was found that Raloxifene did not exert 
growth inhibitory effects in the breast cancer cell line panel. This agent is also found 
to function as an AhR ligand [10]. Thus, its action as an AhR ligand was evaluated 
which is discussed further below.  
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As EGF and Gefitinib were potent in the HER2 overexpressing SKBR3 cell line, the 
effect of these agents were evaluated in more detail using this cell line. Clonogenic 
assays demonstrated that both agents induced a moderate cytotoxic effect together 
with a cytostatic effect at 1x and 2x GI50 concentrations of EGF and Gefitinib by 
reducing colony size and inhibiting SKBR3 colony formation. Both EGF and Gefitinib 
treatment down-regulated P-EGFR in SKBR3 cells significantly while only Gefitinib 
down-regulated P-HER2 levels significantly. Further, downstream RAS/MAPK and 
PI3K/AKT pathways were down-regulated with EGF and Gefitinib treatment leading 
to cell cycle arrest and small significant apoptotic populations in SKBR3 cells with 
prolonged treatment. The rational selection of breast cancer patients for EGFR TKIs 
still remains a challenge. Thus, these results may provide experimental evidence that 
EGF and Gefitinib could improve outcomes of breast cancer patients that fall into the 
HER2 molecular subtype. However, the effect of EGF on HER2 overexpressing breast 
cancer merits additional studies.  
 
Although, Gefitinib is used in the clinic to treat patients currently, its therapeutic 
window is drastically narrowed by poor bioavailability, acquired resistance and 
systemic toxicity [123]. Thus, to minimise these effects this agent was encapsulated 
within H-AFt NPs by diffusion. TfR1 is highly expressed in cancer cells compared to 
normal human cells and these receptors are found to be associated with the uptake of 
H-AFt [222]. Thus, TfR1 receptors were considered as a targeting molecule. This 
novel agent was tested against the Gefitinib sensitive SKBR3 cell line and it was found 
that H-AFt-encapsulated-Gefitinib demonstrated slightly reduced potency compared 
to Gefitinib alone at 72 h which implied that encapsulated Gefitinib may require time 
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to be released from the H-AFt cavity. Interestingly, a longer exposure time showed 
increased anti-tumour activity in the SKBR3 cell line compared to Gefitinib alone 
supporting the hypothesis that the H-AFt cage allows controlled release of drug 
molecules which is a characteristic of a successful nanotechnology drug delivery 
system. Further, H-AFt-encapsulated-Gefitinib was successfully taken up by SKBR3 
cells in a manner similar to Gefitinib alone. Thus, encapsulation of Gefitinib in H-AFt 
may reduce off target toxicities and decrease drug deposition in normal tissues. This 
agent might be a promising agent in the clinic.  
 
HER2 overexpression in breast cancer is mostly associated with an aggressive 
phenotype [51]. Although Trastuzumab improved the outcome of HER2+ breast 
cancer, it is associated with the development of resistance [55]. Thus, novel targeting 
therapies especially agents that fall into the category of nanomedicine will be 
beneficial to treat HER2+ breast cancers. The mechanism of action of 2 novel HER2 
targeting agents - H-AFt-fusion protein and L-AFt-fusion protein was explored and it 
was found that the H-AFt-fusion protein was more effective in inhibiting SKBR3 cell 
growth and proliferation compared to the L-AFt-fusion protein. SKBR3 cells failed to 
proliferate and form colonies in the presence of the H-AFt-fusion protein suggesting 
that this agent has a highly cytotoxic effect compared to Trastuzumab which showed 
a moderate cytotoxic and a cytostatic effect. Further, this novel agent inhibited the 
expression levels of total and phosphorylated HER2 extremely significantly which 
resulted in significant down-regulation of RAS/MAPK, PI3K/AKT and JAK/STAT 
pathways. This again, led to reduced orchestrations of cell cycle events and a high 
level of apoptosis in SKBR3 cells. Further, co-expression of 2 or more HER family 
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members has shown to be correlated with an aggressive phenotype in breast cancer. 
Interestingly, it was found by protein microarray analysis, that this novel H-AFt-fusion 
protein is able to inhibit not just HER2 but also P-EGFR, HER3 and P-HER3. This 
suggests inhibition of mitogenic heterodimerisation of the HER receptors. Thus, this 
novel agent is an attractive nanodrug for HER2 overexpressing breast cancer.  
 
The heterogeneity of breast cancer rarely depends on the aberrant expression or 
function of a single receptor or a signalling pathway but depends on a considerable 
capacity for compensatory cross talk between signalling pathways. Thus, a 
combination therapy approach was explored and several agents in combination were 
tested  [143].  As outlined before, eIF4E of the mTOR pathway plays a key regulatory 
role in initiating mRNA translation. mTOR directly phosphorylates 4E-BP1 which 
thereby increases functional eIF4E [79]. Sirolimus which is known as an mTOR 
inhibitor, is found to inhibit 4E-BP1 phosphorylation resulting in suppression of cap 
dependent mRNA translation [277]. Paradoxically, it has also been shown that, 
Sirolimus in fact increases eIF4E phosphorylation secondary to inhibition of 4E-BP1 
phosphorylation. Additionally, MNK1 and MNK2 which are activated by the 
RAS/MAPK pathway are also found to phosphorylate eIF4E. Previously, it has been 
shown that eIF4E phosphorylation by mTOR inhibitors is abolished only when both 
MNK1 and MNK2 were knocked out, suggesting that mTOR inhibitors increase MNK 
dependent phosphorylation of eIF4E [277]. Thus, a strategy to improve the efficacy 
of Sirolimus would be to combine it with a MNK inhibitor. Thus, the activity of 
Sirolimus together with CGP57380 which is an inhibitor of MNK1 and MNK2, was 
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tested on the panel of breast cancer cell lines. Unexpectedly, agents in combination, 
showed an antagonistic result according to the CI method of Chou and Talalay.  
 
The PI3K/AKT pathway is commonly deregulated in cancer with the most common 
events being mutations or increased gene copy numbers of the PIK3CA gene or 
mutations or loss of expression of the PTEN gene [314]. Thus, inhibiting PI3K, in 
cancer remains an attractive strategy. Furthermore, it has been demonstrated that the 
PI3K/AKT pathway is paradoxically activated following mTOR inhibition [277]. 
Therefore, inhibition of both PI3K and mTOR together provides a compelling 
rationale for testing dual PI3K/mTOR kinase inhibitors in breast cancer [77]. Hence, 
3 dual PI3K/mTOR agents (MS-73, MS-74 and MS-76) were tested against the panel 
of breast cancer cell lines. MS-73 currently has entered clinical trials, while MS-74 
and MS-76 are novel analogues of MS-73. MS-73 showed the highest potency while 
MS-74 showed moderate potency and MS-76 showed the least potency against the 
panel of breast cancer cell lines. Interestingly, MDA-MB 468 cell line which is TNBC, 
PTEN and TP53 deficient (categorised under the basal molecular subtype) was the 
most sensitive towards all 3 agents tested. Further, it was also found that HER2 
overexpressing SKBR3 cells were unable to form large number of colonies in the 
presence of 1500 nM of MS-73 and MS-74. In this regard, the activity of the 3 agents 
were further evaluated by using MDA-MB 468 and SKBR3 cell lines. MS-73 caused 
large significant apoptotic populations in both MDA-MB 468 and SKBR3 cell lines. 
Interestingly the novel analogue, MS-74 also caused similar significant apoptotic 
populations in both cell lines which was observed in cell cycle and apoptosis 
experiments as well. All 3 agents significantly down-regulated P-4E-BP1 in MDA-
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MB 468 and SKBR3 cells confirming that these agents inhibited the mTOR pathway 
by down-regulating P-4E-BP1. However, all 3 agents failed to down-regulate the 
PI3K/AKT pathway in MDA-MB 468 cells at the tested concentrations. In contrast, 
2x GI50 MS-73, down-regulated P-AKT (Ser473) and P-AKT (Thr308) marginally in 
SKBR3 cells. However, higher concentrations of these agents may down-regulate this 
pathway significantly. Thus, these results would suggest that, indeed these novel 
agents function as dual PI3K/mTOR inhibitors and also that the novel analogues MS-
74 and MS-76 have similar activity to MS-73, but with reduced potency.   
 
AhR is the main transcriptional regulator of CYP1A1 and it has been shown previously 
that 5F 203 which is an experimental AhR ligand induces AhR signalling in sensitive 
breast cancer cells [92]. The effect of 5F 203 was tested against the panel of breast 
cancer cell lines; the HER2 overexpressing SKBR3 cell line was the most sensitive 
towards 5F 203. AhR is shown to cross talk with a number of key signalling pathways 
in breast cancer including EGFR and RAS/MAPK. Alternately, signalling molecules 
down stream of EGFR such as PI3K is known to be involved in cross talk with the 
RAS/MAPK pathway and may be responsive to AhR ligands [61] [297]. Thus, a 
number of agents were combined with 5F 203 to determine the combination effect. 
The effect of MS agents in combination with 5F 203 demonstrated an antagonistic 
effect according to the CI method of Chou and Talalay. In addition, Raloxifene which 
is found to function as an AhR ligand was tested in combination with 5F 203. It has 
been previously shown that Raloxifene, activates AhR and induces apoptosis in ER- 
cell lines such as MDA-MB 231 cells [141]. Therefore, the activity of Raloxifene was 
tested in combination with 5F 203 in ER- cell lines in this study.  MDA-MB 468 and 
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SKBR3 cell lines were chosen. An antagonistic result was found according to the CI 
method of Chou and Talalay. As mentioned above AhR and EGFR cross talk has been 
identified [61]. It has been demonstrated that the EGFR inhibitor Gefitinib induces 
CYP1A1 activity which is associated with drug metabolism in Gefitinib sensitive cells 
[301]. 5F 203 also induces CYP1A1 activity [92]. Thus, the effects of the agents in 
combination were determined by MTT assays. Intriguingly, it was found that the 
agents in combination showed a CI value of 0.68 ± 0.08 which is indicative of 
synergism according to the Chou and Talalay method in sensitive SKBR3 cells. It was 
found that agents in combination showed a remarkable level of CYP1A1 induction by 
QPCR analysis which was ~ 1385-fold higher, relative to control SKBR3 cells. These 
results corroborated with the results of the protein expression levels of CYP1A1. 
Further, the agents in combination generated ROS which resulted in greater DDSBs 
in SKBR3 cells at 24 h. This led to a large apoptotic population at 24 h. In fact, the 
total apoptotic population observed (46.83%) was higher than the expected total 
population (25.24%) at 24 h confirming the synergistic effect observed within the 
MTT assay results. Furthermore, the agents in combination portrayed a greater 
inhibition of phosphorylation of EGFR and HER2 in SKBR3 cells compared to 
Gefitinib alone which would have been associated with enhanced persistence of 
Gefitinib in SKBR3 cells with the agents in combination; potentiating the effect of 
Gefitinib by 5F 203 [301]. c-MET expression was also down-regulated in SKBR3 
cells treated with both Gefitinib and 5F 203 compared to Gefitinib alone, which 
certainly would minimise resistance, as it has been demonstrated previously that 
amplification of c-MET is correlated to Gefitinib resistance [101]. The agents in 
combination may offer a potent approach to controlling HER2 overexpressing breast 
tumours and could also help to delay or avoid acquired resistance to Gefitinib alone.  
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models may provide a native microenvironment in which the tumour 
resides and these models might be more advantageous compared to studies 
carried out in vitro or in 3-dimentional cultures [315] [316].  
 
  A combination therapy approach is shown to be potent in controlling and 
delaying acquired resistance. However, multi kinase blockade may lead to 
increased toxicities in the clinic [299]. Thus, nanoformulations can help 
avoid such limitations by carrying several therapies in combination. 
Therefore, agents such as 5F 203 and Gefitinib which has different 
pharmacological behaviour could be encapsulated in one NP and tested for 
its functionality. These NPs may carry an optimised synergistic drug ratio 
in a single NP to the targeted tumour.  
 
  NP drug delivery systems offer revolutionary opportunities to develop 
highly effective personalised targeted therapy. As NPs are foreign 
materials the immune system may result in immunosuppression or immune 
stimulation which may at times bring unwanted responses [317]. However, 
AFt NPs have shown excellent activity in vivo with reduced toxicities, 
nevertheless the lack of human clinical trials regarding AFt associated 
agents may suggest insufficient information regarding its activity in 
humans as yet [228]. Thus, it could be investigated whether, ferritin from 
each ✁✂✄☎✆✝ ✞☎✟✞✄✂ ✠☎✝✡✄✟✝☛✆ ✁☞✌✍ could be extracted, and carry out the 
process of removing the iron atoms and subsequently encapsulating with 
the pharmacological agent/s and testing for its functionality. This system 
would certainly enable personalisation of therapeutic regimens for each 
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breast cancer patient and ideally improve the field of nanomedicine which 
yet remains to reach its full potential.   
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9.1.1.2 Densitometry analysis for the PI3K/AKT pathway   P-AKT (Ser473) 
and P-AKT (Thr308) 
 
 
 
 
 
 
Figure 9.2: ARD levels of the PI3K/AKT pathway for results in chapter 3. (a) P-
AKT (Ser473) and (b) P-AKT (Thr308) expression levels in SKBR3 cells. Cells were 
treated with EGF or ✁✂✄☎✆☎✝☎✞ ✄✟✠ ✡☛ ☞✌ ✍✂✎✝ ✎✝✏ ✑✒ ✟✄ ✆✠☎✎✓✔ ✕ ✖✌ ✗ ☎✝✏☎✘✎✆✂✔
significant difference compared to control, * (P < 0.05), ** (P < 0.01), *** (P < 0.001), 
**** (P < 0.0001). 
  
9.1.1.3 Densitometry analysis for the JAK/STAT pathway and Cyclin D1 
 
 P-
STAT5 
 
 
 
 
Figure 9.3: ARD levels of the JAK/STAT pathway and Cyclin D1 for results in 
chapter 3. (a) P-STAT5 and (b) Cyclin D1 expression levels in SKBR3 cells. Cells 
were treated with EGF or ✁✂✄☎✆☎✝☎✞ ✄✟✠ ✡☛ ☞✌ ✍✂✎✝ ✎✝✏ ✑✒ ✟✄ ✆✠☎✎✓✔ ✕ ✖✌ ✗ ☎✝✏☎✘✎✆✂✔
significant difference compared to control, * (P < 0.05), ** (P < 0.01), *** (P < 0.001), 
**** (P < 0.0001). 
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9.1.2 Densitometry analysis for Western blotting experiments in chapter 5 
9.1.2.1 Densitometry analysis for the RAS/MAPK pathway   CRAF, P-CRAF, 
ERK1/2, P-ERK1/2, P-p38 and P-SAPK/JNK 
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Figure 9.4: ARD levels of the RAS/MAPK pathway for results in chapter 5. (a) 
C-RAF, (b) P-CRAF, (c) ERK1/2, (d) P-ERK1/2, (e) P-p38 and (f) P-SAPK/JNK 
expression levels in SKBR3 and MDA-MB 231 cells. Cells were treated with H-AFt-
 ✁✂✄☎✆ ✝✞☎✟✠✄✆✡ ✟☛✞☞✠✟✄✆☞ ✝✞☎✟✠✄✆ ☎✞ ✌✞☛✂✟✁✍✁✎☛✏  ☎✞ ✑✒ ✓✔ ✕✠☛✆ ☛✆✖ ✗✘ ☎  ✟✞✄☛✙✂ ✚ ✛✔
* indicates significant difference compared to control, * (P < 0.05), ** (P < 0.01), *** 
(P < 0.001), **** (P < 0.0001). 
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9.1.2.2 Densitometry analysis for the PI3K/AKT pathway   AKT, P-AKT 
(Ser473), P-AKT (Thr308) and P-PTEN  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.5: ARD levels of the PI3K/AKT pathway for results in chapter 5. (a) 
AKT, (b) P-AKT (Ser473), (c) P-AKT (Thr308) and (d) P-PTEN expression levels in 
SKBR3 and MDA-MB 231 cells. Cells were treated with H-AFt-fusion protein, 
✁✂✄☎✆✁✝✞☎ ✟✄✠✁✆✝✞ ✠✄ ✡✄✂☛✁☞✌☞✍✂✎ ✏✠✄ ✑✒ ✓✔ ✕✆✂✞ ✂✞✖ ✗✘ ✠✏ ✁✄✝✂✙☛ ✚ ✛✔ ✜ ✝✞✖✝✢✂✁✆☛
significant difference compared to control, * (P < 0.05), ** (P < 0.01), *** (P < 0.001), 
**** (P < 0.0001).  
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9.1.2.3 Densitometry analysis for the JAK/STAT pathway and PARP   P-
STAT5 and PARP 
9.1.2.4  
 
 
 
 
 
 
Figure 9.6: ARD levels of the JAK/STAT pathway and PARP for results in 
chapter 5. (a) P-STAT5 and (b) PARP expression levels in SKBR3 and MDA-MB 
231 cells. Cells were treated with H-AFt-fusion protein, targeting protein or 
Trastuzumab for 24 h. Mean and SD of trials ✁ ✂✄ ☎ ✆✝✞✆✟✠✡☛☞ ☞✆✌✝✆✍✆✟✠✝✡ ✞✆✍✍☛✎☛✝✟☛
compared to control, * (P < 0.05), ** (P < 0.01), *** (P < 0.001), **** (P < 0.0001). 
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9.1.3 Densitometry analysis for Western blotting experiments in chapter 6 
9.1.3.1 Densitometry analysis for the PI3K/AKT and mTOR pathways   P-4E-
BP1, P-eIF4E, P-AKT (Ser473) and P-AKT (Thr308) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.7: ARD levels of the PI3K/AKT and mTOR pathways for results in 
chapter 6. (a) P-4E-BP1, (b) P-eIF4E, (c) P-AKT (Ser473) and (d) P-AKT (Thr308) 
expression levels in MDA-MB 468 and SKBR3 cells. Cells were treated with MS-73, 
MS-74 or MS-✁✂ ✄☎✆ ✝✞ ✟✠ ✡☛☞✌ ☞✌✍ ✎✏ ☎✄ ✑✆✒☞✓✔ ✕ ✖✠ ✗ ✒✌✍✒✘☞✑☛✔ ✔✒✙✌✒✄✒✘☞✌✑ ✍✒✄✄☛✆☛✌✘☛
compared to control, * (P < 0.05), ** (P < 0.01), *** (P < 0.001), **** (P < 0.0001). 
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9.1.3.2 Densitometry analysis for EGFR, HER2, CYP1A1, RAS/MAPK and c-
MET pathways   P-EGFR, P-HER2, CYP1A1, P-ERK1/2 and c-MET 
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Figure 9.8: ARD levels of EGFR, HER2, CYP1A1, RAS/MAPK and c-MET 
pathways for results in chapter 6. (a) P-EGFR, (b) P-HER2, (c) CYP1A1, (d) P-
ERK1/2 and (e) c-MET expression levels in SKBR3 cells. Cells were treated with 5F 
203, Gefitinib or agents in combination  ✁✂ ✄☎ ✆✝ ✞✟✠✡ ✠✡☛ ☞✌ ✁  ✍✂✎✠✏✑ ✒ ✓✝ ✔ ✎✡☛✎✕✠✍✟✑
significant difference compared to control, * (P < 0.05), ** (P < 0.01), *** (P < 0.001), 
**** (P < 0.0001). 
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Figure 9.9: In vitro growth inhibitory effect of (a) Sirolimus and CGP57380 alone 
and in (b) combination against the Mia PaCa-2 cell line. Mean and SD of 
representative experiments are shown; trials   ✁, (n = 8 per trial). * indicates 
significant difference compared to control, * (P < 0.05), ** (P < 0.01), *** (P < 0.001), 
**** (P < 0.0001). 
 
The results in combination showed a CI value of > 1.1 which is antagonistic. Mia 
PaCa-2 cells have shown to have a K-RAS mutation. Due to this K-RAS mutation the 
RAS/MAPK pathway is constantly up-regulated. ERK and p38 phosphorylates MNK1 
which in turn phosphorylates eIF4E phosphorylation [78]. Thus, in this cell line eIF4E 
phosphorylation is constantly up-regulated. Further, resistance to Sirolimus could also 
be due to the up-regulation of the RAS/MAPK pathway, because it is has been shown 
that mTORC1 inhibition could lead to the activation of ERK [281]. Thus, these reasons 
could be associated with the antagonistic results shown in this experiment.  
 
This experiment was conducted by an MPharm undergraduate student ✂ H. K. Sin, 
under the supervision of the author.  
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